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SUMMARY 
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy that is 
activated by increases in the intracellular AMP:ATP or ADP:ATP ratios. Once active, 
AMPK activates catabolic pathways and inhibits anabolic pathways to restore cellular 
energy homeostasis. AMPK activity can be increased by phosphorylation of Thr172, a 
conserved residue in the activation loop of the kinase domain, by either LKB1 or 
CaMKKβ. Increases in Thr172 phosphorylation can be mediated by either protecting 
this site against dephosphorylation by protein phosphatases, or by promoting its 
phosphorylation by upstream kinases, both of which were proposed to be mediated by 
binding of AMP or ADP to the γ-subunit of AMPK. AMPK is also allosterically activated 
by binding of AMP, but not ADP.  
 
Recently, ADP has been proposed as the major regulator of AMPK and the role of AMP 
has been questioned. The reasons for this are: (i) while both AMP and ADP can 
increase phosphorylation of Thr172, ADP is present at higher concentrations in the cell 
and it was proposed that AMP would be unable to compete with ADP for binding at 
the γ-subunit; (ii) allosteric activation by AMP was reported to increase AMPK activity 
by less than 2-fold, whereas changes in the phosphorylation of Thr172 can increase 
AMPK activity by 100-fold. 
 
Using cell-free systems and intact cells, the regulation of Thr172 phosphorylation and 
AMPK activity by AMP, ADP and ATP was re-investigated. AMP promoted Thr172 
phosphorylation by LKB1 but not by CaMKKβ, while ADP had no effect on Thr172 
phosphorylation by either upstream kinase. Additionally, while both AMP and ADP 
xvi 
 
could protect Thr172 against dephosphorylation, AMP was more potent. The allosteric 
activation of AMPK by AMP was demonstrated to be a significant component of the 
overall activation mechanism. Using phosphorylation of ACC (a downstream target of 
AMPK) as a marker, allosteric activation of AMPK was observed under conditions 
where there were no changes in Thr172 phosphorylation. The changes in Thr172 
phosphorylation and AMPK activity observed in intact cells in response to AMPK 
activators were also examined, and demonstrated to be far lower than the maximal 
effects observed in cell-free systems. Taken together, these results demonstrate that 
AMP is a true physiological regulator of AMPK activity. 
 
The regulation of LKB1 has also been the subject of much interest. Whilst it appears 
that LKB1 is constitutively active, several groups have reported that LKB1 activity is 
regulated by post-translational modifications, particularly phosphorylation. The role of 
phosphorylation of LKB1 on Ser31 by AMPK was investigated. While AMPK could 
phosphorylate LKB1 in a cell-free system, an effect lost in an LKB1 [S31A] mutant, this 
phosphorylation was not observed in intact cells. Additionally, mutation of Ser31 did 
not appear to alter LKB1 activity. These results suggest that phosphorylation of Ser31 
of LKB1 by AMPK, whilst possible, may not be a physiologically relevant event. 
 
The mTOR pathway is a key regulator of cell growth and protein synthesis in response 
to a number of stimuli, including growth factors, nutrients and energy status. The 
mTOR pathway is frequently deregulated in a number of cancers and cancer 
syndromes, and inhibition of mTOR is a promising therapeutic approach. The nature of 
the genetic lesion in tumours may determine the response of cells to mTOR inhibition. 
The LKB1-AMPK pathway, as well as being a negative regulator of the mTOR pathway, 
xvii 
 
is also frequently inactivated in human cancers. The role that the LKB1-AMPK pathway 
plays in determining the cellular response to AZ4, a dual mTORC1 and mTORC2 
inhibitor, was investigated. AZ4 induced apoptosis in a number of cell lines, confirming 
its potential as an anti-cancer therapeutic. However, the presence of an active LKB1-
AMPK pathway protected cells against AZ4-induced apoptosis, suggesting that the 
status of this pathway may determine how cells respond to mTOR inhibition. 
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CHAPTER 1: INTRODUCTION 
1.1 Protein phosphorylation 
Protein phosphorylation is a form of post-translational modification whereby a 
phosphate group is transferred from ATP to the hydroxyl group of a serine, threonine 
or tyrosine residue on a target protein. This is catalysed by a group of enzymes termed 
protein kinases. Phosphorylation is a reversible modification, with the phosphate 
group being removed by a protein phosphatase (Fig 1.1). Proteins can therefore cycle 
between phosphorylated and dephosphorylated states and this can modify their 
function in a variety of ways, including: (i) increased or decreased biological activity; (ii) 
altered interaction with other proteins; (iii) changes in subcellular location; (iv) 
increased stability. Protein phosphorylation is an essential component of many signal 
transduction pathways. Indeed, it has been estimated that 30% of proteins in the 
human genome are phosphorylated, and abnormally regulated phosphorylation events 
are present in a number of diseases (Cohen, 2002a). Indeed, the importance of protein 
phosphorylation events in human diseases is illustrated by the number of kinase 
inhibitors either approved for clinical use or undergoing clinical trials for a range of 
conditions (Cohen and Alessi, 2013; Cohen, 2002b). 
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Figure 1.1: Protein phosphorylation 
Schematic diagram of a protein phosphorylation/dephosphorylation cycle. 
Phosphorylation of the target protein is catalysed by a protein kinase and 
dephosphorylation by a protein phosphatase. The phosphate group is donated from 
ATP, producing ADP. 
 
The first protein that was demonstrated to be reversibly regulated by phosphorylation 
was glycogen phosphorylase. Conversion of inactive phosphorylase b to active 
phosphorylase a could be achieved in the presence of Mg.ATP and an enzyme termed 
phosphorylase kinase (Fischer and Krebs, 1955). The conversion of active to inactive 
phosphorylase by protein phosphatase-1 was subsequently demonstrated (Ingebritsen 
and Cohen, 1983). The concept of protein kinases acting as signalling cascades was  
demonstrated when cyclic-AMP dependent protein kinase (PKA) was shown to 
phosphorylate and inactivate phosphorylase kinase (Walsh et al., 1968). Protein 
phosphorylation is now universally accepted as playing a major role in the regulation 
of almost all cellular processes. 
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1.2 The human kinome 
The publication of the human genome sequence allowed for the identification of 
protein kinase genes by searching sequences for the presence of eukaryotic protein 
kinase (ePK) catalytic domains. A total of 518 kinases were identified, comprising 478 
typical protein kinases and an additional 40 atypical protein kinases (Manning et al., 
2002). The latter, while possessing kinase activity, lack sequence similarity to the ePK 
domain. Kinases therefore comprise nearly 2% of the total genes in the human 
genome. The kinases, the full complement of which is termed the kinome, were 
grouped into families based upon the sequence similarities of their catalytic domains, 
the domain structure outside the catalytic domain and known biological functions 
(Manning et al., 2002). A number of these identified kinases are actually considered to 
be catalytically inactive, lacking key conserved residues within the kinase domain. 
These pseudokinases are proposed to regulate the function of active kinases, and may 
also function as scaffolds in the formation of protein complexes (Boudeau et al., 2006; 
Manning et al., 2002). 
 
1.3 AMP-activated protein kinase 
1.3.1 Discovery and historical background 
1.3.1.1 HMG CoA-reductase 
3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), a key enzyme in the 
cholesterol biosynthesis pathway, converts HMG-CoA to mevalonic acid. Beg et al 
(1973) reported that HMGR activity associated with microsomes extracted from rat 
liver was reduced by incubation with Mg.ATP. This inactivation was dependent upon a 
cytosolic fraction, as the HMGR activity of washed microsomes was not reduced by 
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Mg.ATP unless the cytosolic fraction was included in the incubation. The authors also 
demonstrated that inactivated HMGR could be reactivated by incubation with a 
cytosolic fraction distinct from the inactivation factor (Beg et al., 1973). This was the 
first evidence that HMGR activity was converted from an active to inactive state and 
that this modulation was dependent upon a cytosolic fraction. The authors suggested 
that the inactivation could be due to protein phosphorylation. 
 
Brown and colleagues (1975) reported that an HMGR inactivation factor was present in 
human fibroblast extracts. This factor could inactivate both fibroblast HMGR and the 
rat liver HMGR described by Beg et al (1973). HMGR activity was reduced by Mg.ATP, 
an effect prevented by EDTA. A number of observations in this study pointed to the 
inactivation factor in the fibroblast extract being an enzyme:  
i. although ATP was required for inactivation, a derivative of ATP with a non-
hydrolysable γ-phosphate group had no effect, suggesting that the cleavage or 
transfer of a phosphate group was necessary;  
ii. an examination of the kinetics of HMGR inactivation demonstrated that a small 
amount of inactivation factor could inactivate the same amount of HMGR as a 
larger amount of inactivation factor, but over a longer period of time;  
iii. the reduction in HMGR activity required a direct association between the 
fibroblast extract and the microsomal HMGR, as incubation of either component 
alone, followed by enzymatic inactivation and addition to fresh HMGR, resulted 
in no decrease in HMGR activity. This proved that the reduction in activity was 
not due to the production of an allosteric inhibitor and required the presence of 
an active fibroblast extract.  
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Interestingly, the authors also proposed that the activity of the inactivation factor was 
itself regulated, as the activity was present in samples isolated under conditions where 
HMGR activity was both high and low (Brown et al., 1975). This was early evidence for 
the presence of an upstream regulator of the HMGR inactivation factor. 
 
Work by Nordstrom et al (1977) demonstrated that the inactivation of HMGR could be 
reversed by the addition of an activating factor, supporting the earlier work of Beg and 
colleagues (1973). This protein, present in the cytosol, could completely reverse the 
effects of HMGR inactivation by Mg.ATP. The activating factor was completely 
inhibited by sodium fluoride, a protein phosphatase inhibitor, suggesting that the 
activity of HMGR was regulated by changes in phosphorylation status. This was 
confirmed when it was demonstrated that incubation of HMGR with Mg2+ and            
[γ-32P]ATP resulted in a reciprocal increase in 32P incorporation into the enzyme and a 
decrease in enzyme activity (Beg et al., 1978). Incubation with partially purified 
phosphatase released 32P and increased enzyme activity (Beg et al., 1978). This was the 
first conclusive evidence that HMGR activity was rapidly and reversibly regulated by a 
cycle of phosphorylation and dephosphorylation, being active when dephosphorylated 
and inactivate when phosphorylated. 
 
Work by Ingebritsen et al (1978) demonstrated that the HMGR reactivating system 
could be replaced by a purified phosphatase. The authors also demonstrated that the 
inactivating system, the HMGR kinase, was itself regulated by phosphorylation. In this 
case the HMGR kinase was inactivated by the purified phosphatase and activated by an 
upstream kinase present in a microsomal extract, supporting the previous suggestion 
of Brown et al (1975). 
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Early work on the HMGR pathway had suggested that the inactivation of HMGR 
required both ATP and ADP, with the former proposed as a substrate for the HMGR 
kinase and the latter as an allosteric regulator (Brown et al., 1975). This theory was 
disproved when Ferrer et al (1985) demonstrated that AMP, and not ADP, was the 
activating ligand for the HMGR kinase. It is possible that the early preparations used 
were contaminated with adenylate kinase and it was the conversion of ADP to AMP 
that was necessary for activation of the HMGR kinase. HMGR activity was therefore 
proposed to be regulated by phosphorylation by an upstream kinase, HMGR kinase, 
which was itself regulated by phosphorylation. These effects were antagonized by 
protein phosphatases. Furthermore, HMGR kinase activity was allosterically increased 
by 5’-AMP.  
 
1.3.1.2 Acetyl Co-A Carboxylase 
In parallel, but unrelated, studies to the work on HMGR, Carlson and Kim (1973) 
discovered that acetyl Co-A carboxylase (ACC), a key enzyme in long-chain fatty acid 
synthesis, was inactivated by incubation with ATP. The reduction in catalytic activity 
mirrored the incorporation of 32P into ACC. This inactivation was dependent upon 
time, temperature and the presence of a protein fraction, termed ACC kinase, leading 
to the proposal that ACC is inactivated by phosphorylation (Carlson and Kim, 1973). In 
addition to this, incubation of ACC with MgCl2 caused an activation that was sensitive 
to sodium fluoride, suggesting the activity of a phosphatase (Carlson and Kim, 1973). 
This was confirmed by the demonstration that inactive ACC could be reactivated by 
incubation with partially purified phosphatase and that this correlated with 32P release 
from ACC (Lee and Kim, 1977). That the reactivation was due to dephosphorylation 
was shown conclusively by purification of ACC in the presence and absence of sodium 
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fluoride (Hardie and Cohen, 1979). In the presence of fluoride, ACC was less active and 
contained more covalently bound phosphate than ACC prepared in the absence of 
fluoride. ACC could be converted to a more active form by incubation with highly 
purified protein phosphatase-1, which also reduced the amount of covalently bound 
phosphate (Hardie and Cohen, 1979).  
 
Kim’s group had reported that 5’-AMP stimulated the inactivation of ACC, although this 
was incorrectly attributed to a direct effect of AMP on ACC itself (Yeh et al., 1980). This 
mechanism of regulation therefore bore remarkable similarity to that seen with 
HMGR, and evidence was obtained to show that the same kinase inactivated both ACC 
and HMGR, in an AMP-stimulated manner (Carling et al., 1987). The kinase activity 
towards ACC and HMGR co-purified through six chromatography steps, confirming that 
they were functions of the same protein kinase (Carling et al., 1989). As the protein 
kinase now had two distinct substrates, neither of the original names, ACC kinase or 
HMGR kinase, were deemed suitable and AMP-activated protein kinase (AMPK) was 
proposed as the unifying name for the two previously distinct activities (Munday et al., 
1988). This latter paper marked the first appearance of the name AMPK in the 
literature. 
 
1.3.2 Identification of AMPK subunits 
The first subunit to be identified was the catalytic α subunit, with an apparent 
molecular mass of 63 kDa (Carling et al., 1989). Using ATP-γ-Sepharose affinity 
chromatography, AMPK was subsequently purified to homogeneity and two additional 
polypeptides of 38 and 35 kDa were identified (Davies et al., 1994). Independently, 
AMPK purified from porcine liver was demonstrated to contain polypeptides of 63, 40 
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and 38 kDa (Mitchelhill et al., 1994). The three polypeptides co-migrated through gel 
filtration (Davies et al., 1994) and were present in a molar ration of 1:1:1 (Davies et al., 
1994; Mitchelhill et al., 1994). This suggested that AMPK existed as a heterotrimeric 
complex. The three polypeptides identified, p63, p38 and p35, are now referred to as 
the α, β and γ subunits respectively (Fig. 1.2). 
 
Figure 1.2: The α, β and γ subunits of AMPK 
Domain maps of typical mammalian AMPK. AMPK exists as heterotrimeric complexes 
composed of α, β and γ subunits in a 1:1:1 ratio. AID, autoinhibitory domain; CTD, C-
terminal domain; CBM, carbohydrate binding module; CBS, cystathione β synthase.  
 
1.3.2.1 The α subunit 
The mammalian AMPK-α subunit was cloned and showed a remarkable degree of 
sequence homology to the yeast sucrose non-fermenting (Snf1) protein (Carling et al., 
1994). AMPK and Snf1 were demonstrated to be functionally homologous when their 
roles in the regulation of ACC function were shown to be conserved (Woods et al., 
1994). In addition, Snf1 was shown to phosphorylate the SAMS peptide, a relatively 
specific substrate for AMPK, and, like AMPK, to be regulated by reversible 
phosphorylation (Woods et al., 1994). A second α subunit was later identified, named 
α1, with the original subunit renamed α2 (Stapleton et al., 1996). The two isoforms 
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also differed in their tissue distribution, assessed by probing for both mRNA and 
protein. Whilst α1 was evenly distributed throughout tissues, α2 was found to be more 
abundant in skeletal muscle, cardiac muscle and liver (Stapleton et al., 1996). The two 
isoforms, despite being encoded by distinct genes, share a high degree of sequence 
identity of 90% within the kinase domain, and 61% elsewhere (Stapleton et al., 1996). 
 
The α subunits contain conventional kinase domains at their N-termini, with the 
conserved Thr172 residue in their activation loop. Phosphorylation of this residue by 
upstream kinases is required for AMPK activation (Hawley et al., 1996). The C-terminal 
domain (CTD) of the α1 subunit (residues 392-548) was reported to be required for 
interaction with the β and γ subunits (Crute et al., 1998). Further truncation of the α1 
subunit to residue 312 resulted in a large increase in kinase activity, suggesting the 
presence of an autoinhibitory domain (AID) between residues 313 and 392 (Crute et 
al., 1998). This sequence was mapped to residues 313-335 of α1 (residues 311-333 of 
α2) and was predicted to be α-helical in nature (Pang et al., 2007). This helix was 
proposed to bind to the kinase domain, restricting its mobility and resulting in 
autoinhibition (Chen et al., 2009). A short linker region between the AID and the CTD 
appears to interact with the γ subunit and may play a key role in regulation of the 
kinase by nucleotides (Xiao et al., 2011; Chen et al., 2013). Regulation of AMPK is 
discussed further in section 1.4. 
 
1.3.2.2 The β subunit 
In mammals, there are two β isoforms, termed β1 and β2, encoded by two distinct 
genes and sharing 71% sequence identity (Woods et al., 1996a; Thornton et al., 1998) 
Expression of β1 protein is highest in the liver and the brain, whereas β2 protein is 
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most abundant in skeletal muscle (Thornton et al., 1998). The mammalian β subunits 
are closely related to the Sip1/Sip2/Gal83 proteins in budding yeast (Woods et al., 
1996a). These proteins were known to interact with Snf1, the yeast homologue of 
AMPK-α, further supporting the conserved functions of the SNF1 and AMPK complexes 
(Jiang and Carlson, 1997). The C-terminal domain of the β subunit interacts with both 
the α and the γ subunits, functioning as a scaffold for complex assembly (Woods et al., 
1996a). A conserved region in the C-terminus of the AMPK-β subunits (186-270) is 
homologous to the ASC domain present in the Sip1/Sip2/Gal83 proteins (Jiang and 
Carlson, 1997) and is required for binding to the α and γ subunits (Hudson et al., 2003; 
Iseli et al., 2005). 
 
The β subunits also contain a carbohydrate-binding module (CBM), which causes the 
kinase to associate with glycogen particles (Hudson et al., 2003; Polekhina et al., 2003). 
The functional significance of this is unclear, although it may localize AMPK close to 
glycogen-bound substrates, such as glycogen synthase. Alternatively, AMPK activity 
may be regulated by glycogen itself and therefore respond to energy stores in the cell 
(Hardie, 2007). Indeed, AMPK activity is negatively regulated by glycogen both in 
purified cell-free systems (McBride et al., 2009) and in skeletal muscle (Wojtaszewski 
et al., 2002). 
 
The β subunits are also subject to extensive post-translational modifications. Several 
phosphorylation sites have been mapped, including Ser24/25, Ser108 and Ser182 
(Mitchelhill et al., 1997). Phosphorylation at Ser24/25 or Ser182 had no effect on 
AMPK activity. However, mutation of Ser108 reduced AMPK activity (Warden et al., 
2001). In addition, the β subunits are N-terminally myristoylated at Gly2 (Mitchelhill et 
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al., 1997). Mutation of this residue to an alanine increased AMPK activity, as measured 
by immunoprecipitation and subsequent kinase assay (Warden et al., 2001). 
 
1.3.2.3 The γ subunit 
Three mammalian γ subunits are encoded by three distinct genes (Woods et al., 1996a; 
Cheung et al., 2000). The first isoform to be characterized, γ1, lacks a variable N-
terminal extension present in the other two isoforms (Cheung et al., 2000). In contrast 
to the variable N-terminal regions, the C-terminal regions are highly conserved across 
the three isoforms, with sequence identities of 63 to 77% (Cheung et al., 2000). The 
tissue distribution varies amongst the isoforms, with γ1 and γ2 being ubiquitously 
expressed whilst γ3 expression appears to be restricted to skeletal muscle (Cheung et 
al., 2000). Evidence was also presented to suggest that the γ subunit was responsible 
for nucleotide binding, based upon its covalent labelling using the reactive AMP 
analogue 8-azido-[32P]AMP, an effect that was abolished by adding unlabelled AMP 
(Cheung et al., 2000). 
 
The γ subunits contain four tandem repeats of a 60 amino acid sequence motif termed 
a cystathionine β synthase (CBS) motif (Bateman, 1997). These repeats, labelled CBS1-
4 in Fig. 1.2, associate in pairs to form AMP-binding domains (Scott et al., 2004). It was 
proposed that AMPK could bind two AMP molecules with positive co-operativity (Scott 
et al., 2004). A recent crystal structure of AMPK has revealed that the four CBS repeats 
appear to form a flattened disc, with nucleotides binding in the clefts between CBS 
repeats 1 and 2 and CBS repeats 3 and 4 (Xiao et al., 2011). Thus, AMPK contains four 
potential binding sites for nucleotides, which are numbered 1-4 according to the 
number of the CBS repeat carrying an aspartate residue that is positioned to bind the 
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ribose ring of the nucleotide (Kemp et al., 2007). Sites 1 and 3 were proposed to 
reversibly bind AMP or ATP, whilst site 4 was proposed to contain a permanently-
bound AMP molecule. Site 2, which lacks the key aspartate residue, appeared to be 
empty (Xiao et al., 2011). The crystal structure also revealed that ADP could bind at site 
1 or site 3 and played a role in regulation of AMPK activity (Xiao et al., 2011). The 
crystal structures and the regulation of AMPK are discussed in further detail in section 
1.4. 
 
Point mutations in the human γ2 CBS domains are associated with familial 
hypertrophic cardiomyopathy (abnormal thickening of the heart walls) and Wolff-
Parkinson-White (WPW) syndrome (a condition characterized by ventricular pre-
excitation, a premature electrical excitation of the ventricles, the large chambers of 
the heart) (Gollob et al., 2001). These mutations, when introduced in mammalian 
heterotrimers, reduced the sensitivity of the kinase to AMP (Daniel and Carling, 2002) 
and impaired AMP binding to the CBS domains (Scott et al., 2004). Interestingly, the 
mutations also increased the basal activity of the kinase, most likely due to the CBS 
domains also displaying reduced binding of the inhibitor ATP (Daniel and Carling, 2002; 
Hawley et al., 2010). Two of the more severe mutations, R531Q and R384T, were 
associated with death during infancy (Burwinkel et al., 2005; Akman et al., 2007). A 
common feature of the phenotype caused by the mutations is elevated cardiac 
glycogen content which may (when present during foetal development of the heart) 
prevent the normal electrical separation of the atria and ventricles, leading to 
ventricular pre-excitation (Arad et al., 2003; Gollob, 2003; Hardie, 2007). A similar 
mutation in the γ3 subunit of pigs caused elevated glycogen storage in skeletal muscle 
(Milan et al., 2000). 
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1.4 Regulation and crystal structures of AMPK  
1.4.1 Regulation by phosphorylation and AMP 
When AMPK was proposed as the unifying name for HMGR kinase and ACC kinase, it 
was already known that the kinase was allosterically activated by AMP and regulated 
by changes in phosphorylation. Early studies of its role as an HMGR kinase had found 
evidence for an upstream kinase present in the crude preparations, but it was not 
known how its phosphorylation was regulated in vivo. Moore et al (1991) reported that 
treatment of isolated rat hepatocytes with 20 mM fructose caused reciprocal changes 
in the activities of AMPK and ACC over time. Measurement of nucleotide levels in the 
isolated cells revealed a transient increase in the AMP:ATP ratio following addition of 
fructose, which returned to basal values with time. This correlated with a transient 
activation of AMPK and a transient inactivation of ACC. The transient inactivation of 
ACC in response to fructose could be explained by AMP allosterically activating AMPK 
and consequent ACC phosphorylation. However, the changes in AMPK activity, which 
were measured with saturating AMP in the assays (200 µM), could not be explained by 
allosteric activation and must have been due to changes in phosphorylation of AMPK 
itself. Moore et al (1991) also performed experiments with partially purified AMPK 
suggesting that, while AMP seemed to have little effect on dephosphorylation, the 
phosphorylation by the upstream kinase (at that time unidentified) was almost 
completely dependent upon AMP. This paper provided the first evidence that changes 
in AMPK phosphorylation might be mediated by nucleotide levels. However, the AMPK 
preparation used was relatively impure, containing both AMPK and the upstream 
kinase (AMPK kinase or AMPKK), and further investigation into this mechanism 
required purification of the individual components of the kinase cascade. 
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Further support for the idea that AMP promoted phosphorylation of AMPK by the 
upstream kinase came when Weekes et al (1994) succeeded in separating the AMPK 
and AMPKK activities. Phosphorylation of AMPK was dependent upon the addition of 
the upstream kinase and this was stimulated by AMP. It appeared at the time that 
AMP could allosterically activate the upstream kinase (Hawley et al., 1995). An 
important breakthrough came when Thr172, a conserved residue within the activation 
loop of the catalytic subunit, was identified as the target site for the upstream kinase 
(Hawley et al., 1996). Site-directed mutagenesis later confirmed the necessity of this 
residue for AMPK activation (Stein et al., 2000). The upstream kinase was also isolated 
at a far higher purity than that obtained previously, although its identity still remained 
unclear (Hawley et al., 1996). 
 
Work in Saccharomyces cerevisiae identified three kinases (Elm1, Pak1/Sak1 and Tos3) 
that could activate Snf1 (the yeast homologue of AMPK) by phosphorylating Thr210 
(equivalent to Thr172 in mammals) in a  partially redundant manner (Hong et al., 2003; 
Sutherland et al., 2003). The catalytic domains of these kinases are closely related to 
that of the kinase LKB1 in mammals, and it was reported that LKB1 could 
phosphorylate and activate bacterially-expressed AMPK (Hong et al., 2003). 
Subsequently, three groups independently reported that LKB1, acting in a complex 
with STRAD and MO25, was the major upstream kinase acting on AMPK (Hawley et al., 
2003; Woods et al., 2003; Shaw et al., 2004). In contrast with previous suggestions, 
however, it was demonstrated that LKB1 was not allosterically activated by AMP and 
that the effects of AMP on AMPK phosphorylation by the upstream kinase were 
substrate-mediated (Hawley et al., 2003). This view was, however, opposed by Woods 
et al (2003) who did not detect any effect of AMP on promotion of Thr172 
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phosphorylation by LKB1. The original observation that the upstream kinase was 
allosterically activated by AMP was made with less pure preparations and could have 
been due to contaminants.  
 
Although LKB1 appeared to be the major kinase upstream of AMPK in many different 
cell types (Sakamoto et al., 2005; Shaw et al., 2005) it was clear that there must be an 
alternative upstream kinase, as LKB1-null cell lines still retained a basal Thr172 
phosphorylation and AMPK activity. Earlier work had demonstrated that 
Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) purified from pig brain 
could phosphorylate and activate AMPK in cell-free assays (Hawley et al., 1995). 
However, the partially characterised upstream kinase (LKB1) being studied at that time 
was not activated by Ca2+ (Hawley et al., 1995).  In 2005, it was demonstrated that 
CaMKKβ, one of the two isoforms of CaMKK, could also act as an upstream kinase for 
AMPK, with particular relevance in neuronal tissue (Hawley et al., 2005; Hurley et al., 
2005; Woods et al., 2005). In contrast to LKB1, however, AMP did not promote Thr172 
phosphorylation by CaMKKβ (Hawley et al., 2005). The effect of AMP, therefore, 
appeared to be specific for LKB1. 
 
Remarkably, AMP was found to elicit a third effect on AMPK, when it was 
demonstrated that AMP protected the kinase from dephosphorylation by protein 
phosphatases (Davies et al., 1995). Like the effects on promoting phosphorylation, this 
was proposed to be substrate-mediated, for a number of reasons: (i) the IC50 for the 
effect of AMP on dephosphorylation was very similar to the EC50 for allosteric 
activation; (ii) the effect was mimicked by AMP analogues that allosterically activated 
the kinase; (iii) the effect was not specific for a particular phosphatase; and (iv) the 
16 
 
activity of the phosphatases themselves were unaffected by AMP. This was later 
confirmed when it was demonstrated that mutation of the nucleotide binding sites on 
the γ subunit abolished AMP-mediated protection against dephosphorylation (Sanders 
et al., 2007b). The effects of AMP on inhibition of dephosphorylation are therefore 
substrate-mediated.  
 
A model for AMPK regulation was therefore proposed where AMP elicited three 
effects: 
1. allosteric activation of AMPK; 
2. inhibition of dephosphorylation of Thr172 by protein phosphatases; 
3. promotion of phosphorylation of Thr172 by LKB1. 
 
This model suggested that AMPK represented an ultrasensitive system in which small 
increases in the AMP:ATP ratio can produce large changes in the final output (i.e. 
AMPK activity) (Hardie et al., 1999). Later work, however, cast doubt on mechanism 3 
above, proposing instead that the observed increase in net phosphorylation induced 
by AMP was due to contamination of one of the preparations used with a protein 
phosphatase (Sanders et al., 2007b). 
 
1.4.2 Crystal structures of AMPK and regulation by ADP 
Further insight into the regulation of AMPK came from crystal structures of the 
complex. In 2007, the crystal structure of a mammalian heterotrimer, consisting of the 
C-terminal regions of α1 and β2, and full length γ1 with bound AMP, was solved (Xiao 
et al., 2007). The structure revealed that the two pairs of CBS repeats (CBS1:CBS2 and 
CBS3:CBS4) in the γ subunit were arranged in a pseudosymmetrical, head-to-head 
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manner, generating 4 potential nucleotide binding sites in the centre. Sites 1 and 3 
appeared to reversibly bind AMP, site 4 appeared to contain a permanently bound, 
“non-exchangeable”, AMP molecule, while site 2 was empty (in site 2 the key aspartate 
residue is replaced by an arginine, and this was proposed to prevent nucleotide 
binding). Thus it appeared that AMPK could bind 3 molecules of AMP in total. Earlier 
work investigating binding of [14C]AMP to isolated CBS repeats had suggested that 
AMPK could bind only 2 molecules of AMP (Scott et al., 2004). However, this remains 
consistent with the new results (Xiao et al., 2007), which suggested that AMP bound in 
an exchangeable manner at two sites (1 and 3) and in a non-exchangeable manner at a 
third site (site 4), where [14C]AMP would not be able to displace the endogenous, 
unlabelled AMP. 
 
In the crystal structure (Xiao et al., 2007) AMP was bound in pockets at the interfaces 
between the two CBS repeats (CBS1:CBS2 and CBS3:CBS4), making interactions with a 
number of nearby basic residues. Interestingly, mapping of mutations present in Wolff-
Parkinson-White patients onto the γ subunit structure revealed that the majority of 
these involve amino acids in very close proximity to the AMP binding sites (Xiao et al., 
2007). ATP was shown to compete with AMP for binding at sites 1 and 3 but no major 
differences in conformation were observed between the AMP- and ATP- bound forms 
of the γ subunit (Xiao et al., 2007). A simple model was proposed whereby, under basal 
conditions, sites 1 and 3 contain mainly ATP. However, small rises in AMP levels were 
proposed to progressively replace ATP at these sites, resulting in AMPK activation. 
 
Another important development came when ADP, despite having no effect on 
allosteric activation of AMPK, was reported (like AMP) to protect the kinase from 
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dephosphorylation in a substrate-mediated manner (Xiao et al., 2011). Investigation of 
the binding affinities of the two different binding sites for AMP, ADP and ATP was 
performed by using coumarin adducts of ADP and ATP as fluorescent reporters, and 
deriving the binding constants for unlabelled nucleotides by competition assays. The 
results suggested that the two exchangeable sites, 1 and 3, bound AMP, ADP and free 
ATP (ATP4-) with similar affinities but that one (thought to be site 1) bound all three 
nucleotides with ≈30-fold higher affinity (KD = 2.5, 1.5 and 1.7 µM respectively) than 
the other (KD = 80, 50 and 65 µM respectively). Interestingly, the affinities for Mg.ATP
2- 
(KD = 18 and 230 µM at the two sites) were estimated to be 5- to 10-fold lower than 
those for free ATP (ATP4-). Since the bulk of cellular ATP is present as the Mg.ATP2- 
complex, this provides a partial explanation as to how AMP and ADP can compete with 
the much higher levels of ATP normally present in the cell. Based upon the nucleotide 
concentrations giving half-maximal effects on allosteric activation and protection 
against dephosphorylation, and comparing these to the modelled binding affinities, it 
was proposed that binding of AMP or ADP to the lower affinity binding site, (thought 
to be site 3), was responsible for protection against dephosphorylation, while binding 
of AMP at the higher affinity binding site (thought to be site 1) was responsible for 
allosteric activation of the kinase.  
 
The more complete crystal structure for AMPK that was obtained in this study, 
consisting of the majority of the α subunit, the C-terminus of the β subunit and the 
complete γ subunit, provided further clues as to how AMPK was regulated by 
nucleotide binding (Xiao et al., 2011). In the structure of the active complex 
(phosphorylated on Thr172) that was determined, the activation loop containing 
Thr172 could be seen to bind to the C-terminal domains of the α and β subunits, and 
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this was proposed to limit access of protein phosphatases to Thr172. Another region of 
the α subunit, called the α hook (part of the extended linker that connects the auto-
inhibitory domain and the C-terminal domain) appeared to interact with the molecule 
of AMP that was bound in site 3. This was proposed to stabilize the association of the α 
and β C-terminal domains with the activation loop, thus protecting the kinase against 
dephosphorylation when AMP was bound in site 3. Based on previous structures 
(lacking the α-hook) that had ATP bound at site 3, it was thought that binding of ATP at 
site 3 would disrupt α-hook binding to site 3, weakening the association of the α/β C-
terminal domains with the activation loop and allowing access of phosphatases to 
Thr172. Further modelling suggested that ADP binding at site 3 would not disrupt 
binding of the α-hook, explaining how ADP protects against dephosphorylation, like 
AMP. This model was supported by mutation of residues in the β subunit that would 
be predicted to weaken the interaction between the α/β C-terminal domains and the 
activation loop, which exhibited an increased rate of dephosphorylation. Mutation of 
residues within the α-hook region also removed the protective effects of AMP and ADP 
on dephosphorylation. 
 
The proposed model, therefore, was that the γ subunit of mammalian AMPK contains 
four potential nucleotide binding sites although one (site 2) appears to be unused. Site 
4 contains a permanently bound, non-exchangeable, AMP molecule, which is 
presumably inserted during synthesis and initial folding of the heterotrimeric complex. 
Sites 1 and 3 reversibly bind AMP, ADP or ATP, with one site (thought to be site 1) 
having a higher affinity for all three nucleotides. Binding of AMP at site 1 was proposed 
to cause allosteric activation, while binding of AMP or ADP at site 3 was proposed to 
cause protection of Thr172 from dephosphorylation. This was thought to be due to 
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increased association of the α-hook region with AMP or ADP bound in site 3, leading to 
stabilization of the interaction between the α/β C-terminal domains and the activation 
loop, restricting access of protein phosphatases to Thr172 (Xiao et al., 2011). 
 
A somewhat different model has also been proposed. The ATP-bound crystal 
structures outlined above were determined by soaking AMP-bound crystals with ATP. 
Using this method, no conformational changes were apparent when comparing the 
AMP- and ATP-bound structures (Xiao et al., 2007). However, when the core of the 
heterotrimer was crystallized independently with AMP or ATP, small changes in the 
conformation of the γ subunits were observed (Chen et al., 2012). In contrast to the 
previous structure (Xiao et al., 2011), ATP was able to bind at site 4 (Chen et al., 2012), 
which had previously been proposed to be a “non-exchangeable” site for AMP (Xiao et 
al., 2007). It was also suggested (Chen et al., 2012) that binding of ATP site 4 would 
preclude binding of any nucleotide at site 3. Mutation of site 1, the proposed allosteric 
regulatory site, was also reported to have no effect on allosteric activation by AMP, 
while this was completely abolished by mutation of sites 3 or 4 (Chen et al., 2012). The 
conformational changes observed upon AMP binding to the γ subunit were most 
apparent around site 3, and the authors suggest that this conformational change may 
contribute to the allosteric activation of AMPK by AMP (Chen et al., 2012). 
 
The role of the α-hook region in the α-subunit linker has also been questioned. The α 
subunit of AMPK contains an auto-inhibitory domain (AID), the removal of which 
increases kinase activity (Pang et al., 2007). The AID was proposed to comprise three 
α-helices which bind to the kinase domain, promoting an “open” conformation and 
reducing kinase activity (Chen et al., 2009). Mutation of key residues at this interface 
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prevented allosteric activation by AMP and the authors proposed that binding of AMP 
at the γ subunit disrupts the interaction between the AID and the kinase domain, thus 
activating AMPK (Chen et al., 2009). Rather than the α-hook interacting with the γ 
subunit, a small section of the α-subunit linker region, termed the α-RIM (regulatory-
subunit-interacting motif) was proposed to be important for transmitting the signal 
from AMP binding at the γ subunit to the kinase domain (Chen et al., 2013). Mutation 
of residues at the interface between the α-RIM and the kinase domain abolished 
allosteric activation by AMP, whereas mutation of the proposed α-hook region had no 
effect (Chen et al., 2013). However, the authors did not examine the effects of α-RIM 
mutation on protection against dephosphorylation, an effect lost in α-hook mutants 
which themselves had no effect on allosteric activation (Xiao et al., 2011). 
 
Interestingly, ADP was originally proposed to be an activating ligand for the HMGR 
kinase, (Brown et al., 1975) one of the activities that was later renamed as AMPK. 
However HMGR kinase was later shown to be much more sensitive to AMP (Ferrer et 
al., 1985) and the original results were attributed to contamination of the crude 
preparations of HMGR kinase used with adenylate kinase, which would generate AMP 
from ADP. Prior to the observations that ADP could protect AMPK from 
dephosphorylation (Xiao et al., 2011), ADP was also reported to bind to the AMPK 
orthologue from the fission yeast Schizosaccharomyces pombe (Jin et al., 2007). 
Binding occurred at two sites, one of which was equivalent to site 4 and was unique for 
ADP binding, while the other (equivalent to site 3) was also able to accept either AMP 
or ATP. However, the functional significance of these results remains unknown, 
because the regulation of the S. pombe enzyme by adenine nucleotides has never been 
studied. The SNF1 complex, the AMPK orthologue from budding yeast (S. cerevisiae, 
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which is only very distantly related to S. pombe) is not allosterically activated by AMP 
(Mitchelhill et al., 1994; Woods et al., 1994). However, activation of the complex in 
intact cells starved for glucose, which is due to phosphorylation at Thr210 (equivalent 
to Thr172 on AMPK) correlated with large decreases in cellular ATP and increases in 
ADP and AMP (Wilson et al., 1996). This was later demonstrated to be due to a 
decreased rate of dephosphorylation of Thr210  by protein phosphatases, rather than 
an increase in the rate of phosphorylation by upstream kinases (Rubenstein et al., 
2008). The signal for this remained unclear, as AMP was shown to have no effect on 
dephosphorylation of the SNF1 complex (Sanders et al., 2007b). It has recently been 
demonstrated that dephosphorylation of the SNF1 complex was regulated by ADP, 
rather than AMP (Mayer et al., 2011). The mechanism for this seems to be similar to 
that in the mammalian enzyme, with ADP promoting association of the activation loop 
with the Snf1 and Gal83 subunits (equivalent to the α and β subunits in mammals) and 
preventing access of phosphatases. The mechanism is not identical, however, because 
AMP has no effect on dephosphorylation of Thr210. 
 
1.4.3 Promotion of phosphorylation by AMP and ADP 
Although a proposed aspect of the original regulatory mechanism for AMPK by AMP 
(Moore et al., 1991), the role of AMP to promote phosphorylation of Thr172 had been 
challenged, as discussed above (Sanders et al., 2007b). However, work from the Kemp 
laboratory suggested that Thr172 phosphorylation and activation of AMPK could 
indeed be promoted by AMP, although only when the β subunit was myristoylated on 
Gly2 (Oakhill et al., 2010). This effect was demonstrated for both LKB1 and CaMKKβ, in 
contrast to the previous work from Hawley et al (2005) where no effect of AMP on 
phosphorylation by CaMKKβ had been observed. Mutation of Gly2 had no effect on 
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either allosteric activation of AMPK or the ability of AMP to protect against 
dephosphorylation. During attempts to define which nucleotide binding site was 
responsible for promotion of phosphorylation, mutation of the conserved aspartate 
residues in sites 1, 3, and 4 all resulted in a reduction of both promotion of 
phosphorylation and allosteric activation by AMP. This suggests that there is a close 
interaction between the three nucleotide binding sites, casting doubt on the proposals 
that a specific effect can be attributed to a particular binding site. Positive                    
co-operativity of binding of AMP or ATP to a construct containing all 4 CBS motifs of 
AMPK-γ2 had previously been observed (Scott et al., 2004), although this has not been 
reported in other studies. 
 
The myristoyl group of the β subunit was known to promote AMPK association with 
cellular membranes (Warden et al., 2001) and a number of AMPK substrates are 
membrane-associated, including ACC2 and HMGR. Glucose deprivation induced Thr172 
phosphorylation and membrane association of wild-type AMPK, with the effect being 
lost with the non-myristoylatable G2A mutant (Oakhill et al., 2010). A myristoyl-switch 
mechanism for AMPK regulation was proposed, similar to that of other proteins, such 
as recoverin (Ames et al., 1997). In the model for AMPK, high ATP levels result in the 
myristoyl group associating with the kinase domain and preventing access of upstream 
kinases to Thr172. In response to cellular stresses, AMP replaces ATP at the γ subunit 
and causes a release of the myristoyl group, promoting membrane association (thus 
targeting AMPK to its substrates) and also promoting Thr172 phosphorylation by LKB1 
or CaMKKβ. The continued presence of AMP also causes allosteric activation and 
protects against dephosphorylation. Rising ATP levels reverses the switch and 
inactivates AMPK (Oakhill et al., 2010). 
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 In addition to AMP, ADP was also reported to promote phosphorylation of AMPK by 
CaMKKβ (Oakhill et al., 2011). The concentrations of AMP (73 µM) and ADP (56 µM) 
giving half-maximal effects on the promotion of phosphorylation by CaMKKβ were 
similar. The promotion of phosphorylation by ADP when LKB1 was the upstream kinase 
was not investigated. Mutation of the aspartate residues in nucleotide binding sites 1 
and 3 (but not 4) prevented ADP from promoting Thr172 phosphorylation, as did use 
of a truncated α subunit, rather than an αβγ heterotrimer. The effect was also lost 
with a non-myristoylated G2A mutant of the β subunit. This suggested that β subunit 
myristoylation, and nucleotide binding sites 1 and 3, were required for promotion of 
Thr172 phosphorylation. The current model for AMPK regulation is shown in Fig. 1.3. 
 
Figure 1.3: Regulation of AMPK 
Proposed mechanism by which AMP and ADP regulate AMPK, based on Xiao et al 
(2011) and Oakhill et al (2011): (1) binding of AMP/ADP to AMPK promotes Thr172 
phosphorylation; (2) binding of AMP or ADP protect Thr172 against dephosphorylation 
by protein phosphatases; (3) binding of AMP causes allosteric activation of AMPK. All 
three effects are antagonized by binding of ATP. 
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1.5 Activators of AMPK 
AMPK is activated in mammalian cells primarily during energetic stresses that increase 
the AMP:ATP and ADP:ATP ratios in the cell. This can occur either by increasing ATP 
consumption (e.g. muscle contraction during exercise) or by decreasing ATP 
production (e.g. ischaemia or hypoxia). AMPK is also activated by a large number of 
drugs and xenobiotics (Hardie et al., 2012) and hormones (Kahn et al., 2005). The 
diverse mechanisms available to activate AMPK are discussed below. 
 
1.5.1 Activation of AMPK by exercise 
The classical, physiological mode of AMPK activation is via muscle contraction during 
exercise, observed in both rodents (Winder and Hardie, 1996) and humans 
(Wojtaszewski et al., 2000) in an intensity-dependent manner. Both AICAR (discussed 
below) and contraction caused an increase in muscle glucose uptake coupled with 
AMPK activation (Hayashi et al., 1998). The activation of AMPK in response to muscle 
contraction, and the associated glucose uptake, is dependent upon LKB1 (Sakamoto et 
al., 2005). The AMPK-related kinases, which are also targets of LKB1, are not activated 
by muscle contraction, suggesting that the LKB1-dependent effects on glucose uptake 
in skeletal muscle are mediated by AMPK (Sakamoto et al., 2004). AMPK may also be 
responsible for other beneficial effects of exercise, including increased mitochondrial 
biogenesis (Zong et al., 2002) and fatty acid oxidation (Aschenbach et al., 2004). 
 
 
 
 
26 
 
1.5.2 Activation of AMPK by other metabolic stresses 
In addition to exercise, AMPK is regulated by other metabolic stresses, such as glucose 
deprivation (Salt et al., 1998). Although total glucose withdrawal from cells would be 
unlikely to happen in vivo, specialized glucose-sensing cells in the pancreas (Salt et al., 
1998; da Silva Xavier et al., 2003; Beall et al., 2010) and the hypothalamus (Minokoshi 
et al., 2004; Beall et al., 2012) respond to glucose levels and regulate hormone 
secretion in an AMPK-dependent manner. Hypoxia, by inhibiting mitochondrial 
function and decreasing ATP levels, also activates AMPK (Evans et al., 2005). Once 
activated, AMPK phosphorylates and inhibits K+ channels in carotid body type I cells 
(Ross et al., 2011; Wyatt et al., 2007), resulting in membrane depolarization, increased 
intracellular calcium levels and neurosecretion. The secreted neurotransmitters 
increase afferent discharge to the central nervous system and increase breathing. 
 
1.5.3 Activation of AMPK by hormones 
AMPK is regulated by a range of hormones secreted from adipocytes, termed 
adipokines (Kahn et al., 2005). Leptin, produced in proportion to the fat levels of the 
body and generally acting as an appetite suppressor, increases fatty acid oxidation and 
glucose uptake in skeletal muscle in an AMPK-dependent manner (Minokoshi et al., 
2002). Leptin has a distinct role in the hypothalamus, where it decreases AMPK activity 
and thus acts to suppresses appetite (Minokoshi et al., 2004). AMPK, as well as 
dictating local responses to energy depletion, may thus also play a key role in 
regulating global energy intake via changes in appetite. 
 
Adiponectin, released by adipocytes in a manner inversely proportional to body fat, 
also regulates AMPK in the hypothalamus, although in this case it activates the kinase 
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to promote feeding (Kubota et al., 2007). Similarly, the hormone ghrelin also increases 
AMPK activity in the hypothalamus (Andersson et al., 2004) in a CaMKKβ-dependent 
manner (Anderson et al., 2008). The activation of AMPK by ghrelin in response to 
hunger is proposed to form part of a positive feedback loop promoting Ca2+ release 
from intracellular stores, maintaining AMPK activity and release of the appetite-
stimulating peptides AGRP and NYP. This imparts a form of memory to the circuit, with 
the circuit being reset by leptin released from adipocytes (Yang et al., 2011). 
 
1.5.4 Activation of AMPK by drugs and xenobiotics 
AMPK is activated by a diverse range of compounds (Fig 1.4), acting by a variety of 
mechanisms. Key to the understanding of the mode of action of these compounds was 
the development of HEK293 cells expressing an AMP-insensitive mutant of the AMPK-
γ2 subunit, the R531G mutant (Hawley et al., 2010). This residue, which is mutated in 
some cases of WPW syndrome, is located in CBS repeat 4 and its mutation to glycine 
disrupts nucleotide binding to the γ subunit, rendering the kinase insensitive to 
changes in nucleotide levels. Compounds that activated complexes containing both 
wild-type γ2 and the R531G mutant of γ2 are clearly operating through AMP-
independent mechanisms, whereas those that activated only wild-type γ2 complexes 
are dependent upon changes in nucleotides (Hawley et al., 2010). The compounds that 
activated the wild-type cells only were also demonstrated to increase the ADP:ATP 
ratio and to alter mitochondrial function, both hallmarks of disrupted energy status 
(Hawley et al., 2010). 
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Figure 1.4: Drugs and xenobiotics acting on AMPK 
A wide range of drugs and xenobiotics activate AMPK, some of which are shown here. 
 
1.5.4.1 AICAR 
The first compound identified to activate AMPK in intact cells and in vivo was the 
nucleoside 5-aminoimidazole-4-carboxamide riboside (AICAR). AICAR enters the cell 
where it is converted to the monophosphate form 5-aminoimidazole-4-carboxamide 
ribonucleoside monophosphate (ZMP) (Sabina et al., 1985), which acts as an AMP-
mimetic and activates AMPK both by allosteric activation and protection against 
Thr172 dephosphorylation (Corton et al., 1995). As expected, AICAR had no effect on 
the AMP-insensitive R531G-γ2 cells (Hawley et al., 2010). AICAR has been used 
extensively to characterize the downstream effects of AMPK and beneficial effects 
related with this in a number of pathological conditions. AICAR can reverse some of 
the defects associated with the metabolic syndrome and diabetes, such as improved 
glucose tolerance and uptake, in a variety of diabetic animal models, including the 
ob/ob mouse (Song et al., 2002) and the fa/fa rat (Bergeron et al., 2001). In addition, 
AICAR treatment can also induce the expression of genes linked to oxidative 
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metabolism and increased the running endurance of mice independently of any 
training (Narkar et al., 2008). Given these benefits, AICAR has been suspected to be 
used as a doping agent by professional cyclists (Benkimoun, 2009) and subsequently 
banned by anti-doping agencies (Thomas et al., 2010). As an AMP mimetic, AICAR can 
also regulate other AMP-sensitive enzymes. AICAR inhibits fructose-1,6-
bisphosphatase to reduce gluconeogenesis (Vincent et al., 1991) and stimulates 
glycogen phosphorylase to increase glycogenolysis (Longnus et al., 2003). Thus AICAR, 
whilst a useful research tool for investigating AMPK, may be unsuitable for clinical use 
given its lack of specificity and poor oral availability. 
 
1.5.4.2 A769662 and salicylate 
A769662, identified in a high throughput cell-free screen by Abbott laboratories, is a 
direct activator of AMPK (Cool et al., 2006). A769662 increases AMPK activity both by 
allosteric activation and by protecting Thr172 against dephosphorylation (Göransson 
et al., 2007; Sanders et al., 2007a). Unlike AMP, A769662 activation does not require 
the AMP-binding sites on the γ subunit, but appears to bind to a region containing the 
Ser108 residue of the β subunit (Sanders et al., 2007a). The identity of the β subunit 
isoform also appears to be important for activation by A769662, as the compound was 
demonstrated to primarily activate complexes containing β1, although activation of β2 
complexes is possible at high concentrations of the compound (Scott et al., 2008; 
Hawley et al., 2012). Treatment of ob/ob mice with A769662 caused a reduction in 
plasma glucose and triglyceride levels, as well as decreased expression of 
gluconeogenic and lipogenic genes (Cool et al., 2006). A769662 has poor oral 
availability (Cool et al., 2006) and may possess AMPK-independent functions (Moreno 
et al., 2008), limiting its use as a therapeutic agent. 
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Salicylate, a compound present in willow bark but also produced by other plants as a 
defence mechanism in response to infection, has been used in traditional medicine for 
millennia. For current medicinal use, it has been replaced by aspirin or by salsalate, 
both of which are broken down to form salicylate following oral administration. Both 
aspirin and salicylate have shown promise for the treatment of type 2 diabetes 
(Goldfine et al., 2010; Hundal et al., 2002). Although salicylate inhibits other targets, 
including prostaglandin synthesis by cyclo-oxygenases (Vane, 1971) and IKKβ (Yin et al., 
1998), it has recently been demonstrated to directly activate AMPK, independent of 
changes in cellular energy (Hawley et al., 2012). The binding site of salicylate appears 
to overlap with that of A769662, as they both require the Ser108 site of the β-subunit 
and activate β2-containing complexes poorly. Additionally, salicylate can antagonize 
allosteric activation by A769662, suggesting that they are competing for binding at the 
same site. Salicylate, like A769662, allosterically activates AMPK (albeit to a small 
extent) and protects Thr172 from dephosphorylation by protein phosphatases. 
Salicylate treatment can alter in vivo metabolism, causing a switch from carbohydrate 
to fat utilization and decreased serum levels of fatty acids, with both effects requiring 
the presence of the β1 isoform of AMPK (Hawley et al., 2012). However, some of the 
beneficial effects of salicylate, including improved glucose tolerance, occurred 
independently of AMPK, suggesting that other pathways are also important in dictating 
the response to salicylate. In addition to the changes in metabolic function, it is also 
possible that AMPK is mediating some of the other benefits attributed to aspirin, such 
as anti-inflammatory effects and protection against cancer (Rothwell et al., 2011). 
 
 
 
31 
 
1.5.4.3 Calcium 
CaMKKβ, one of the Thr172 kinases, is activated in response to rising levels of calcium 
(Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005). Although CaMKKβ is most 
highly expressed in neural tissue, there is evidence that the CaMKKβ-AMPK pathway 
operates in other tissues, including in endothelial cells treated with thrombin 
(Stahmann et al., 2006) and in T cells in response to antigen (Tamás et al., 2006). 
Pharmacological agents that increase intracellular calcium are potent AMPK activators, 
acting independently of LKB1 and changes in nucleotide levels. These include the 
calcium ionophores A23187 (Hawley et al., 2010) and ionomycin (Hurley et al., 2005) 
as well as caffeine (Jensen et al., 2007). 
 
1.5.4.4 Metformin, phenformin and galegine 
Metformin is one of the most widely prescribed drugs in the world, being the first-
choice treatment for type 2 diabetes (Rena et al., 2013). Metformin, along with the 
related compound phenformin, is derived from galegine, a natural product of Galega 
officianalis (French lilac, also known as goat’s rue) (Hardie et al., 2012). Extracts of this 
plant have been used for centuries to treat symptoms of diabetes.  
 
Metformin was shown to reduce hepatic glucose production in type 2 diabetics by 
reducing gluconeogenesis (Hundal et al., 2000) but the molecular mechanism was 
unclear. Metformin was demonstrated to activate AMPK in intact cells, resulting in 
decreased glucose production and increased glucose uptake (Zhou et al., 2001) and 
both phenformin and galegine are potent AMPK activators (Hawley et al., 2003; 
Mooney et al., 2008). Metformin had no effect on in vitro AMPK activity, suggesting 
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that the effects were indirect (Hawley et al., 2002). A candidate for this was changes in 
cellular nucleotide levels, as metformin had been shown to inhibit complex I of the 
mitochondrial chain (El-Mir et al., 2000; Owen et al., 2000) and this was confirmed 
using the R531G-γ2 mutant cell line (Hawley et al., 2010). A similar mechanism of 
action was demonstrated for both phenformin and galegine (Hawley et al., 2010). The 
effects of metformin appeared to be AMPK-dependent as they were reversed by the 
addition of compound C, an AMPK inhibitor (Zhou et al., 2001). Compound C, however, 
is a relatively non-specific inhibitor and may have several off-target effects (Bain et al., 
2007). Further support for AMPK as the key mediator of the beneficial effects of 
metformin came from studies where LKB1 has been genetically deleted from the liver 
of adult mice (Shaw et al., 2005). These mice had hyperglycaemia and impaired 
glucose tolerance as well as increased expression of gluconeogenic and lipogenic 
genes. Metformin, whilst reducing the blood glucose of wild-type mice or ob/ob mice, 
had no effect on mice which had lost expression of LKB1 in the liver (Shaw et al., 2005).  
 
Controversy over the role of AMPK remains, as mice with both catalytic subunits of 
AMPK deleted from the liver displayed normal responses to metformin (Foretz et al., 
2010). In the same study, hepatocytes from mice lacking liver LKB1 also displayed 
normal responses to metformin (Foretz et al., 2010). A possible explanation of this is 
that other AMP-sensitive enzymes, such as fructose-1,6,-bisphosphatase, exist and 
treatment with metformin could reduce hepatic glucose production through these 
pathways (Hardie et al., 2012). In addition, metformin was demonstrated to inhibit 
TORC1 signalling (Kalender et al., 2010) and glucose uptake independently of AMPK in 
skeletal muscle (Kalender et al., 2010; Turban et al., 2012). One recent study has 
proposed that AMP produced in response to metformin inhibits adenylate cyclase, 
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reducing cAMP levels and PKA activity, blocking glucagon-mediated hepatic glucose 
output in an AMPK-independent manner (Miller et al., 2013).  
 
However, a recent study from the Steinberg laboratory has suggested that AMPK does 
play a major role in the response to metformin (Fullerton et al., 2013). Mice with 
alanine knock-in mutations at the site phosphorylated by AMPK in both ACC1 (Ser79) 
and ACC2 (Ser212, equivalent to Ser79), termed double knock-in (dKI), were generated 
and displayed increased hepatic lipogenesis and decreased fatty oxidation compared 
to wild-type mice, resulting in elevated hepatic lipid content. Excess lipid storage is 
associated with insulin resistance and the dKI mice were found to be hyperglycaemic, 
hyperinsulinemic, glucose intolerant and insulin resistant, but not obese. In mice made 
obese by a high-fat diet (HFD), long-term treatment with metformin reduced hepatic 
lipid content and improved insulin-sensitivity in wild-type, but not dKI, mice. While 
Foretz (2010) and Miller (2013) reported AMPK-independent effects of metformin, 
these were short-term treatments and were performed under fasting conditions in the 
absence of insulin stimulation. It seems that phosphorylation and inhibition of ACC by 
AMPK plays a crucial role in mediating the long-term beneficial effects of metformin in 
type 2 diabetes, which are likely due to insulin-sensitization (Fullerton et al., 2013). 
 
1.5.4.5 Thiazolidinediones 
Another class of anti-diabetic drugs, the thiazolidinediones (TZDs), including 
troglitazone (LeBrasseur et al., 2006), pioglitazone (Saha et al., 2004) and rosiglitazone 
(Fryer et al., 2002) increase AMPK activity. TZDs are known to bind to and activate the 
transcription factor PPAR-γ. One effect of this is to trigger release of adiponectin, an 
insulin-sensitizing hormone which is itself an activator of AMPK (Yamauchi et al., 
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2002). The improvements in glucose tolerance associated with adiponectin are AMPK-
dependent (Yamauchi et al., 2002). Transcriptional changes and increased adiponectin 
release via PPAR-γ action are likely to be the main method by which the TZDs elicit 
their beneficial effects on diabetes, because knocking out adiponectin abolished any 
beneficial effects of the TZDs (Kubota et al., 2006). However, the TZDs also acutely 
activate AMPK by disrupting mitochondrial function (Brunmair et al., 2004; Fryer et al., 
2002; Hawley et al., 2010) and caused rapid glucose uptake and fatty acid oxidation 
that are unlikely to be explained by changes in transcription and could be AMPK-
dependent (LeBrasseur et al., 2006). 
 
1.5.4.6 Other plant compounds 
There are a large number of natural plant products that can increase AMPK activity, 
many of which, like salicylate, have been used in traditional medicine. These include 
resveratrol, present in red wine and grapes (Baur et al., 2006), berberine, from Chinese 
Goldthread (Turner et al., 2008), and quercetin, present in a number of fruits and 
vegetables (Ahn et al., 2008). How these diverse, structurally-unrelated, compounds 
were activating the kinase was, in many cases, unclear although some studies had 
suggested that it could be due to disruption of mitochondrial function (Turner et al., 
2008). Use of the R531G-γ2 cell line demonstrated that most of these compounds 
were acting in an AMP-dependent manner, since they did not activate the AMP-
insensitive R531G mutant (Hawley et al., 2010). In addition, the classical mitochondrial 
poisons dinitrophenol (DNP) and oligomycin operated in a similar manner. 
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1.6 Processes regulated by AMPK 
Although first characterized as a regulator of lipid metabolism, AMPK is now thought 
to act as the major energy sensor of the eukaryotic cell and, once activated, regulates 
a wide variety of both metabolic and non-metabolic pathways (Fig. 1.5). AMPK inhibits 
anabolic pathways and activates catabolic pathways to protect the cell from further 
energy depletion and to redress the energy imbalance. 
 
 
 
Figure 1.5: Processes regulated by AMPK 
AMPK, in response to changes in energy levels, acts to redress the cellular energy 
balance by regulating a wide range of catabolic and anabolic pathways. Figure adapted 
from Hardie et al., 2012. 
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1.6.1 Carbohydrate and lipid metabolism 
1.6.1.1 Lipid metabolism 
ACC and HMGR were the first two substrates identified for AMPK (Beg et al., 1973; 
Carlson and Kim, 1973). ACC converts acetyl-CoA to malonyl-CoA, the first committed 
step in fatty acid synthesis. AMPK phosphorylates ACC1 on Ser79, reducing its catalytic 
activity thus inhibiting fatty acid synthesis (Davies et al., 1990, 1992). A second isoform 
of ACC, ACC2, is also phosphorylated and inactivated by AMPK (Winder et al., 1997). 
ACC2 is associated with mitochondrial membranes and is thought to increase malonyl-
CoA levels at the mitochondrial surface (Abu-Elheiga et al., 2000). Malonyl-CoA is an 
inhibitor of carnitine:palmitoyl-CoA transferase 1 (CPT1), which mediates the entry of 
long-chain fatty acids into the mitochondria for fatty acid oxidation. Inhibition of ACC2 
activity by AMPK phosphorylation therefore reduces the levels of malonyl-CoA and 
increases fatty acid oxidation (Merrill et al., 1997). It is likely, however, that there is 
redundancy between the two isoforms of ACC. Mice with alanine knock-in mutations 
at the site phosphorylated by AMPK in either ACC1 or ACC2 displayed normal hepatic 
lipogenesis and fatty acid oxidation compared with wild-type mice (Fullerton et al., 
2013). In contrast, mice with alanine knock-in mutations at both sites (the dKI mice 
discussed in Section 1.5.4.4) displayed increased hepatic lipogenesis and reduced fatty 
acid oxidation (Fullerton et al., 2013), suggesting that the pools of malonyl-CoA 
generated by ACC1 and ACC2 are not separate. 
 
AMPK also phosphorylates and inactivates HMGR, a key enzyme in the cholesterol 
synthesis pathway (Carling et al., 1987; Clarke and Hardie, 1990). Activation of AMPK 
therefore reduces fatty acid synthesis and cholesterol synthesis, whilst increasing fatty 
acid oxidation. 
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1.6.1.2 Glucose and glycogen 
AMPK can increase the rate of glucose uptake via glucose transporter type 4 (GLUT4). 
Glucose uptake is mediated by increased translocation of GLUT4 from intracellular 
vesicles to the plasma membrane; this is considered a rate-limiting step (Steinberg and 
Kemp, 2009). Fusion of these storage vesicles with the plasma membrane requires 
members of the Rab family of GTPases to be in their GTP bound state. These Rabs are 
held in their inactive state by the action of Rab GTPase activating proteins (GAPs), 
including TBC1D4 (also known as Akt substrate of 160 kDa, AS160) and TBC1D1, which 
associate with GLUT4 vesicles. Akt (also known as PKB) phosphorylates TBC1D4 in 
response to insulin, and AMPK, in response to muscle contraction, phosphorylates 
TBC1D1, with phosphorylation at these sites inducing 14-3-3 binding (Chen et al., 
2008). Phosphorylation of TBC1D4 at the PKB site is important in regulating insulin-
mediated glucose uptake (Chen et al., 2011). By analogy with TBC1D4, it seems likely 
that AMPK phosphorylation of TBC1D1 and subsequent 14-3-3 binding would inhibit 
the GAP activity of TBC1D1, resulting in GTP-loaded Rabs and increased fusion of 
GLUT4 vesicles with the plasma membrane (O’Neill, 2013). Recent work has also 
proposed a role for PIKfyve (FYVE domain-containing phosphatidylinositol 3-phosphate 
5-kinase) in mediating exercise-induced glucose uptake. PIKfyve catalyses the 
production of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2), an important 
regulator of vesicle trafficking. Inhibition of PIKfyve catalytic activity reduced glucose 
uptake and AMPK-mediated phosphorylation of PIKfyve promoted its association with 
endosomal vesicles (Liu et al., 2013). Interestingly, PKB phosphorylates the same site 
on PIKfyve as AMPK, and this is implicated in controlling insulin-mediated glucose 
uptake (Berwick et al., 2004). 
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Whether AMPK is the only regulator of contraction-mediated glucose uptake is not 
completely clear. The loss of AMPK-α2 in mouse muscle abolished the effects of AICAR 
on glucose uptake, but not the effects of contraction, while the loss of AMPK-α1 had 
no effect (Jørgensen et al., 2004b). In contrast, the loss of LKB1 from mouse muscle 
completely abolished the effects of AICAR on glucose uptake, while the effects of 
contraction were greatly reduced although not completely abolished (Sakamoto et al., 
2005). Interestingly, muscle-specific deletion of the AMPK-β1 and -β2 subunits in mice 
was reported to have no effect on insulin-mediated glucose uptake, but completely 
prevented any contraction-mediated increases and had a severe effect on the ability of 
the mice to exercise (O’Neill et al., 2011). Although these latter results suggest that 
activation of AMPK may be entirely responsible for contraction-stimulated glucose 
uptake in muscle, the effects of knocking out both catalytic subunits (α1 and α2) in 
muscle have not yet been reported. 
 
AMPK also increases the activity of the glucose transporter GLUT1. While the 
molecular mechanism for this is not currently known it appears to involve activation of 
GLUT1 already located at the plasma membrane, rather than its translocation to the 
membrane (Barnes et al., 2002). 
 
AMPK down-regulates the expression of a number of gluconeogenic genes, including 
glucose-6-phosphatase, by controlling the activity of transcription factors, including 
CRTC2 (CREB-regulated transcription co-activator 2) (Koo et al., 2005). AMPK has also 
been reported to inhibit the function of class IIa histone deacetylases by promoting 
their nuclear exclusion (Mihaylova et al., 2011). These deacetylates act on FOXO 
transcription factors and promote the expression of gluconeogenic genes. 
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AMPK phosphorylates and inhibits glycogen synthase, causing decreased rates of 
glycogen synthesis (Jørgensen et al., 2004a). One function of the carbohydrate-binding 
module of the β subunit may be to target AMPK to glycogen synthase. AMPK can also, 
in certain contexts, increase the rate of glycolysis (the conversion of glucose into 
pyruvate), by phosphorylating and activating the PFKFB2 and PFKB3 isoforms of 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Marsin et al., 2000, 2002). This 
enzyme catalyses the generation of fructose-2,6-bisphosphate, an allosteric activator 
of the glycolytic enzyme phosphofructokinase. 
 
1.6.2 Cell growth and protein synthesis 
Cell growth and the production of new proteins consume large amounts of cellular 
energy. A key regulator of these processes, the mTOR complex 1 (mTORC1, discussed 
further in section 1.8), controls protein synthesis and cell growth in response to 
nutrients and growth factors (Zoncu et al., 2011b). In addition, the activity of mTORC1 
is also sensitive to the energy status of the cell, which it senses indirectly via the LKB1-
AMPK pathway. AMPK phosphorylates and activates TSC1/2, an upstream negative 
regulator of mTORC1, and this plays a key role in determining the cellular response to 
energy starvation (Inoki et al., 2003b). Interestingly, cells lacking TSC2 still respond to 
energy stress, although less so than wild-type cells, which suggested that additional 
AMPK targets may be involved in regulating mTORC1 activity (Hahn-Windgassen et al., 
2005; Gwinn et al., 2008). It was subsequently demonstrated that AMPK directly 
influences the mTORC1 complex by phosphorylating the Raptor subunit, causing 
binding of 14-3-3 proteins and inhibition of mTOR catalytic activity (Gwinn et al., 2008). 
Mutation of the AMPK phosphorylation sites on Raptor prevents TSC2/p53 null cells 
from undergoing growth arrest in response to AICAR, as well as sensitizing cells to 
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apoptosis in response to energy stress (Gwinn et al., 2008). AMPK therefore couples 
cellular energy status to protein synthesis. 
 
1.6.3 Autophagy and mitochondrial biogenesis 
Autophagy is the controlled degradation of damaged or dysfunctional cellular 
components, such as organelles or proteins, in order to recycle valuable components 
such as amino acids and lipids. It is a key survival response during times of stress or 
starvation. Autophagy involves the formation of large vesicles that engulf cytoplasmic 
components, which then fuse with lysosomes to form autophagosomes. The contents 
of the autophagosome are digested by lysosomal hydrolases, providing a source of 
amino acids and nutrients when these are unavailable from elsewhere (reviewed in 
Mizushima et al., 2008). In yeast, autophagosomal formation is initiated by a 
conserved complex containing the kinase Atg1 and its subunits Atg13 and Atg17. The 
mammalian orthologue of Atg1, ULK1, is phosphorylated and activated by AMPK, 
resulting in increased autophagy and mitophagy (Egan et al., 2011). Mitophagy is a 
special form of autophagy by which dysfunctional mitochondria are degraded, which is 
important for mitochondrial turnover. In cells lacking functional ULK1 or lacking the 
AMPK phosphorylation site, aberrant accumulation of mitochondria was observed, 
along with impaired mitochondrial function (Egan et al., 2011). AMPK, by increasing 
autophagy, maintains the energy status of the cell under times of stress and, by 
increasing mitophagy, acts to maintain the health and functionality of the 
mitochondrial population. 
 
Additionally, AMPK has also been proposed to increase the rate of mitochondrial 
biogenesis. Administration of AICAR to rats caused increased expression of 
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mitochondrial genes (Winder et al., 2000) and the loss of AMPK activity in muscle 
caused a reduction in mitochondrial content and exercise endurance (O’Neill et al., 
2011). The mechanism for this may involve phosphorylation of peroxisome 
proliferator-activated receptor-γ co-activator 1α (PGC1α), a co-activator that enhances 
the activity of transcription factors acting on mitochondrial genes, including 
cytochrome c, a component of the electron transport chain (Jäger et al., 2007). 
 
1.6.4 Membrane excitability 
As discussed in section 1.5.2, AMPK responds to hypoxia and phosphorylates and 
inhibits membrane-bound ion channels, resulting in changes to membrane excitability 
in the carotid body and increases in respiration. Additionally, AMPK phosphorylates 
the voltage-gated K+ channel Kv2.1, a regulator of membrane excitability and action 
potential firing frequency in central neurons. Phosphorylation by AMPK causes 
hyperpolarizing shifts in the current-voltage relationship for channel activation, 
causing channels to become less sensitive to membrane depolarization (Ikematsu et 
al., 2011). Treatment of cultured rat neurons with A769662, or the introduction of 
active AMPK, reduced the frequency of action potential firing (Ikematsu et al., 2011).  
The firing of action potentials is a major source of energy consumption in the brain 
and, by reducing their rate of firing, AMPK would act to conserve energy. 
 
1.7 LKB1 
1.7.1 Discovery of LKB1 
Peutz-Jeghers syndrome (PJS) is an inherited, autosomal dominant, condition 
characterized by the formation of benign hamartomatous polyps, particularly in the 
gastrointestinal tract. The syndrome was first described in 1921 by Johannes Peutz and 
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further characterized by Harold Jeghers in the 1940s. PJS is a rare disease, with 
incidences estimated from 1 in 10,000 to 1 in 120,000 births (Alessi et al., 2006) 
 
Genetic linkage analysis revealed that PJS was caused by mutation of the LKB1 gene 
(Hemminki et al., 1998). Multiple mutations in LKB1 have been identified from PJS 
patients, the majority of which cause truncations in the kinase domain and should 
therefore ablate catalytic activity. A number of mutations have also been observed in 
the C-terminal tail of LKB1, suggesting a possible regulatory role for this region. No 
point mutations in the N-terminal non-catalytic region have been identified in PJS, 
suggesting that this region does not regulate LKB1 function (Alessi et al., 2006). 
 
1.7.2 LKB1 as a tumour suppressor 
Early work demonstrated that expression of LKB1 in HeLa and G361 cells, which were 
derived from human cancers (cervical and skin melanoma respectively) and lack LKB1, 
resulted in a cell cycle arrest. This effect was lost with catalytically-inactive LKB1 
mutants and it was reasoned that the intrinsic kinase activity was necessary to halt cell 
division (Tiainen et al., 1999). Additionally, sufferers of PJS have a greatly increased risk 
of developing malignant tumours in multiple tissues (Giardiello et al., 2000). As PJS 
patients have mutations in the LKB1 gene and are predisposed to cancers this, 
together with the effects of LKB1 on the cell cycle, suggested that LKB1 was a classical 
tumour suppressor and support comes from the observation that sporadic mutations 
in the LKB1 gene are present in 30% of non-small cell lung cancers (Sanchez-Cespedes 
et al., 2002), 20% of invasive cervical cancers (Wingo et al., 2009) and 10% of 
melanomas (Liu et al., 2012). 
 
43 
 
1.7.3 The LKB1 complex 
LKB1 exists as a heterotrimeric complex with two other proteins, STRAD (Ste-20 
related adaptor) and MO25 (mouse protein 25) (Alessi et al., 2006). There are two 
closely related isoforms of STRAD, α and β, which possess high sequence similarity to 
protein kinases but lacking several crucial residues required for catalytic function. They 
have therefore been termed pseudokinases. Like STRAD, there exist two closely related 
isoforms of MO25, again termed α and β. LKB1, STRAD and MO25 complexes can be 
isolated with the three members at equal stoichiometry, suggesting they are tightly 
associated and form a 1:1:1 ratio in the cell (Boudeau et al., 2003a), later confirmed 
when the crystal structure of the complex was determined (Zeqiraj et al., 2009a) 
 
One manner in which the complex can be regulated is through changes in subcellular 
localization. Cytoplasmic localization of LKB1 appears to be important for its function, 
as mutant forms of LKB1 found in PJS patients localize exclusively in the nucleus and 
are unable to suppress cell growth (Boudeau et al., 2003b). LKB1 possesses a nuclear 
localization sequence in the N-terminus, and overexpression of LKB1 alone resulted in 
the kinase localizing to the nucleus, while mutation of this sequence resulted in 
distribution throughout the cell (Smith et al., 1999). Co-expression of LKB1 and STRAD 
targeted the majority of LKB1 to the cytoplasm, although a significant amount 
remained nuclear, while expression of LKB1, STRAD and MO25 fully localized LKB1 to 
the cytoplasm. 
 
Binding of both STRAD and MO25 is also required for the full catalytic activity of LKB1 
(Hawley et al., 2003). The crystal structure of an LKB1:STRAD:MO25 complex revealed 
that STRAD and MO25 stabilized the active loop of LKB1 in a conformation required for 
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phosphorylation of substrates (Zeqiraj et al., 2009a). As a pseudokinase, STRAD does 
not have any catalytic activity but still binds ATP and adopts a closed conformation 
that is similar to that of active kinases (Zeqiraj et al., 2009b). This conformation of 
STRAD is critical for LKB1 activation, because mutation of residues in the ATP-binding 
pocket of STRAD prevent association with MO25 and activation of LKB1 (Zeqiraj et al., 
2009b). 
 
1.8 mTOR  
The mTOR pathway is a key regulator of cell growth and protein synthesis. In addition 
to the regulation of AMPK, this thesis also examines the relationship between the 
LKB1-AMPK pathway and the mTOR pathway. 
 
1.8.1 Discovery of mTOR 
In 1975, a soil sample from Easter Island was discovered to contain a bacterial strain 
that produced an antifungal metabolite with potent growth suppressive properties 
against a range of organisms (Vézina et al., 1975). The metabolite was named 
rapamycin after Rapa Nui, the local name for Easter Island.  
 
The target-of-rapamycin (TOR) was identified by screening the budding yeast, 
Saccharomyces cerevisiae, for mutations that caused rapamycin resistance (Heitman et 
al., 1991). This identified two genes, TOR1 and TOR2, that were required for rapamycin 
sensitivity. This study also identified that rapamycin requires a cofactor, FKBP12 
(FK506 binding protein), for its growth suppressive functions. FKBP12 is a cis-trans 
peptidyl-prolyl isomerase, and prolyl isomerization is a key step in the correct folding 
of proteins (Fischer and Schmid, 1990). However, inhibition of the prolyl isomerase 
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activity of FKBP12 was not sufficient for immunosuppression (Bierer et al., 1990), so 
the mechanism of action of rapamycin remains unclear. Rapamycin treatment was 
shown to cause a G1 cell cycle arrest in yeast (Heitman et al., 1991) and to prevent 
interleukin-2 induced T cell proliferation, also via a G1 arrest (Bierer et al., 1990; 
Dumont et al., 1990). This inhibition of proliferation by rapamycin seemed to be 
correlated with decreased activity of p70 S6  kinase, a known effector of the 
interleukin-2 response (Chung et al., 1992; Kuo et al., 1992). The deletion of TOR1 and 
TOR2 mimicked the G1 cell cycle arrest seen with rapamycin treatment, and it was 
subsequently demonstrated that TOR mutations prevented interactions with FKBP12-
rapamycin, confirming that this was the direct target for rapamycin (Lorenz and 
Heitman, 1995). A mammalian homolog of the yeast TOR, mTOR (mechanistic TOR), 
was also shown to bind to the rapamycin-FKBP12 complex, an event necessary for 
rapamycin-induced cell cycle arrest (Brown et al., 1994; Sabatini et al., 1994; Sabers et 
al., 1995). 
 
The product of the yeast TOR2 gene had significant homology to PI 3-kinases  (Kunz et 
al., 1993) and it was subsequently demonstrated that mTOR contained a kinase activity 
and had the ability to autophosphorylate (Brown et al., 1995; Brunn et al., 1996). 
mTOR was demonstrated to be the regulator of p70 S6 kinase in vivo, an effect that 
was rapamycin-FKBP12 sensitive and that required a functional mTOR kinase domain 
(Brown et al., 1995). mTOR was also implicated in the phosphorylation of 4E-BP1, as 
this was observed to be rapamycin-sensitive, with similar kinetics to that of p70 S6 
kinase activation, and also required the kinase activity of mTOR (Brunn et al., 1997, 
1996; Hara et al., 1997; von Manteuffel et al., 1996). Further insight came when mTOR 
was shown to directly phosphorylate and regulate p70 S6 kinase and 4E-BP1, two 
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regulators of protein synthesis, in a rapamycin-sensitive manner (Burnett et al., 1998). 
mTOR therefore appeared to be a central regulator of protein synthesis. 
 
1.8.2 Identification of two mTOR complexes and their targets 
1.8.2.1 mTORC1 
A wide range of factors was known to regulate the in vivo function of mTOR, including 
amino acids (Hara et al., 1998), although these failed to alter the kinase activity of 
mTOR in cell-free assays (Hara et al., 1997). These findings, coupled with the presence 
of HEAT repeats and FAT domains on mTOR, both of which were suspected to mediate 
protein:protein interactions (Schmelzle and Hall, 2000), suggested that mTOR may 
exist within multiprotein complexes. Two groups independently identified Raptor 
(regulatory associated protein of mTOR) as a binding partner for mTOR (Hara et al., 
2002; Kim et al., 2002). Raptor is a highly conserved 150 kDa protein that plays a 
positive role in mediating nutrient-induced mTOR signalling to p70 S6 kinase (Kim et 
al., 2002). In addition to Raptor, the complex contains: PRAS40 (40 kDa proline-rich Akt 
substrate), a negative regulator of mTOR (Sancak et al., 2007); mLST8 (mammalian 
lethal with SEC13), a positive regulator (Loewith et al., 2002); and the negative 
regulator DEPTOR (DEP domain-containing mTOR-interacting protein) (Peterson et al., 
2009).  In light of the discovery of a second TOR complex (see below), the complex 
containing Raptor is now referred to as mTORC1. The composition of mTORC1 is 
detailed in Fig. 1.6. 
 
As discussed above, mTORC1 phosphorylates  p70 S6 kinase on Thr389, a residue 
within the hydrophobic motif of the kinase domain, and this is required for the 
catalytic activity of p70 S6 kinase (Burnett et al., 1998). When active, p70 S6 kinase 
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phosphorylates a host of proteins involved in the regulation of mRNA translation, 
including ribosomal S6 (rS6). Although rS6 is often used as a measure of p70 S6 kinase 
activity, the physiological role of this remains unclear. Phosphorylation of rS6 was 
initially proposed to regulate the translation of 5’TOP mRNAs (an abundant subclass of 
mRNAs characterized by an oligopyrimidine tract at the 5’ end), although this has now 
been disproven as p70 S6 kinase and rS6 appear to be dispensable for this process 
(Laplante and Sabatini, 2012). Phosphorylation of rS6 does, however, influence cell size 
and growth rate (Ruvinsky and Meyuhas, 2006).  
 
Despite this, signalling through the mTORC1-p70 S6 kinase axis regulates mRNA 
translation through other targets. p70 S6 kinase phosphorylates eIF4B, which then 
enhances the activity of eIF4A, an RNA helicase. This causes an unwinding of the          
5’-untranslated regions (5’-UTRs) of many mRNAs and promotes translation (Raught et 
al., 2004). PCDC4 (programmed cell death 4) binds to eIF4A and inhibits its helicase 
activity. p70 S6 kinase phosphorylates PDCD4, targeting it for degradation and 
preventing the inhibitory effect of PDCD4 on eIF4A (Dorrello et al., 2006).  
 
mTORC1 also phosphorylates 4E-BP1, which plays a key role in the initiation of cap-
dependent mRNA translation. The initiation factor eIF4E binds to the 5’ mRNA cap and 
forms part of the eIF4F complex, which can then recruit ribosomes to the mRNA. 
4EBP1 binds to eIF4E and prevents it from forming the eIF4F complex. When 
phosphorylated by mTORC1 on Thr36 and Thr45, 4E-BP1 is released, allowing 
formation of the eIF4F complex, ribosomal recruitment and subsequent initiation of 
protein translation (Pause et al., 1994).  
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Inhibition of TOR in yeast (Noda and Ohsumi, 1998) and in mammals (Thoreen et al., 
2009) causes an increase in autophagy, a process which recycles cellular components 
to provide energy and nutrients during times of stress. Phosphorylation of ULK1 (the 
mammalian homologue of yeast Atg1) and Atg13 by mTORC1 blocks autophagosome 
assembly and prevents autophagy under nutrient replete conditions (Hosokawa et al., 
2009; Jung et al., 2009). Other processes regulated by mTORC1 include ribosome 
biogenesis and the activity of transcription factors involved in mitochondrial 
metabolism and lipid synthesis, such as SREBP (Laplante and Sabatini, 2012). 
 
1.8.2.2 mTORC2 
Most of the work characterizing the targets of mTOR had been performed using 
rapamycin. In yeast, however, it was known that there were two TORs, one of which, 
TOR2, had unique properties and was rapamycin-insensitive (Helliwell et al., 1994; 
Zheng et al., 1995). Yeast TOR was shown to exist as two complexes: TORC1 and 
TORC2 (Loewith et al., 2002). TORC1 comprises the catalytic TOR1 or TOR2, KOG1 (the 
yeast homolog of raptor) and LST8. TORC2 comprises TOR2, LST8, AVO1, AVO2 and 
AVO3. TORC1 is rapamycin-sensitive and was proposed to regulate temporal control of 
cell growth, whereas TORC2 was rapamycin-insensitive and proposed to regulate the 
spatial control of cell growth. Similar findings were made in mammalian cells when a 
rapamycin-insensitive complex, mTORC2, was identified (Jacinto et al., 2004; Sarbassov 
et al., 2004). This complex was defined by the presence of Rictor (rapamycin-
insensitive companion of mTOR), a homologue of AVO3. Like mTORC1, mTORC2 
contains mLST8 and DEPTOR. In addition, TORC2 contains PROTOR (protein observed 
with Rictor) and mSin1, both of which are required for full activity of mTORC2 (Frias et 
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al., 2006; Pearce et al., 2011, 2007; Yang et al., 2006). The composition of mTORC2 is 
detailed in Fig 1.6. 
 
mTORC2 was initially characterized as a kinase phosphorylating PKCα (Guertin et al., 
2006; Sarbassov et al., 2004)  but other targets of mTORC2 were soon identified. Full 
activation of PKB in response to growth factors, such as insulin, requires 
phosphorylation of Thr308 in the activation loop and Ser473 in the C-terminal 
hydrophobic motif (Alessi et al., 1996). PDK1 was determined to be the Thr308 kinase 
(Alessi et al., 1997) but the identity of the Ser473 kinase remained unknown. 
Subsequently, mTORC2 was identified as the elusive PDK2 acting on Ser473 of PKB 
(Sarbassov et al., 2005). mTORC2 was also demonstrated to phosphorylate and 
activate serum- and glucocorticoid-induced protein kinase 1 (SGK1), like PKB a member 
of the AGC family of protein kinases (García-Martínez and Alessi, 2008).  
 
TOR, either in yeast or in mammals, therefore exists as two complexes. TORC1 is 
defined by the presence of Raptor, is rapamycin-sensitive and phosphorylates p70 S6 
kinase, 4E-BP1 and ULK1. Rapamycin-insensitive TORC2 is defined by the presence of 
Rictor and phosphorylates PKCα, PKB and SGK. 
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Figure 1.6: Summary of the two mTOR complexes and their targets 
The components of the two TOR complexes are shown, together with some of their 
immediate downstream targets. Also shown are two inhibitors of the mTOR 
complexes, rapamycin (mTORC1 specific) and AZ4 (dual mTORC1/mTORC2 inhibitor). 
Discussed further in Chapter 5. 
 
1.8.3 Regulation of mTOR  
As depicted in Fig 1.7, mTOR is a nexus for signalling inputs from a large number of 
pathways (Zoncu et al., 2011b). The mTORC1 pathway responds to growth factors, like 
insulin or insulin-like growth factors (IGFs), via the PI3K (phosphatidylinositide 3-
kinase) pathway. Binding of the growth factors to their membrane-bound receptors 
results in autophosphorylation on key tyrosine residues and subsequent recruitment 
and phosphorylation of the membrane-bound insulin-receptor substrate (IRS). PI3K is 
recruited to bind to phosphorylated IRS, where it is activated and converts 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
trisphosphate (PIP3). PKB is recruited to the plasma membrane by interaction of its 
pleckstrin homology domain with PIP3, where it is phosphorylated by PDK1 (at Thr308 
in the activation loop) and mTORC2 (at Ser473 in the hydrophobic motif). PKB then 
phosphorylates and inactivates the TSC1/TSC2 complex, which contains a GTPase 
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activator protein (GAP) acting on Rheb (Inoki et al., 2003a). GDP-bound Rheb, does not 
activate mTORC1, but binding of GTP converts it to an activator of mTORC1 (Long et 
al., 2005). Inactivation of TSC1/TSC2 therefore promotes the GTP-bound form of Rheb 
and activates mTORC1. 
 
The activity of mTORC1 is also regulated by amino acids. Withdrawal of amino acids, 
particularly leucine, from the culture medium abolishes mTORC1 activity (Hara et al., 
1998); available evidence suggests that amino acid levels are sensed intracellularly, 
rather than at the cell surface (Christie et al., 2002). The Rag family of GTPases, which 
exist as a heterodimer of either RagA or RagB with either RagC or RagD, change their 
GTP loading state in response to amino acids (Sancak et al., 2008). GTP-bound RagA or 
RagB bind to Raptor and recruit mTORC1 to the lysosome, where the mTORC1 
activator Rheb resides. This recruitment is mediated by a recently discovered protein 
complex termed the Ragulator (Sancak et al., 2010). Amino acids enter the lysosomal 
lumen where, via the vascuolar-ATPase, they promote the guanine nucleotide 
exchange factor (GEF) activity of the Ragulator complex towards the Rag proteins (Bar-
Peled et al., 2012; Zoncu et al., 2011a). This results in the exchange of GDP for GTP on 
RagA or RagB, followed by the dissociation of the Rag proteins from the Ragulator 
complex and subsequent recruitment of mTORC1 to the lysosome, where it can be 
activated by Rheb. In addition to the GEF activity of Ragulator, a protein complex 
termed GATOR (GAP activity towards Rags) has been identified that plays a negative 
role in mTORC1 signalling by converting GTP-bound RagA or RagB to the GDP-bound 
form (Bar-Peled et al., 2013). This complex appears to play an analogous role to that of 
TSC1/2 in the regulation of mTORC1 activity. 
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As discussed in Section 1.6, the activity of mTORC1 is also opposed by the LKB1-AMPK 
pathway in response to energy depletion. AMPK phosphorylates and activates TSC1/2, 
promoting its GAP activity towards the mTORC1 activator Rheb (Inoki et al., 2003b). 
AMPK also phosphorylates Raptor, promoting its association with 14-3-3 proteins and 
inhibiting mTORC1 catalytic activity (Gwinn et al., 2008). 
 
In contrast to the regulation of mTORC1, comparatively little is known about the 
upstream activators of mTORC2. Insulin stimulation of cells increases Ser473 
phosphorylation of PKB by mTORC2, suggesting that the complex, like mTORC1, 
responds to growth factors, either directly or indirectly (Sarbassov et al., 2004) and 
ribosomes have recently been proposed as the regulator of mTORC2 in response to 
growth factors (Zinzalla et al., 2011). mTORC2 is known to phosphorylate PKB, PKC and 
SGK, all of which respond to different growth factors, but it remains unclear how 
signalling inputs are processed. One proposed model is that mSin1, one of the unique 
components of mTORC2, exists in multiple isoforms that are differentially regulated by 
growth factors (Frias et al., 2006). Recently, phosphorylation of Sin1, in response to a 
range of stimuli including insulin and IGF-1, was reported to dissociate Sin1 from 
mTORC2 and reduce the catalytic activity of the complex, providing a form of negative 
feedback regulation (Liu et al., 2013). 
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Figure 1.7: Regulation of mTORC1 and mTORC2 signalling 
The mTOR complexes respond to a number of different inputs, including energy stress, 
amino acids and growth factors. The activity of the mTOR complexes is regulated by 
the activity of a number of tumour suppressors (shown in green) and oncogenes 
(shown in red). The downstream targets of the mTOR complexes are not shown here, 
with the exception of p70 S6K (dark blue), which forms part of a feedback loop to the 
IGF receptor. See text for more details. 
 
1.8.4 mTOR and cancer 
As mTOR plays such a central role in integrating the cellular response to growth factors 
and controlling cell growth, survival and proliferation, it is not surprising that it is 
heavily implicated in tumourigenesis. Evidence that mTOR plays a role in tumour 
formation comes from the study of familial cancer syndromes caused by mutations in 
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negative regulators of the mTOR pathway. Tuberous sclerosis (loss of TSC1/2), Peutz-
Jeghers syndrome (loss of LKB1) and Cowden’s syndrome (loss of PTEN) are all 
characterized by the formation of benign hamartomas in various tissues of the body, 
and in the case of Peutz-Jeghers and Cowden’s syndromes there is also an increased 
risk of developing malignant tumours. In addition, activating mutations in PKB and 
PI3K, and inactivating mutations in PTEN are some of the most common mutations 
observed in human cancers (Yuan and Cantley, 2008). Sporadic LKB1 loss is also 
observed in a high proportion of lung adenocarcinomas (Sanchez-Cespedes et al., 
2002). Loss of these negative regulators would result in hyperactive mTOR signalling. 
Additionally, activating mutations in mTOR itself have been identified in a number of 
human cancers (Sato et al., 2010) while overexpression of Rictor and subsequent 
mTORC2 activation is observed in glioma cell lines and primary tumours (Masri et al., 
2007). 
 
Over-activation of mTORC1 results in increased phosphorylation and inhibition of 4E-
BP1 with subsequent activation of eIF4E. 4E-BP1 appears to play a key role in 
regulating cell proliferation, because MEFs lacking 4E-BP1 and 4E-BP2 displayed 
increased rates of proliferation (Dowling et al., 2010) and expression of 4E-BP1 is lost 
in a large proportion of pancreatic tumours (Martineau et al., 2013). eIF4E, which is 
inhibited by 4E-BP1, drives the expression of pro-tumorigenic proteins, including cyclin 
D3 and ornithine decarboxylase (Dowling et al., 2010) and the anti-apoptotic MCL1 
(myeloid leukemia cell differentiation 1, a member of the Bcl-2 family) (Laplante and 
Sabatini, 2012). Additionally, the loss of 4E-BP1 and 4E-BP2 increased tumourigenesis 
in mice lacking p53 (Petroulakis et al., 2009). mTORC1, by phosphorylation of ULK1, 
inhibits autophagy, which appears to have important roles during tumourigenesis as 
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mice deficient in autophagic proteins are more tumour-prone than their wild-type 
counterparts (Yue et al., 2003). mTORC1 also drives the activation of the transcription 
factor SREBP which, amongst other targets, increases expression of fatty acid synthase 
(FAS), required to produce the high amounts of lipid required to fuel synthesis of new 
membranes to facilitate cellular proliferation (Menendez et al., 2009). 
 
The activation of PKB and SGK by mTORC2 drives nutrient uptake, proliferation and cell 
survival. One reason is that PKB, by inhibiting TSC1/TSC2, will increase the activity of 
mTORC1. Additionally, both PKB (Brunet et al., 1999) and SGK1 (Brunet et al., 2001) 
phosphorylate members of the FOXO family of transcription factors, resulting in their 
exclusion from the nucleus and preventing them from regulating gene expression. The 
FOXO family regulate the expression of a number of genes, including those of pro-
apoptotic proteins, such as Puma, and mutation of the sites phosphorylated by PKB 
and SGK sensitizes cells to apoptosis (Brunet et al., 1999, 2001). 
 
PKB also has other pro-survival functions (reviewed in Manning and Cantley, 2007). 
The transmembrane Bcl-XL protein prevents apoptosis by preventing cytochrome c 
release from the mitochondria, which would result in caspase cleavage and 
subsequent activation, followed by apoptosis. The activity of Bcl-XL is inhibited by Bcl-2 
homology domain 3 (BH3)-only family members, such as BAD (Bcl-2 associated death 
promoter), which sequesters Bcl-XL and inhibits its function. In response to growth 
factors and mTORC2 activity, PKB directly phosphorylates BAD, resulting in 14-3-3 
binding and cytoplasmic sequestration. This prevents BAD from eliciting its pro-
apoptotic effects on Bcl-XL. In addition, the expression of BH3-only proteins are 
controlled by FOXO transcription factors, which, as discussed above, are negatively 
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regulated by PKB. PKB also phosphorylates HDM2, an E3 ubiquitin ligase that triggers 
degradation of the pro-apoptotic tumour suppressor protein, p53. By regulating SGK 
and PKB, mTORC2 therefore has a key role in regulation of cell growth and survival. As 
mTOR regulates many pathways that impinge upon cell growth and proliferation, it is 
not surprising that mTOR inhibitors are considered exciting prospects for anti-cancer 
therapies. 
 
1.9 Experimental aims 
The role of AMP in regulating the activity of AMPK has recently been questioned. One 
aim of this thesis was to re-investigate the regulation of AMPK by AMP, ADP and ATP 
using both cell-free assays and intact cells. The crosstalk between LKB1 and AMPK was 
also examined by investigating whether AMPK could phosphorylate LKB1 and whether 
this had any functional relevance. The inhibition of mTOR is a promising avenue for 
anti-cancer therapies and this thesis also examines the role that the LKB1-AMPK 
pathway plays in determining the response of a number of cell types to mTOR 
inhibition.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
Sodium fluoride, sodium pyrophosphate, Triton X-100, benzamidine, 
phenylmethylsulfonylfluoride (PMSF), soyabean trypsin inhibitor (SBTI), berberine 
chloride, A23187, sodium salicylate, phenformin, troglitazone, quercetin, 2,4-
dinitrophenol (DNP), dimethyl sulfoxide (DMSO), magnesium chloride, Serva blue G, 
sodium pyruvate, glucose, glutathione, phenol red and Dulbecco’s modified Eagle’s 
medium (DMEM) Base were from Sigma (Poole, UK). Hepes, 
Tris(hydroxymethyl)methylamine (Tris), dithiothreitol (DTT) and isopropyl-α-D-thio-
galactopyranoside (IPTG) were from Formedium (Hunstanton, UK). Sodium 
ethylenediaminetetraacetate (EDTA), sodium ethylenebis(oxyethylenenitrilo)-
tetraacetate (EGTA), sodium chloride, orthophosphoric acid, Brij-35, Tween-20 
ethanol, methanol and orthophosphoric acid were from VWR (UK). STO609 was from 
Tocris (UK). AICAR was from Calbiochem (Beeston, UK). [γ-32P]ATP was from Perkin 
Elmer (Bucks, UK). ATP, ADP and AMP were from Melford (Chelsworth, UK). EDTA free 
protease cocktail inhibitor tablets were from Roche Diagnostics (Lewisham, UK). 
Protein G-Sepharose and 5 ml GSTrap FF columns were from GE Healthcare (Bucks, 
UK). Dulbecco’s Modified Eagle’s Medium (DMEM), McCoy’s 5A medium, Opti-MEM, 
Foetal Bovine Serum (FBS), trypsin-EDTA, L-glutamine, penicillin-streptomycin solution 
(pen-strep), GlutaMax, zeocin, blasticidin, hygromycin B and Lipofectamine 2000 were 
from Life Technologies (UK). Effectene was from QIAGEN (Crawley, UK). FuGENE was 
from Promega (UK). AZ4 was supplied by Astra-Zeneca (Macclesfield, UK). A769662 
was manufactured as described previously (Iyengar et al., 2005). 
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2.1.2 Molecular biology reagents 
QIAprep Spin Miniprep kit, QIAprep Hi-Speed Plasmid Maxi kit and QIAquick PCR 
purification kits were from QIAGEN (Crawley, UK). Quikchange II site-directed 
mutagenesis kit was from Stratagene (La Jolla, CA). Molecular grade agarose and 
dNTPs were from Sigma (Poole, UK). Blue/orange 6X loading dye was from Promega 
(Southhampton, UK). XL-10 Gold, OneShot BL21 (DE3) and XL-1 competent Escherichia 
coli and the Flp-In system were from Life Technologies (UK). Liquid LB media and plates 
supplemented with ampicillin or kanamycin, SOC media and autoinduction media were 
supplied by Media Service, College of Life Sciences, University of Dundee. 
 
2.1.3 Plasmids 
Plasmids used in this thesis are outlined in table 2.1. The GST-LKB1 plasmid was 
provided by the DSTT (University of Dundee). Other plasmids were kindly provided by 
Dr. Fiona Ross, University of Dundee. 
 
Plasmid Vector Expression Tag 
GST-LKB1 pGEX6P2 Bacterial GST 
GFP-LKB1 pEGFP-C2 Mammalian GFP 
AMPK-α1 pCMV Mammalian Myc 
AMPK-α1 KD pGEX6P2 Bacterial GST 
AMPK-α2 KD pGEX6P2 Bacterial GST 
Table 2.1: Plasmids used in this thesis. 
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2.1.4 Primers 
Primers were from Sigma (Poole, UK) and are outlined in table 2.2. 
Mutation Forward primer Reverse primer 
LKB1[S31A] 
CACGTTCATCCACCGCATCGACGCCA
CCGAGGTCATCTACCAG 
CTGGTAGATGACCTCGGTGGCGTCG
ATGCGGTGGATGAACGTG 
LKB1[S31D] 
CACGTTCATCCACCGCATCGACGACA
CCGAGGTCATCTACCAG 
CTGGTAGATGACCTCGGTGTCGTCG
ATGCGGTGGATGAACGTG 
AMPK-
α[T172D] 
GTCAGATGGTGAATTTTTAAGAGAT
AGTTGTGGCTCACCCAACTATGC 
GCATAGTTGGGTGAGCCACAACTAT
CTCTTAAAAATTCACCATCTGAC 
LKB1-FRT 
CCCAAGCTTGGGTTACCATGGAGGT
GGTGGACCCGCAG 
CCGCTCGAGCGGTCACTTATCATCAT
CATCCTTATAATCCTGCTGCTTGCAG
GCCGACAG 
Table 2.2: Primers used in this thesis. 
 
Mutants created by site-directed mutagenesis are outlined in table 2.3. 
Mutant Plasmid DNA Primers 
LKB1 [S31A] GST-LKB1 LKB1 [S31A] 
LKB1 [S31A] GFP-LKB1 LKB1 [S31A] 
LKB1 [S31D] GFP-LKB1 LKB1 [S31D] 
AMPK-α1 [T172D] AMPK-α1 AMPK-α [T172D] 
Table 2.3: Mutants created as part of this thesis 
 
 
2.1.5 Protein biochemistry reagents 
XCell Surelock Mini-Cell, XCell Blot Module, iBlot transfer module, NuPAGE LDS 
Sample Buffer (4x), pre-cast NuPAGE Novex 4-12% Bis-Tris gels and 3-8% Tris-acetate 
gels, NuPAGE MOPS SDS running buffer (20x), NuPAGE Tris-acetate SDS running 
buffer (20x), NuPAGE Transfer Buffer (20x), SeeBlue Plus2 Pre-Stained Standard 
and IRDye 680 secondary antibodies were from Life Technologies (UK). IRDye800 
secondary antibodies were from Rockland (Gilbertsville, PA). BSA was from Sigma 
(Poole, UK). Vivaspin protein concentrators were from Sartorius (UK). 
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2.1.6 Peptides 
The AMARA and SAMS peptides were synthesised by GL Biochem (Shanghai, China) 
and are detailed in table 2.4. 
Peptide Sequence Reference 
AMARA AMARAASAAALARRR Dale et al. 1995 
SAMS HMRSAMSGLHLVKRR Davies et al. 1989 
Table 2.4: Peptides used in this thesis 
 
2.1.7 Proteins 
CD73 5’-ectonucleotidase was from R&D systems (Abingdon, UK). Rat liver purified 
AMPK was prepared as described previously (Hawley et al., 1996) except that the final 
size-exclusion chromatography was on a Superdex 200 (Hi load 16/60) column, not a 
Sephacryl S-200. Human [His]LKB1-STRAD-MO25 complex was prepared using an 
insect cell baculovirus system (Jaleel et al., 2006) by the Division of Signal Transduction 
Therapy (DSTT), University of Dundee. The GST fusion of human LKB1, also prepared by 
the DSTT, was expressed and purified from E. coli. A GST-fusion of human CaMKKβ and 
a His-fusion of human AMPK α1[D157A]β2γ1, both kind gifts from Dr Fiona Ross, 
University of Dundee, were expressed and purified from E. coli. PP2AC was purified 
from bovine heart (Cohen et al., 1988) and PP2Cα from E. coli (Davies et al., 1995) and 
were kind gifts from Dr Simon Hawley, University of Dundee. 
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Figure 2.1: Protein preparations used in this thesis. 
Proteins were resolved by SDS-PAGE and visualized using Coomassie staining. (A) 
AMPK purified from rat liver, GST-LKB1 and GST-LKB1[S31A]. (B) His fusion of AMPK 
α1[D157A]β2γ1. (C) His fusion of LKB1-STRAD-MO25 complex. (D) GST fusion of 
CaMKKβ. 
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2.1.8 Antibodies 
Antibody Species Recognises Company 
Catalogue. 
No. 
Phospho  
AMPK-α 
(Thr172) 
rabbit 
AMPK-α1 and -α2 
phosphorylated at 
Thr172 
Cell Signalling 2531 
Actin mouse β-actin Sigma A5441 
Phospho-PKB 
(Ser473) 
rabbit 
PKB phosphorylated at 
Ser473 
Cell Signalling 4060 
PKB rabbit PKB Cell Signalling 9272 
Phospho p70 
S6K (Thr389) 
mouse 
p70 S6K and p85 S6K 
phosphorylated at 
Thr389 or Thr412 
respectively 
Cell Signalling 9206 
p70 S6K rabbit p70 and p85 S6K Cell Signalling 2708 
PARP rabbit PARP (total and cleaved) Cell Signalling 9542 
Caspase-3 rabbit 
Caspase-3 (total and 
cleaved) 
Cell Signalling 9665 
FLAG mouse 
FLAG peptide 
(DYKDDDDK) 
Sigma F1804 
Phospho-GSK3 
α/β (Ser 21/9) 
rabbit 
GSK3α and GSK3β 
phosphorylated at Ser21 
or Ser9 respectively 
Cell Signalling 9331 
GSK3 mouse GSK3α and GSK3β 
Santa Cruz 
Biotechnology 
sc-7291 
GFP mouse GFP Roche 11814460001 
Table 2.5: Commercial antibodies used in this thesis. 
 
Antibody Species Immunogen Recognizes Reference 
AMPK-α1 sheep 
CTSPPDSFLDDHHLTR 
 (344-358 of rat AMPK-α1) 
AMPK-α1 
Woods et 
al. 1996 
AMPK-α2 sheep 
CMDDSAMHIPPGLKPH  
(352-366 of rat AMPK-α2) 
AMPK-α2 
Woods et 
al. 1996 
Phospho-
ACC 
sheep 
TMRPSMSGLHLVK          
 (217-226 of human ACC2) 
ACC1/ACC2 
phosphorylated 
at Ser79/ 
Ser221 
respectively 
Hawley et 
al. 2003 
pSer31 
LKB1 
sheep 
TFIHRIDSTEVIYQPR 
(24 to 39 of LKB1) 
LKB1 
phosphorylated 
on Ser 31 
N/A 
Total LKB1 sheep 
MDVADPQPLGLFPEGELMSVGM
DTFIHRIDS (1-31 of rat LKB1) 
LKB1 N/A 
Table 2.6: Non-commercial antibodies used in this thesis. 
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2.1.9 Buffers 
IP buffer (low salt): 50 mM Tris-HCl, pH 7.25, 150 mM NaCl, 50 mM NaF,         
5 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 
mM benzamidine, 0.1 mM PMSF, 5 g/ml SBTI,                
1% (v/v) Triton-X100 
IP buffer (high salt):  as above, but containing 500 mM NaCl 
Hepes assay buffer:  50 mM Hepes, pH 7.4, 50 mM NaCl, 1 mM DTT,  
0.02% (v/v) Brij-35 
Lysis buffer (mammalian): 50 mM Tris-HCl, pH 7.2, 50 mM NaF, 1 mM NaPPi,            
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM 
benzamidine, 0.1 mM PMSF, 5 g/ml soyabean trypsin 
inhibitor, 1% (v/v) Triton-X100 
Lysis buffer (bacterial): 50 mM Tris-HCl pH 8.2, 500 mM NaCl, 1 mM 
dithiothreitol, 1 mM EGTA, 1 mM EDTA with Complete 
Protease Inhibitor mix 
Elution buffer:   50 mM Hepes, pH 8, 200 mM NaCl, 20 mM glutathione 
TBS:     20 mM Tris-HCl, pH 7.4, 137 mM NaCl 
TBS-T:    20 mM Tris-HCl, pH 7.4, 137 mM NaCl, 0.1% Tween-20 
Coomassie stain:  50% (v/v) methanol, 10% (v/v) acetic acid and  
0.1% (w/v) Coomassie blue 
Coomassie destain:  10% (v/v) methanol, 10 % (v/v) acetic acid   
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2.2 Methods 
2.2.1 Site-directed mutagenesis 
Site-directed mutagenesis of DNA constructs was performed using Stratagene 
QuikChange® II site-directed mutagenesis kit according to manufacturer’s instructions. 
Briefly, the mutagenesis reactions were set up in sterile 0.2 ml PCR tubes and each 
reaction contained: 1X reaction buffer, template plasmid dsDNA (50 ng), forward and 
reverse mutagenic oligonucleotide primers (0.3 µM each), 1 mM dNTPs, 2.5 U Pfu 
turbo DNA polymerase made up to a final volume of 50 µl with sterile de-ionised 
water. The reactions were performed in a Hybrid PCR express thermal cycler using the 
following conditions: [95°C (1 min)] x 1, [95°C (1 min), 55°C (1 min), 68°C (1 min/kb 
plasmid length)] x 18, [68°C (10 min)] x 1. After cycling, 10 U of DpnI restriction 
endonuclease was added and the reaction incubated at 37°C for 1 hour. DpnI digests 
methylated DNA (template plasmid DNA) but not non-methylated DNA (mutant 
plasmid). This reaction (10 µl) was used to transform competent XL-10 Gold E. coli cells 
as described in section 2.2.2. DNA constructs were verified by DNA sequencing. 
 
Template DNA and primers used in this thesis are outlined in tables 2.1 and 2.2 
respectively. Mutants created as part of this thesis are outlined in table 2.3. 
 
2.2.2 Transformation of E. coli 
E. coli cells were thawed on ice. DNA was added to cells and incubated on ice for 30 
minutes. The cells were subjected to a heat shock at 42°C for 1 minute, before being 
incubated on ice for a further 5 minutes. SOC media (250 µl) was added to the cells. 
Cells were then incubated in a shaking incubator at 37°C for 1 hr before being streaked 
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onto an LB plate containing the appropriate selective antibody. Plates were incubated 
at 37°C overnight to allow appearance of colonies. 
 
2.2.3 Purification of plasmid DNA from E. coli 
2.2.3.1 Small scale purification: 
Transformed E. coli cells were grown overnight at 37°C in 5 ml of LB broth plus the 
appropriate selective antibiotic. Cells were pelleted by centrifugation at 13000 rpm for 
2 minutes. Plasmid DNA was then purified using the QIAGEN QIAprep® Spin Miniprep 
kit according to the manufacturer’s instructions. Briefly, the cells were resuspended 
and lysed in buffers P1 and P2. These buffers contain SDS, sodium hydroxide and 
RNase. The SDS solubilizes the protein and phospholipid components, leading to lysis 
of the cells and the alkaline conditions ensure denaturation of chromosomal/plasmid 
DNAs and proteins. The lysates are then neutralized and adjusted to high salt 
conditions in buffer N3, where the chromosomal DNA, proteins and SDS precipitate. 
Plasmid DNA remains in solution and is separated from the precipitate by 
centrifugation before being applied to a column containing a silica membrane. This 
membrane binds the plasmid DNA under high salt conditions. Salts are then removed 
by washing with an ethanol-based buffer and plasmid DNA eluted using sterile de-
ionized water. DNA was then sequenced (see section 2.2.5). 
 
2.3.2.2 Large scale purification: 
Transformed E. coli cells were grown overnight at 37°C in 200 ml of LB broth plus the 
appropriate selective antibody. Cells were pelleted by centrifugation (7000 rpm, 15 
minutes, 4°C). Plasmid DNA was purified using the QIAGEN Hi-Speed Plasmid Maxi kit 
according to manufacturer’s instructions. The principal behind this kit is similar to that 
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outlined for the small-scale purification but briefly, cells were resuspended in buffer P1 
and lysed in buffer P2. The lysates were then neutralized in buffer P3 and the lysate 
cleared by filtration and applied to a column containing a silica membrane. DNA binds 
to the membrane and washed with buffer QC and eluted with buffer QF. DNA was 
precipitated by the addition of isopropanol and was collected using the 
QIAPrecipitator, before elution in sterile de-ionized water. DNA was then sequenced 
(see section 2.2.5). 
 
2.2.4 DNA quantification 
Plasmid DNA was diluted in deionized water to a final volume of 500 µl in a quartz 
cuvette. Absorbance was measured at 260 nm, against a water blank, to give an 
estimation of the DNA present in the sample. A DNA solution of 50 µg/ml has an 
absorbance at 260 nm of 1. The purity of the DNA was assessed by measuring the 
absorbance at 280 nm. Proteins and RNA absorb light at 280 nm. A 260 nm/280 nm 
ratio of 1.6 or greater was indicative of highly purified DNA. 
 
2.2.5 DNA sequencing 
DNA sequencing was performed by The Sequencing Service, College of Life Sciences, 
University of Dundee, using Applied Biosystems Big-Dye Ver 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer. 
 
2.2.6 Expression of GST-fusion proteins in E. coli  
GST-LKB1 [Ser31A], GST-AMPK-α1 kinase domain (KD) and GST-AMPK-α2 kinase 
domain (KD) plasmids were used to transform BL21 (DE3) E. coli as outlined in section 
2.2.2 and plated on LB-ampicillin plates overnight. A single colony was selected and 
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used to inoculate 50 ml of LB-ampicillin liquid media and grown overnight at 37°C in a 
shaking incubator. 10 ml of this culture was used to inoculate 1 L of LB-ampicillin liquid 
media. Cultures were placed at 37°C in a shaking incubator and left until the OD600 
reached 0.4 absorbance units. The flask was placed at 2-8°C for 15 minutes. IPTG          
(1 mM) was added and the culture incubated at 20°C in a shaker incubator overnight. 
Cells were pelleted by centrifugation (7000 rpm, 15 minutes, 4°C), frozen in liquid 
nitrogen and stored at -20°C prior to purification (see section 2.2.7). 
 
2.2.7 Purification of GST-fusion proteins from E. coli 
Cell pellets prepared in section 2.2.6 were ground to a fine powder using a mortar and 
pestle in the presence of liquid nitrogen. The powder was resuspended in lysis buffer 
and clarified by centrifugation (30000 rpm, 30 minutes, 4°C). Supernatant was applied 
to a GST-FF column (equilibrated with lysis buffer) at 4°C and the column washed with 
10 volumes of lysis buffer. Elution buffer was added and the protein collected. Proteins 
were concentrated using an Amicon Ultra centrifugal concentrator and stored at -80°C. 
 
2.2.8 General mammalian tissue culture 
All media and buffers used for tissue culture were warmed to 37C prior to use. Cells 
were cultured and maintained in 75 cm3 or 175 cm3 flasks at 37C in an atmosphere 
containing 5% CO2. The cells were grown until 80-90% confluency before splitting for 
routine maintenance. For passaging of cells, the culture medium was aspirated, 5-10 
ml of trypsin-EDTA was added and the cells were returned to the 37C incubator for 3-
5 minutes. After the cells detached from the surface of the flask, 1 ml of the cell 
suspension was used to seed a fresh 75 cm3 or 175 cm3 flask containing 15 ml or 25 ml 
of complete culture medium. 
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2.2.9 Freezing and thawing cell lines 
Cells were grown to confluency in 175 cm3 flasks and trypsinised as described in 
section 2.2.8. Cells were pelleted by centrifugation at 1000 rpm for 5 minutes, the 
trypsin aspirated and cells resuspended in growth media containing 10% (v/v) DMSO. 
Cells were transferred to cryo-protective tubes and placed in a cell freezer. Cells were 
frozen in a -80°C freezer before being transferred to liquid nitrogen for long-term 
storage. Frozen cell stocks were thawed in a 37°C water bath and transferred to 10 ml 
of pre-warmed media. Cells were pelleted and the supernatant was aspirated to 
remove DMSO. The cells were resuspended in fresh growth media and seeded into     
75 cm3 flasks. 
 
2.2.10 G361 cell line 
G361 cells were cultured in McCoys 5A media supplemented with 10 % (v/v) foetal 
bovine serum (FBS), 2 mM glutamine, 100 IU/ml penicillin and 100 µg/ml 
streptomycin. The G361 FRT parental cells (see section 2.2.15) were cultured as above 
except that the media was supplemented with zeocin (100 µg/ml). The G361 cells 
stably expressing AMPK-α2 [D157A] (see section 2.2.15) were cultured as above except 
that the media was supplemented with hygromycin B (100 µg/ml). 
 
2.2.11 Mouse embryonic fibroblasts (MEF) 
Wild-type and AMPK-α1-/- -α2-/- double knockout MEFs (kind gifts from Dr Benoit 
Viollet, Institut Cochin, Paris) were cultured in DMEM supplemented with 10 % (v/v) 
foetal bovine serum (FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin. 
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2.2.12 HEK293 cell line 
HEK293 cells were cultured in DMEM supplemented with 10 % (v/v) foetal bovine 
serum (FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin. HEK293 cells stably 
expressing AMPK-β-FLAG, both β1 and β2 and G2A mutants, were kind gifts from Dr 
Fiona Ross, University of Dundee and cultured as above except that the media was 
supplemented with hygromycin B (200 µg/ml) and blasticidin (15 µg/ml). These 
HEK293 cells were generated using the Flp-In system to stably express AMPK-β under 
the control of a tetracycline repressor. In the absence of tetracycline, the tet repressor 
(constitutively expressed from a gene stably inserted into the host genome) forms a 
homodimer that binds to a tet operator sequence in the promoter of the gene of 
interest (in this case, AMPK-β-FLAG) which has also been stably inserted to the 
genome. This represses transcription of the gene of interest. Upon addition, 
tetracycline binds to the tet repressor, rendering it unable to bind to the tet operator 
and allowing transcription of the gene of interest. Tetracycline (1 µg/ml) was added to 
the cells for 48 hr prior to treatment and lysis. 
 
2.2.13 HeLa cell line 
HeLa cells were cultured in DMEM supplemented with 10 % (v/v) foetal bovine serum 
(FBS), 100 IU/ml penicillin and 100 µg/ml streptomycin. 
 
2.2.14 Generation of HeLa cells expressing wild-type and kinase-dead LKB1 
These cell lines were generated using Flp-In technology according to the 
manufacturer’s instructions. HeLa cells were transfected with pFRT/lacZeo plasmid 
using Lipofectamine 2000 and after 48 hr washed into medium containing zeocin               
(100 µg/ml). The medium was replaced every 3-4 days until single clones could be 
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identified and expanded. The incorporation of an FRT site was measured by                   
β-galactosidase activity.  
 
Wild-type and kinase-dead (D194A) LKB1 plasmids, provided by the DSTT, were used as 
DNA templates and LKB1 was amplified by PCR using the LKB1-FRT primers (designed 
to incorporate a C-terminal FLAG tag and HindIII/XhoI restriction sites). The PCR 
reaction contained primers (0.3 µM), 100 ng dsDNA template, 0.5 mM dNTPs, 4 mM 
MgCl2, 5% DMSO (v/v) and 2.5 U Pfu DNA polymerase, made up to 50 µl with sterile 
de-ionized water. The reactions were incubated in a Hybrid PCR Express thermal cycler 
using the following conditions: [95°C (7 min)] x 1, [95°C (1 min), 50°C (1 min), 72°C (2 
min)] x 38, [72°C (10 min)] x 1. The PCR reactions were analysed on a 1% agarose gel 
and the appropriate bands were excised using a sterile scalpel. The PCR products were 
purified using a QIAquick PCR purification kit according to the manufacturer’s 
instructions. Purified PCR product and pFRT/FRT vector were digested with 
HindIII/XhoI at 37°C for 2 hours. The restriction digest reactions were analysed on 1% 
agarose gel and linearised plasmids were purified as above. The purified digest 
products were incubated overnight at 4°C with T4 DNA ligase at a vector: insert ratio of 
1:7. XL-1 E. coli were transformed with these ligation reactions (as described in section 
2.2.2) and plasmid DNA extracted from positive clones. DNA constructs were verified 
by DNA sequencing. 
 
The FRT site-containing HeLa cells were transfected with the LKB1 plasmids and a 
plasmid (pOG44) encoding a Flp recombinase. Transfection was performed, in the 
absence of zeocin, using Lipofectamine, according to manufacturer’s instructions. After 
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48 hr, hygromycin B (150 µg/ml) was added and the medium changed every 3-4 days 
until single clones could be identified and expanded. 
 
2.2.15 Transient transfection of G361 cells 
G361 cells were transfected with DNAs encoding GFP-LKB1 (wild-type, S31A mutant or 
S31D mutant), FLAG-STRADα and myc-MO25 (all human). G361 cells were grown to 
60% confluency in 6 cm diameter dishes then transfected using Effectene according to 
manufacturer’s instructions. After 36 hr, cells were treated as indicated in the figure 
legends for 1 hr prior to lysis. 
 
2.2.16 Generation of G361 cells stably expressing dominant negative AMPK-α2  
These cell lines were generated using Flp-In technology according to the 
manufacturer’s instructions. G361 cells were transfected with pFRT/lacZeo plasmid 
using FuGENE and after 48 hr washed into medium containing zeocin (100 µg/ml). The 
medium was replaced every 3-4 days until single clones could be identified and 
expanded. The incorporation of an FRT site was measured by β-galactosidase activity. 
A construct encoding kinase-dead human AMPK-α2[D157A] fused to a C-terminal FLAG 
tag was inserted into pcDNA5/FRT plasmid. The FRT site-containing G361 cells were 
transfected with the AMPK-α2 plasmid and a plasmid (pOG44) encoding a Flp 
recombinase. Transfection was performed, in the absence of zeocin, using Effectene, 
according to manufacturer’s instructions. After 48 hr, hygromycin B (100 µg/ml) was 
added and the medium changed every 3-4 days until single clones could be identified 
and expanded. The transfection of the G361 parental FRT cells with the AMPK-α2 
construct was performed by Dr Fiona Ross, University of Dundee. 
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2.2.17 Transfection of AMPK α1-/--α2-/- double knockout MEFs 
MEF cells lacking the catalytic AMPK-α subunits were transfected with DNAs encoding 
myc-α1, β2 and FLAG-γ1 (all human). The myc-α1 construct had either the wild-type 
sequence or a T172D mutation (see table 2.2). MEFs were grown to 90% confluency in 
6 cm diameter dishes then transfected using Lipofectamine 2000 according to 
manufacturer’s instructions. Cells were washed into Opti-MEM reduced serum media 
(in the absence of antibiotics) prior to transfection then back into growth media after 5 
hr. After 48 hr cells were treated as indicated in the figure legend for 1 hr prior to lysis. 
 
2.2.18 Lysis of mammalian cells 
Cells were harvested using a rapid lysis method, a technique which minimizes 
activation of AMPK. Dishes were placed on ice and the media aspirated. Cells were 
washed twice with ice-cold PBS, lysed in 200 µl of ice-cold lysis buffer and scraped into 
pre-chilled 1.5 ml eppendorf tubes. Lysates were clarified by centrifugation for 10 
minutes at 13000 rpm, 4°C. The supernatant was collected and the protein 
concentration determined. Lysates were flash frozen on liquid nitrogen and stored at    
-80°C. Prior to use, lysates were thawed on ice. 
 
2.2.19 Estimation of protein concentrations 
Protein concentrations were estimated using Bradford reagent. Bradford reagent was 
prepared by dissolving 30 mg of Serva blue in 50 ml of 100% ethanol and 55 ml of 85% 
(v/v) orthophosphoric acid. The solution was made up to 1 L using deionised water and 
filtered to 0.2 µm. The solution was stored at room temperature and protected from 
light. A standard curve was generated using a range of BSA concentrations. Protein 
concentrations of samples were determined by adding 1 ml of Bradford reagent to 
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protein samples in 100 µl of water and measuring the absorbance at 595 nm. The A595 
was then read off the BSA standard curve to give an estimate of the protein 
concentration in the sample. 
 
2.2.20 SDS-PAGE 
SDS-PAGE resolves proteins based upon their molecular weight. The anionic 
detergents sodium or lithium dodecyl sulphate (SDS or LDS) are used to denature 
proteins and confer a negative charge proportional to their size resulting in a constant 
mass/charge ratio. When placed under an electric field, these proteins migrate 
towards the anode at a rate proportional to their molecular weight. 
 
Samples to be resolved were denatured by the addition of Invitrogen NuPAGE 4X LDS 
(lithium dodecyl sulphate) sample buffer and heated to 70°C for 10 minutes. Samples, 
along with pre-stained molecular weight standards (Invitrogen SeeBlue Plus 2), were 
loaded onto pre-cast NuPAGE 4-12% bis-tris gels and resolved at 200 V for 1 hour in 
NuPAGE 1X MOPS running buffer. For analysis of acetyl Co-A carboxylase (ACC), pre-
cast 3-8% tris-acetate polyacrylamide gels were used and proteins were resolved at 
150 V for 80 minutes in NuPAGE 1X tris-acectate running buffer after which proteins 
were transferred to nitrocellulose membranes for immunoblotting or stained with 
Coomassie blue for visualization of protein bands. 
 
2.2.21 Coomassie staining of gels 
To visualize proteins after SDS-PAGE separation, gels were soaked for 30 minutes in 
Coomassie staining buffer. Gels were then washed in Coomassie destain buffer 
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overnight. All incubations were performed at room temperature on a rocker platform. 
Imaging was performed using the LiCor Odyssey detection system (700 nm channel). 
 
2.2.22 Immunoblotting (Western blotting) 
Proteins were resolved by SDS-PAGE and transferred to nitrocellulose membrane for 
immunoblotting. For gels consisting of up to 15 wells, transfers were performed using 
an Invitrogen XCell II Blot Module according to the manufacturer’s instructions. The 
gel-membrane sandwich was assembled as: 2x blotting pad, 3 MM filter paper, gel, 
nitrocellulose membrane, 3 MM filter paper, blotting pads. The sandwich was 
orientated to place the gel closest to the cathode and the membrane closest to the 
anode. Transfers were performed at 35 V for 90 minutes using 1X NuPAGE transfer 
buffer containing 20% (v/v) methanol.  
 
For gels containing more than 15 wells, transfers were performed using the Invitrogen 
iBlot dry blotting system according to manufacturer’s instructions. The gels were 
soaked for 5 minutes in 2X NuPAGE transfer buffer containing 20% (v/v) methanol. The 
gel-membrane sandwich was prepared as: anode stack (containing nitrocellulose 
membrane), gel, 3 MM filter paper, cathode stack, sponge. Transfers were performed 
for 7 minutes at 20V. 
 
Membranes were blocked in LiCor Odyssey blocking buffer for one hour then probed 
with primary antibody overnight. Membranes were washed as:  
5 x 5 minutes in TBST buffer 
1 x 5 minutes in TBS buffer 
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Membranes were then incubated with appropriate IRDye 680 or IRDye 800 secondary 
antibodies diluted 5000X in LiCor Odyssey blocking buffer for 1 hour. Streptavidin 
coupled IRDye 800 secondary antibodies, used to detect biotinylated ACC, were diluted 
2000X in LiCor Odyssey blocking buffer. Membranes were washed as above and the 
signal detected and quantified (as required) using the LiCor Odyssey IR detection 
system. Where required, densitometry was performed using LiCor Odyssey software. 
Membrane blocking, antibody incubations and washing steps were all carried out on a 
rocker platform at room temperature. 
 
2.2.23 Non-covalent coupling of antibodies to protein G-sepharose beads 
Protein G-sepharose beads (stored in 20% ethanol) were washed four times with low-
salt IP buffer to remove alcohol. Beads were then incubated with the required 
antibody (1 µg of antibody/µl of beads) on a roller mixer at 2-8°C overnight to allow 
coupling of antibody to beads. Beads were then washed three times in IP buffer (high 
salt) to remove unbound antibody. Beads were then washed twice with IP buffer (low 
salt) and stored as a 30% slurry in IP buffer (low salt) at 2-8°C until required. 
 
2.2.24 Immunoprecipitation and assay of AMPK from cell lysates 
Anti-AMPK-α1 and -α2 antibodies were non-covalently coupled to protein G-sepharose 
beads as described in section 2.2.23. Beads were then incubated with cell lysates on a 
roller mixer for 2 hours at 2-8°C to immunoprecipitate AMPK and washed as: 
2 x IP buffer (high salt) 
2 x IP buffer (low salt) 
2 x Hepes assay buffer 
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Beads were resuspended in Hepes assay buffer and aliquoted into 1.5 ml eppendorf 
tubes in a final volume of 20 µl before subsequent kinase assay. 
 
The activity of AMPK was measured by its ability to phosphorylate the synthetic 
AMARA peptide (AMARAASAAALARRR), which was derived from the sequence of rat 
acetyl-coenzyme A carboxylase (ACC), a substrate of AMPK (Dale et al., 1995). Assays 
were started by the addition of 30 µl of assay buffer, containing 200 µM AMP, 200 µM 
[γ32P]-ATP, 5 mM MgCl2 and 200 µM AMARA (final volume of 50 µl). Assays were 
incubated at 30°C in an orbital shaker for 15 minutes. Reactions were terminated by 
pipetting 30 µl of the assay mixture onto squares of P81 filter paper and placing these 
into a solution of 1% (v/v) orthophosphoric acid. Filter papers were washed with water 
to remove any unincorporated ATP and allowed to dry at room temperature. The 
radioactivity incorporated in each sample was measured using an LKB-Wallace 1214-
Rackbeta scintillation counter. One unit of activity was determined as that which 
catalysed the incorporation of one nanomole of 32P into synthetic peptide. 
 
2.2.25 Allosteric activation of AMPK immunoprecipitated from G361 lysates 
Immunoprecipitations and assays were carried out as detailed in section 2.2.24 with 
the following exceptions: the SAMS peptide (Davies et al 1989) was used (200 µM) in 
place of AMARA and the kinase reactions were performed ± AMP (200 µM). 
 
2.2.26 AMPK assays using rat liver purified AMPK and isolated kinase domains 
AMPK assays in-solution were performed using either the SAMS or AMARA peptide 
(200 µM) and a reaction mixture containing AMP (200 µM, except where indicated in 
figure legends), ATP (200 µM, except where indicated in figure legends) and MgCl2          
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(a constant 4.8 mM molar excess over ATP was maintained). Assays (25 µl) were 
incubated at 30°C in a water bath for 15 minutes. Reactions were terminated by 
pipetting 15 µl of the assay mixture onto squares of P81 filter paper then processed as 
section 2.2.24. 
 
2.2.27 Protection against dephosphorylation assays 
Rat liver purified AMPK was incubated with enough PP2Cα to give approximately 70% 
Thr172 dephosphorylation. AMP, ADP and ATP were added at the concentrations given 
in the figures. Aliquots were removed for kinase assays (performed as section 2.2.24) 
and Western blotting (performed as section 2.2.22). When included, 5’-nucleotidase 
was at 3.9 µg/ml and was preincubated with nucleotides for 5 minutes prior to starting 
dephosphorylation reactions. All incubations were at 30°C and performed in Hepes 
assay buffer. 
 
2.2.28 Promotion of phosphorylation assays 
Rat liver AMPK was incubated with PP2Ac to give approximately 95% Thr172 
dephosphorylation. Okadaic acid (5 µM) was added to stop this reaction. 
Dephosphorylated kinase was then incubated with LKB1 or CaMKKβ (as indicated) plus 
MgCl2 (5 mM) and ATP (200 µM) for 10 minutes (unless indicated otherwise), with 
AMP, ADP or A769662 at concentrations given in figures. Aliquots were removed for 
kinase assays (performed as section 2.2.24) and Western blotting (performed as 
section 2.2.22). When included, 5’nucleotidase was at 1.8 µg/ml. All incubations were 
at 30°C and performed in Hepes assay buffer. When A769662 was present in the 
LKB1/CaMKKβ incubations, it was also included at 1 µM in the final kinase assay. This 
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concentration of A769662 is sufficient to give maximal activation of AMPK in a cell-free 
assay. 
 
2.2.29 Estimation of degree of Thr172 phosphorylation in intact cells 
2.2.29.1 CaMKKβ phosphorylation of immunoprecipitated AMPK-α 
Immunoprecipitations were carried out as detailed in section 2.2.24. Beads were then 
incubated ± CaMKKβ for 30 minutes at 30°C in the presence of MgCl2 (5 mM) and ATP 
(200 µM) before being washed in Hepes buffer to remove CaMKKβ. AMPK activity was 
then determined using the AMARA peptide as outlined in section 2.2.23. 
 
2.2.29.2 Comparison to bacterial protein 
Bacterially-expressed kinase-dead AMPK (α1[D157A]β2γ1 complex, a kind gift from Dr 
Fiona Ross, University of Dundee) was incubated with LKB1-STRAD-MO25 complex or 
CaMKKβ (as indicated in figure legends) in the presence of MgCl2 (5 mM) and ATP    
(200 µM) for 15 minutes. Reactions were stopped by the addition of SDS with further 
incubation at 70°C for 10 minutes. Bacterial protein and cell lysates (giving equivalent 
amounts of AMPK-α) were analysed by Western blotting (as detailed in section 2.2.22) 
and the membranes probed with anti-phospho Thr172 and anti-AMPK-α antibodies. 
The signals were quantified and the ratio of phosphorylated to total AMPK calculated. 
 
2.2.30 LKB1 assays 
LKB1 activity was measured by its ability to activate dephosphorylated AMPK. Anti-
LKB1 antibodies were non-covalently coupled to protein-G-sepharose beads as 
described in section 2.2.23. These beads were then incubated with cell lysates on a 
roller mixer for 2 hours at 2-8°C to immunoprecipitate LKB1.  
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Beads were washed as: 
 2 x IP buffer (high salt) 
 2 x IP buffer (low salt) 
 2 x Hepes assay buffer 
Beads were resuspended in Hepes assay buffer and aliquoted into 1.5 ml eppendorf 
tubes in a final volume of 20 µl. The immunoprecipitated LKB1 was incubated with 
bacterially-expressed AMPK αβγ heterotrimer with Mg.ATP for 20 minutes at 30°C. 
AMPK activity was then measured using the AMARA peptide as described in section 
2.2.24. 
 
2.2.31 Nucleotide measurements 
Culture medium was aspirated from cells, followed by washing in ice-cold PBS and lysis 
in ice-cold 5% perchloric acid. Samples were vortexed and lysates clarified by 
centrifugation. The supernatant was collected and an equal volume of 1:1 mixture of 
tri-n-octylamine and 1,1,2-trichlorotrifluoroethane added. Samples were vortexed, 
centrifuged and the top (aqueous) phase collected. This procedure was repeated twice 
more and nucleotides stored at -20°C before analysis. All centrifugation steps were 
performed at 13000 rpm, 4°C for 3 minutes. 
 
Sample analysis was performed using a Beckman Coulter P/ACE 5500 capillary 
electrophoresis instrument using 50 mM Na phosphate and 50 mM NaCl (pH 5.2, 
leading buffer) and 100 mM MES/Tris (pH 5.2, tailing buffer). Each buffer contained 
0.2% hydroxyethylcellulose. Nucleotide peaks were detected by UV absorbance at 254 
nm and nucleotide ratios were calculated using peak heights. Retention times for each 
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nucleotide were determined prior to sample analysis by running a mixture of pure 
nucleotides through the capillary. 
 
2.2.32 Measurement of cellular oxygen consumption rate (OCR) of intact cells 
OCR measurements were performed using a Seahorse Biosciences XF24 analyser. This 
instrument isolates a small volume of medium above a monolayer of cells to create a 
transient microchamber. Fluorescent probes then measure changes in the 
concentration of dissolved oxygen over time and the instrument calculates an OCR 
value. The microchamber is then abolished and the medium mixed to allow cellular 
respiration to return to baseline and prevent cells from becoming hypoxic. The 
instrument also has the ability, via four ports, to inject drugs directly onto the cells and 
measure the effect of these on OCR. 
 
Assays were performed according to the guidelines provided by the manufacturer but 
briefly, cells were seeded into the wells of a microplate in a small volume (100 µl) to 
prevent adhesion to the side of the wells, and placed at 37°C for 3-4 hours. Extra 
medium was then added to the cells (150 µl) and cells left at 37°C overnight. The 
morning of the assay, growth media was changed for unbuffered media (pH 7.4) and 
cells placed in a CO2-free incubator at 37°C for 1 hour. During this time, any required 
drugs were prepared in unbuffered media and the pH adjusted back to 7.4. Drugs were 
then loaded into the injection ports and the probes calibrated. Cells were loaded onto 
the instrument and the assay initiated. 
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2.2.33 Measurement of 32P incorporation into proteins 
Proteins, as indicated in the figure legends, were incubated at 30°C with MgCl2 (5 mM) 
and 200 µM [γ32P]-ATP.  Reactions were stopped by the addition of 4X LDS buffer 
followed by further incubation at 70°C for 10 minutes. Samples were resolved by SDS-
PAGE, alongside known amounts of BSA, and the gels stained with Coomassie buffer. 
Gels were destained overnight, imaged using the LiCor Odyssey detection system and 
the BSA standards used to quantify the amount of protein present. Gels were dried at 
80°C, under a vacuum, for 90 minutes. Dried gels were subjected to autoradiography. 
Bands were excised from the dried gel and the amount of 32P incorporated determined 
as per section 2.2.24. Stoichiometry of substrate phosphorylation was estimated as 
nmol of 32P incorporated per nmol of protein. 
 
2.2.34 Data analysis 
Data, unless indicated otherwise, is mean ± SEM. Unless stated otherwise, statistical 
analysis was by ANOVA, using Bonferroni’s multiple comparison test of selected data 
sets (*p < 0.05, **p < 0.01, ***p < 0.001). 
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CHAPTER 3: REGULATION OF AMPK BY AMP AND ADP 
3.1 Introduction 
Despite AMP being the historical regulator of AMPK that led to its name, the role of 
AMP in regulating AMPK has recently been questioned. This was in part because ADP 
was reported to inhibit dephosphorylation of Thr172 in a similar manner to AMP (Xiao 
et al., 2011). As ADP is present at about 10-fold higher concentrations than AMP in the 
cell, the similar binding affinities of AMP and ADP at both the high affinity site (site 1?) 
and the low affinity site (site 3?) of the mammalian kinase suggest that it would be 
ADP, not AMP, that would be the primary signal that prevented dephosphorylation 
(Xiao et al., 2011). Both ADP and AMP were also reported to promote Thr172 
phosphorylation over a similar concentration range, which again would imply that, 
given the differences in cellular concentrations, ADP rather than AMP would be the 
stress signal that promotes Thr172 phosphorylation (Oakhill et al., 2010, 2011). 
Coupled with the frequent reports that allosteric activation by AMP only increases 
AMPK activity by 2-fold or less,  compared to the >100-fold increase in activity in 
response to Thr172 phosphorylation (Sanders et al., 2007b; Suter et al., 2006), the 
physiological role of AMP as a regulator of AMPK has been questioned (Carling et al., 
2012; Oakhill et al., 2012). The current model for AMPK regulation is outlined in          
Fig. 1.3 of Chapter 1.  
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3.2 Aims 
Recent work has proposed a role for ADP in the regulation of AMPK, as well as casting 
doubt upon the role that AMP plays in the physiological regulation of the kinase. The 
aim of this chapter was to re-investigate the regulation of AMPK by AMP, ADP and 
ATP. Using cell-free systems, the ability of AMP and ADP to promote Thr172 
phosphorylation by either LKB1 or CaMKKβ, and to protect against Thr172 
dephosphorylation by protein phosphatases, were examined. The allosteric activation 
of AMPK by AMP was also investigated both in a cell-free system and in intact LKB1-
null cells. The absolute changes in Thr172 phosphorylation produced in an intact cell 
were also investigated in response to AMPK activators, using two cultured cell models. 
The change in cellular nucleotides in response to various AMPK activators was also 
determined and this data was used to estimate the contributions of AMP and ADP to 
the overall activation mechanism.  
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3.3 Results 
3.3.1 AMP, but not ADP, promotes phosphorylation by LKB1, but not CaMKKβ 
To investigate the regulation of AMPK by adenine nucleotides, native AMPK purified 
from rat liver was used. It has been reported that rat liver AMPK exhibits greater 
allosteric activation by AMP than bacterially expressed human or rat AMPK (Carling et 
al., 1987; Sanders et al., 2007b; Suter et al., 2006). It is possible that this discrepancy 
stems from the fact that bacterially expressed AMPK lacks the post-translational 
modifications possessed by rat liver AMPK. It is also possible that bacteria do not 
express the necessary chaperones required for correct folding of the enzyme into its 
optimal 3D structure. Regardless of the explanation, AMPK purified from rat liver is 
more sensitive to regulation by adenine nucleotides than that purified from bacteria, 
and was used throughout this chapter. 
 
It has recently been reported that AMP can promote Thr172 phosphorylation by LKB1 
and by CaMKKβ, while ADP also promoted phosphorylation by CaMKKβ (LKB1 was not 
tested) (Oakhill et al., 2011, 2010). These effects were reported to be dependent on 
myristoylation of the β subunit, with experiments being performed using recombinant 
AMPK purified from, and expressed in, bacterial or mammalian cells. For this study, the 
promotion of phosphorylation was reinvestigated using AMPK purified from rat liver, 
which is an approximately equal mixture of α1β1γ1 and α2β1γ1 complexes (Woods et 
al., 1996b). AMPK was dephosphorylated by incubation with PP2AC to give 
approximately 95% inactivation and the dephosphorylated kinase was then incubated 
with LKB1 or CaMKKβ. Aliquots from this incubation were removed for kinase assays or 
for Western blots. Fig. 3.1 shows that AMP promoted phosphorylation by LKB1, but 
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not CaMKKβ. No effect of ADP was observed with LKB1, despite several attempts over 
a wide range of ADP concentrations (Fig. 3.2). 
 
 
Figure 3.1: AMP, not ADP, enhances Thr172 phosphorylation by LKB1, not CaMKKβ 
Purified rat liver AMPK was incubated with bacterial PP2Ac to give approximately 95% 
inactivation and the reaction stopped by the addition of okadaic acid. The kinase was 
then incubated with LKB1 or CaMKKβ, with or without AMP or ADP (300 µM). Aliquots 
were taken for kinase assays using the AMARA peptide substrate (top) or Western 
blotting using the indicated antibodies (bottom). Kinase activities are expressed as % of 
the activity without PP2AC treatment and are mean ± SEM (n = 3). Significantly 
different from control without AMP by one-way ANOVA with Dunnett’s multiple 
comparison test: ***p < 0.001. 
 
 
 
 
 
*** 
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Figure 3.2: ADP does not promote phosphorylation of Thr172 by LKB1 
Purified rat liver AMPK was incubated with bacterial PP2Ac to give approximately 95% 
inactivation and the reaction stopped by the addition of okadaic acid. The kinase was 
then incubated with LKB1, with or without AMP or ADP. CD73 nucleotidase was 
included in all phosphorylation reactions to minimize the effects of contaminating 
AMP, with the exception of the AMP control reaction. Aliquots were taken for kinase 
assays using the AMARA peptide substrate (top) or Western blotting using the 
indicated antibodies (bottom). Kinase activities are expressed as % of the activity 
without PP2AC treatment and are mean ± SEM (n = 3). Significantly different from 
control without AMP by one-way ANOVA with Dunnett’s multiple comparison test: 
***p < 0.001. 
 
Next, the concentration dependence of the AMP effect on LKB1-mediated Thr172 
phosphorylation was determined (Fig. 3.3). AMP gave a maximum of 2.8 ± 0.2 fold 
stimulation of the activation rate, with a half-maximal effect (EC50) of 160 ± 60 µM.  
 
*** 
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Figure 3.3: Titration of effect of AMP on LKB1-mediated Thr172 phosphorylation 
Purified rat liver AMPK was incubated with bacterial PP2Ac to give approximately 95% 
inactivation and the reaction stopped by the addition of okadaic acid. The kinase was 
then incubated with LKB1 and the indicated concentration of AMP. Aliquots were 
taken for kinase assays using the AMARA peptide substrate (top) or Western blotting 
using the indicated antibodies (bottom). Kinase activities are expressed as % of the 
activity without PP2AC treatment and are mean ± SEM (n = 3). Data were fitted to the 
equation: Y=basal + (((activation × basal-basal) × X)/(EC50+X)), where Y is kinase activity 
and X is AMP concentration. The curve was generated using the following best-fit 
parameters: basal, 37 ± 3%; activation, 2.8 ± 0.2-fold; EC50, 160 ± 60 µM. 
 
The time courses of the effect of AMP and ADP on LKB1-mediated activation of AMPK 
were also investigated (Fig. 3.4). These data shows that AMP exerts its effects very 
rapidly: at the 2 minute time point the AMPK activity of the incubation with AMP was 
already twice that of the control incubation without AMP. ADP has no effect on the 
rate of activation up to the 10 minute time point that was used for the previous 
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experiments. At later time points, a small stimulatory effect of ADP was observed. 
However, it is likely that this effect is due to generation of AMP from ADP during the 
assay, as it was abolished by the addition of 5’-nucleotidase. This enzyme degrades 
AMP to adenosine, but has no effect on ADP or ATP (Fig. 3.5).  
 
Figure 3.4: Timecourse of AMPK activation by LKB1 
Purified rat liver AMPK was dephosphorylated with PP2Ac and the reaction stopped 
with okadaic acid. Kinase was then incubated with LKB1 either alone or with AMP (300 
µM), ADP (300 µM) or ADP + CD73 nucleotidase. At each timepoint an aliquot was 
removed and the kinase activity determined using the AMARA peptide substrate. 
Kinase activities are expressed as % of the activity without PP2AC treatment. 
 
 
 
Figure 3.5: Effect of 5’-nucleotidase on AMP, ADP and ATP 
AMP, ADP and ATP were incubated with 5’-nucleotidase at 30°C. Aliquots were 
removed and stored on ice prior to analysis by capillary electrophoresis. Results are 
expressed as % of initial peak area. 
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A769662, a direct allosteric activator of AMPK, can also protect the kinase against 
dephosphorylation (Göransson et al., 2007; Sanders et al., 2007a). The ability of 
A769662 to promote phosphorylation of Thr172 was investigated. Results in Fig. 3.6 
show that, unlike AMP, A769662 has no effect on the rate of AMPK activation by LKB1. 
No effect of either AMP or A769662 was observed on the rate of AMPK activation by 
CaMKKβ. These results show that only AMP can promote Thr172 phosphorylation by 
LKB1.  
 
Figure 3.6: A769662 does not promote phosphorylation of Thr172  
Purified rat liver AMPK was incubated with bacterial PP2Ac to give approximately 95% 
inactivation and the reaction stopped by the addition of okadaic acid. The kinase was 
then incubated with LKB1 or CaMKKβ, with or without AMP (100 µM) or A769662       
(1 µM). Aliquots were taken for kinase assays using the AMARA peptide substrate (top) 
or Western blotting using the indicated antibodies (bottom). Kinase assays were 
performed with either AMP (200 µM) or A769662 (1 µM) present, depending on which 
compound was present in the prior phosphorylation reaction. Kinase activities are 
expressed as % of the activity without PP2AC treatment and are mean ± range (n = 2). 
Results are representative of two independent experiments. 
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The effects of AMP on promotion of phosphorylation had previously been disputed on 
the basis that the effects could be explained by the contamination of one of the 
preparations with a Mg2+-dependent protein phosphatase. If such a phosphatase was 
present, inhibition of dephosphorylation of Thr172 by AMP would lead to a net 
increase in phosphorylation. To rule this out, AMPK and LKB1 preparations were 
incubated with and without Mg2+ and the effect on Thr172 phosphorylation measured. 
Fig. 3.7 shows that Mg2+ had no effect on Thr172 phosphorylation, unless exogenous 
PP2C was also added to the incubation. This confirms that the effect of AMP on 
promotion of phosphorylation cannot be ascribed to phosphatase contamination. 
 
Figure 3.7: AMPK and LKB1 preparations are not contaminated with phosphatase 
Purified rat liver AMPK was incubated ± LKB1, ± MgCl2, ± PP2Cα for 15 minutes and 
samples analysed by Western blotting with the indicated antibodies. The bar chart 
shows the ratio of the signals obtained with anti-pThr172 and anti-AMPK-α antibodies 
(mean ± SEM, n = 3). Significantly different from control without AMP by one-way 
ANOVA with Dunnett’s multiple comparison test: ***p < 0.001. 
 
 
*** 
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Recent work (Oakhill et al., 2010) had shown that the promotion of Thr172 
phosphorylation was dependent on the β subunit of AMPK being myristoylated. A 
glycine residue at position 2 was identified as the target for this myristoylation 
(Mitchelhill et al., 1997; Oakhill et al., 2010). To investigate this, HEK293 cells stably 
expressing either wild-type (WT) or G2A mutant β1 or β2 subunits, all containing a C-
terminal FLAG tag, were generated by Dr Fiona Ross. The expression of the 
recombinant protein was under the control of the tetracycline repressor. Expression of 
the recombinant protein, after 48 hr tetracycline treatment, was confirmed by anti-
FLAG immunoblot (Fig. 3.8). As in Oakhill et al (2010), a small band shift was observed 
when comparing the WT and G2A mutant β-subunits.  
 
 
Figure 3.8: Generation of HEK293 cells expressing AMPK-β1 and AMPK-β2 mutants 
DNAs encoding FLAG-tagged AMPK-β1 and AMPK-β2 (and G2A mutants) were inserted 
into HEK293 cells using Flp-In technology. The expression of the recombinant protein 
was under the control of a tetracycline repressor. To induce expression, tetracycline 
was added to the cells for 48 hr. Cells were harvested and subject to Western blotting 
using the indicated antibodies. 
 
Treatment with the Ca2+ ionophore A23187, which activates CaMKKβ, caused an 
increase in pThr172 and pS79 ACC signals by measured by immunoblot (Fig 3.9A.), 
however, no AMPK activity was associated with the recombinant β subunit when anti-
FLAG immunoprecipitates were assayed for AMPK activity (Fig. 3.9B).  
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Figure 3.9: Characterisation of the HEK293 AMPK-β1 cell line 
HEK293 cells were treated ± A23187 (10 µM) for 1 hr. (A) Cell lysates were subject to 
Western blotting using the indicated antibodies. (B) AMPK was immunoprecipitated 
from cell lysates using anti-AMPK-α1/α2 antibodies or anti-FLAG beads and AMPK 
activity determined using the AMARA substrate peptide. Results were similar for β1 
[G2A], β2 and β2 [G2A] cell lines. 
 
AMPK activity could, however, be detected when immunoprecipitation was performed 
using anti-AMPK-α1/-α2 antibodies. This suggested either that the recombinant-β 
subunit could not form a complex with the α and γ subunits, or that the complex was 
not catalytically active. To investigate this, cell lysates were incubated with either anti-
FLAG or anti-AMPK-α1/-α2 antibodies. The supernatant from this incubation was then 
incubated with anti-AMPK-α1/-α2 antibodies. The immunoprecipitates were washed 
and kinase activity measured (Fig. 3.10). The results show that incubation with the 
anti-FLAG antibodies did not deplete any AMPK activity from the lysates, since the 
AMPK activities obtained before and after the anti-FLAG immunoprecipitation were 
very similar. This suggests that the recombinant β subunit is not able to form a 
complex with the other subunits – if it could, the AMPK activity measured after anti-
FLAG immunoprecipitation should be much lower. Without the ability to selectively 
immunoprecipitate the mutant β complexes, attempts to investigate the requirement 
of β-myristoylation for promotion of phosphorylation were abandoned. 
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Figure 3.10: Recombinant AMPK-β cannot form a complex in vitro 
AMPK activity was immunoprecipitated from HEK293 cell lysates (as indicated in 
figure) using either anti-AMPK-α1/-α2 antibodies or anti-FLAG beads. The supernatant 
from this IP was then subjected to a second IP using anti-AMPK-α1/-α2 antibodies. 
AMPK activity was determined for both sets of immunoprecipitates using the AMARA 
substrate peptide. 
 
3.3.2 AMP is better than ADP at protecting AMPK against dephosphorylation  
ADP has recently been reported to protect AMPK against dephosphorylation (Xiao et 
al., 2011). Using the preparation of rat liver AMPK, it was observed that both AMP and 
ADP could protect AMPK against PP2Cα-mediated Thr172 dephosphorylation and 
inactivation (Fig. 3.11, data courtesy of Dr Simon Hawley and Dr Fiona Ross). This 
confirmed the previous results of Xiao et al (Xiao et al., 2011). However, the results 
also show that AMP is more potent than ADP at protecting the kinase against 
inactivation. In experiments performed in the absence of ATP, the half-maximal effect 
of AMP on inactivation (EC50) was 2.6 ± 0.3 µM. The EC50 for ADP was nearly 10-fold 
higher at 23 ± 3 µM. Assays were also performed at 5 mM ATP, a concentration that is 
within the level expected in mammalian cells (Imamura et al., 2009). ATP would be 
expected to compete with both AMP and ADP for binding at the γ subunit, and should 
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therefore increase the EC50 for both nucleotides. Consistent with this, the EC50 of AMP 
was increased to 196 ± 15 µM and that of ADP increased to 1.4 ± 0.1 mM. The almost 
10-fold higher potency of AMP was thus retained under these conditions, again 
demonstrating that AMP is more potent than ADP at protecting the kinase against 
dephosphorylation of Thr172. 
 
Figure 3.11: Effect of AMP and ADP on protecting AMPK from dephosphorylation 
Purified rat liver AMPK was incubated with PP2Cα ± MgCl2 ± ATP (5 mM) with or 
without AMP or ADP at the indicated concentrations. Aliquots were removed for 
kinase assays (top) and Western blotting (bottom). Kinase activities were determined 
using the AMARA substrate peptide. Protection against inactivation is defined as the 
activity differences in assays ± nucleotide, expressed as a percentage of the difference 
obtained ± optimal nucleotide (30 µM for AMP and 300 µM ADP, in the absence of 
ATP). Results are fitted to the equation Y = 100 × X/(EC50 + X) where Y = % protection 
and X = concentration of AMP or ADP. Curves were generated with this equation, using 
best-fit values for EC50 quoted in the text. Results are mean ± range (n = 2). 
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Commercial preparations of ADP, as used in these assays, are often contaminated with 
AMP. Analysis of the preparation used showed that this was at a level of ≈1% (Dr. 
Fiona Ross, personal communication). It is also likely that AMP is generated from ADP 
during incubations (Suter et al. 2006 and Fig. 3.4). As the difference in potencies 
between the nucleotides was approximately 10 fold, but the AMP contamination of 
the ADP preparations was only 1%, it did not seem likely that the effects of ADP on 
protection against dephosphorylation were caused by the small amounts of AMP 
present. However, to completely rule this out, the experiments were repeated using 
saturating amounts of the two nucleotides (100 µM AMP or 300 µM ADP) with and 
without the addition of 5’-nucleotidase. This enzyme, as discussed previously, 
hydrolyses AMP, but not ADP, to adenosine. The 5’-nucleotidase completely abolished 
the effects of AMP, but the effects of ADP were decreased only by a small amount (Fig. 
3.12). This small reduction is likely to be due to the hydrolysis of the small amount of 
contaminating AMP, which, in 300 µM ADP, would be 3 µM. The remaining protection 
must have been caused by ADP, confirming that this is a bona fide regulator of Thr172 
dephosphorylation. 
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Figure 3.12: 5’-nucleotidase treatment abolishes the AMP-mediated, but not ADP-
mediated, effects on protection against Thr172 dephosphorylation 
Purified rat liver AMPK was incubated with PP2Cα ± MgCl2 with or without AMP (100 
µM), ADP (300 µM) or CD73 5’-nucleotidase as indicated. The nucleotides were pre-
incubated with CD73 for 5 min at 30˚C before starting the reaction by the addition of 
AMPK. After 10 minutes, aliquots were removed for kinase assays (top) and Western 
blotting (bottom). Kinase activities were determined using the AMARA substrate 
peptide and are expressed as % of activity without MgCl2 (mean ± SEM, n = 3). 
Significantly different from controls without AMP/ADP: ***p < 0.001; significantly 
different from control without CD73: †††p < 0.001. 
 
3.3.3 Allosteric activation by AMP 
As well as regulation of Thr172 phosphorylation, AMPK can also be regulated by 
allosteric activation. This allosteric activation is caused by AMP, but not ADP, binding 
to the γ subunit. The increase in AMPK activity in response to allosteric activation by 
AMP ranges has been reported as <2 fold with bacterially expressed heterotrimer 
(Sanders et al., 2007b; Suter et al., 2006) but seems to be consistently higher, ≈3-4 
fold, when native AMPK purified from rat liver is used (Carling et al., 1987). 
*** *** 
††† 
††† 
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To determine if AMP is able to compete with ATP for binding at the site on the γ 
subunit responsible for allosteric activation, assays were performed not only at the 
standard ATP concentration (200 µM), but also at 1 mM and 5 mM ATP. These latter 
conditions mimic the higher concentrations of ATP that would be found in intact cells. 
The results in Fig. 3.13 (data courtesy of Dr Simon Hawley and Dr Fiona Ross) show 
that, at all three ATP concentrations tested, AMP activated AMPK at low 
concentrations and then inhibited at higher concentrations.  
 
Figure 3.13: Allosteric activation of rat liver AMPK by AMP 
Purified rat liver AMPK was incubated with increasing concentrations of AMP at three 
concentrations of ATP. Data were fitted to the equation: Y=basal + (((activation × 
basal-basal) × X)/(EC50 + X))-((activation × basal) × X/(IC50 + X)) where Y is activity and X 
is the AMP concentration. The curves were generated using this equation and the best-
fit parameters quoted in the text. Results are mean ± range (n = 2). 
 
To investigate the inhibitory effects observed at high concentrations of AMP, the 
AMPK-α1 and -α2 kinase domains were expressed as GST-fusions and purified from 
bacteria (Fig. 3.14). The kinase domains were incubated with LKB1 (as they are inactive 
when dephosphorylated) and then assayed in the presence of 0.2, 1 or 5 mM ATP and 
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a range of AMP concentrations. The results in Fig. 3.15 show that stimulation by AMP 
was no longer observed, but AMP did inhibit the kinase at high concentrations. 
Increasing the ATP concentration shifted the curve to the right, meaning that a higher 
concentration of AMP was required to inhibit the kinase domain. Taken together, 
these results show that the inhibitory effects of AMP are due to competition with ATP 
at the catalytic site. 
 
The curves obtained in Fig. 3.13 also shifted to the right as ATP increased, supporting 
the idea that ATP competes at the activating site on the γ subunit and the catalytic site 
on the α subunit. The data was fitted to a simple model and the parameters obtained 
are outlined in Table 3.1. Thus, even when ATP is present at physiological 
concentrations, AMP caused a large allosteric activation of AMPK (13-fold). 
 0.2 mM ATP 1 mM ATP 5 mM ATP 
Fold activation 5.4 ± 0.2 10 ± 0.5 13 ± 1.3 
EC50 for AMP activation 5.3 ± 0.4 µM 22 ± 1.1 µM 137 ± 14 µM 
IC50 for AMP inhibition 1.9 ± 0.1 mM 7.1 ± 0.33 mM 22 ± 3 mM 
Table 3.1: Parameters obtained from full length AMPK and kinase domains 
 
 
Figure 3.14: Purification of AMPK α1 and α2 kinase domains 
GST-tagged AMPK-α1 and -α2 kinase domains were expressed in BL21 DE3 cells and 
purified using glutathione Sepharose columns. Purified protein was resolved by SDS-
PAGE and stained using Coomassie Blue dye. 
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Figure 3.15: Effect of AMP on AMPK catalytic domains 
GST fusions of AMPK-α1 (A) and -α2 (B) kinase domains were incubated with 
increasing concentrations of AMP at three concentrations of ATP. Kinase activities 
were determined using the AMARA peptide substrate. Results were fitted to the 
equation: Y = basal – (basal × X/IC50 + X), where Y = kinase activity and X is AMP 
concentration. The curves were generated using this equation and the following best-
fit parameters (± SEM at 0.2, 1 and 5 mM ATP): α1 basal activity: 136 ± 5, 404 ± 6 and 
598 ± 22 nmol/min/mg; IC50 for α1: 2.4 ± 0.4, 3.3 ± 0.3 and 23 ± 68 mM; α2 basal 
activity: 260 ± 6, 351 ± 7 and 669 ± 8 nmol/min/mg; IC50 for α2: 3.2 ± 0.4, 13 ± 1.4 and 
18 ± 1.4 mM. Results are mean ± SEM (n = 3). 
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3.3.4 Allosteric activation of AMPK in intact cells 
To determine the relative contribution of allosteric activation versus changes in Thr172 
phosphorylation in the overall activation mechanism of AMPK, G361 cells were initially 
used. These cells, derived from a human melanoma, do not express LKB1 (Fig. 3.16).  
 
Figure 3.16: G361 cells do not express LKB1 
Lysate from G361 cells and HEK293 cells were probed with the indicated antibodies. 
 
These cells were a useful tool for these studies, because agents that increase cellular 
AMP do not increase Thr172 phosphorylation in LKB1-null cells (Hawley et al., 2003) so 
any effects observed should be entirely due to allosteric activation of the kinase. On 
the other hand, treatments that increase Ca2+, and thus activate the CaMKKβ pathway, 
would activate AMPK entirely through increasing Thr172 phosphorylation. Since AMP 
would not be expected to increase Thr172 phosphorylation and therefore AMPK 
activity measured by kinase assay in an immunoprecipitate, it was necessary to use a 
downstream target of AMPK as a measurement of kinase activity in the intact cells. As 
discussed previously, AMPK phosphorylates ACC1 at S79, and phosphorylation of this 
site was used to monitor AMPK activity in response to a variety of treatments. 
 
G361 cells were treated with the natural product berberine, an inhibitor of 
mitochondrial complex I (Hawley et al., 2010; Turner et al., 2008). As predicted, 
berberine did not increase Thr172 phosphorylation in these cells (Fig. 3.17) and no 
effect of berberine on AMPK activity was observed in well-washed 
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immunoprecipitates, where any bound AMP would have been removed from the 
kinase during the washing steps. In addition, the assays were carried out at 200 µM 
AMP, which, as seen in Fig. 3.13, is sufficient to give maximum allosteric activation of 
the kinase. These steps would therefore remove any effects of allosteric activation 
caused by endogenous AMP derived from the intact cells. As expected, the Ca2+ 
ionophore A23187 increased both Thr172 phosphorylation and kinase activity when 
measured in an immunoprecipitate. Although berberine had no effect on Thr172 
phosphorylation, a large increase in phosphorylation of the downstream target ACC 
was nevertheless observed. An interesting observation was that the ACC 
phosphorylation in response to berberine was actually higher than that obtained with 
A23187, despite the finding that there was no increase in Thr172 phosphorylation. 
 
The CaMKK inhibitor STO609 blocked the effects of A23187 on phosphorylation of 
Thr172 and AMPK activation. It also reduced the basal AMPK activity, suggesting that 
the low basal CaMKKβ activity was sufficient to generate some phosphorylation of 
Thr172. Interestingly, although the effects of berberine were reduced by STO609, they 
were not abolished. 
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Figure 3.17: Effect of berberine on AMPK phosphorylation/activation in G361 cells 
G361 cells were treated with A23187 (10 µM) or berberine (100/150 µM), in the 
presence or absence of STO609 (2.5 µM), for 1 hr. (A) AMPK was immunoprecipitated 
from the cell lysate using anti-AMPK-α1/-α2 antibodies and kinase activity measured 
using the AMARA peptide substrate. Results are mean ± SEM (n = 3). (B) Cell lysates 
were subject to Western blotting with the indicated antibodies. Significantly different 
from control without STO609: *p < 0.05, **p < 0.01, ***p < 0.001; significantly 
different from control without AMPK activator: †††p < 0.001. 
 
Similar experiments were carried out using A769662, a direct AMPK activator. This 
compound does not alter cellular nucleotide ratios (Hawley et al., 2010), instead 
binding directly to AMPK at sites distinct from those on the γ subunit used by 
nucleotides (Göransson et al., 2007; Sanders et al., 2007a; Scott et al., 2008). The 
A769662 compound can allosterically activate the kinase as well as protect against 
Thr172 dephosphorylation. Like berberine, A769662 caused no increase in Thr172 
phosphorylation or AMPK activity but did cause a large increase in ACC 
††† 
*** 
*** ** 
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phosphorylation (Fig. 3.18). The change in ACC phosphorylation in response to 
A769662 was similar to that of A23187, which did increase Thr172 phosphorylation. 
 
 
Figure 3.18: Effect of A769662 on AMPK phosphorylation/activation in G361 cells 
G361 cells were treated with A23187 (10 µM) or A769662 (50/100 µM), in the 
presence or absence of STO609 (2.5 µM), for 1 hr. (A) AMPK was immunoprecipitated 
from the cell lysate using anti-AMPK-α1/-α2 antibodies and kinase activity measured 
using the AMARA peptide substrate. Results are mean ± SEM (n = 3). (B) Cell lysates 
were subject to Western blotting with the indicated antibodies. Significantly different 
from control without STO609: **p < 0.01, ***p < 0.001; significantly different from 
control without AMPK activator: ††† p < 0.001. 
 
To further investigate the degree of ACC phosphorylation obtained with berberine and 
A23187, G361 cells were treated with each compound separately and together. The 
results (Fig. 3.19) show that the phosphorylation of ACC obtained with berberine alone 
is greater than that of A23187 alone and comparable to that obtained with dual 
treatment of berberine/A23187. This suggests that the ACC phosphorylation in 
††† 
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*** 
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response to berberine is close to saturation as it cannot be increased further by 
changes in Thr172 phosphorylation. This data also suggests that AMPK phosphorylated 
on Thr172 can be further activated by allosteric activation – the ACC phosphorylation 
in response to A23187 alone is increased when berberine is included in the incubation. 
 
Figure 3.19: Effect of berberine and A23187 on activation of AMPK in G361 cells 
G361 cells were treated with berberine (100 µM), A23187 (10 µM) or berberine and 
A23187 together for 1 hr. (A) AMPK was immunoprecipitated from cell lysates using 
anti-AMPK-α1/-α2 antibodies and kinase activity measured using the AMARA peptide 
substrate. Results are mean ± SEM (n = 3). (B) Cell lysates were subject to Western 
blotting with the indicated antibodies. The bar chart represents the pACC/total ACC 
ratio obtained from the blots (mean ± SEM, n = 3). Significantly different from control: 
**p < 0.01, ***p < 0.001. 
*** 
*** 
** 
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The ability of mammalian AMPK to be allosterically activated was further examined. 
AMPK was immunoprecipitated from G361 cell lysates (± A23187 treatment) and 
assayed ± AMP (200 µM). Fig. 3.20 shows that the AMPK activity isolated from G361 
cell lysates can be increased approximately two-fold in response to AMP. This is 
smaller than that obtained in Fig. 3.13 (using AMPK purified from rat liver) but this 
could be due to the kinase being bound to antibodies rather than free in solution. The 
restricted conformation of the antibody bound kinase may prevent the necessary 
structural changes required to give maximal allosteric activation in response to AMP. A 
recent report of the crystal structure of the AMPK heterotrimer suggested that the 
kinase does undergo conformational changes upon binding of AMP (Chen et al., 2012). 
The antibody bound conformation may therefore mimic this, giving a higher basal, or 
prevent this, giving decreased maximum activity, both of which could result in a lower 
fold activation than that observed with the kinase in solution. 
 
Figure 3.20: Allosteric activation of AMPK immunoprecipitated from G361 cells 
AMPK was immunoprecipitated from G361 cell lysates (treated ± A23187 (10 µM) for  
1 hr) using anti-AMPK-α1/-α2 antibodies. AMPK activities were then determined using 
the SAMS substrate peptide. Assays were performed ± AMP (200 µM). Results are 
mean ± SEM (n = 6) and are expressed as percentage of no AMP control. Significantly 
different from control without AMP: ***p < 0.001. 
*** 
*** 
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The effects of A23187, berberine and A769662 on AMPK activity, ACC phosphorylation 
and cellular nucleotides in G361 cells were investigated (Fig. 3.21). Like the previous 
experiments, all three compounds increased phosphorylation of ACC, with only 
A23187 having any effect on Thr172 phosphorylation or AMPK activity measured in 
washed immunoprecipitates. Berberine, a mitochondrial poison, caused an increase in 
the cellular ADP:ATP ratio. The other two compounds had no effect on this.  
 
Figure 3.21: Effect of AMPK activators on G361 cellular nucleotides ratios 
G361 cells were incubated for 1 hr with A23187 (10 µM), berberine (100 µM) or 
A769662 (100 µM) and lysed in parallel for analysis of AMPK activities or for analysis of 
ADP:ATP ratios. (A) AMPK was immunoprecipitated from cell lysates using anti-AMPK-
α1/-α2 antibodies and kinase activity measured using the AMARA peptide substrate. 
Results are mean ± SEM (n = 3). (B) Samples lysed for nucleotide analysis were 
analysed by capillary electrophoresis and the ADP:ATP ratios estimated. Results are 
mean ± SEM (n = 3).  (C) Cell lysates were subject to Western blotting with the 
indicated antibodies. Significantly different from DMSO control: ***p < 0.001. 
*** 
*** 
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Cellular AMP was too low to directly measure, so this was estimated from the ADP:ATP 
ratios. The derivation of this estimation is outlined below. 
 
Adenylate kinase catalyses the reaction: 
              
The equation for calculating the equilibrium constant is: 
 (  )  
        
         
 
So for adenylate kinase: 
 (  )  
       
    
 
Rearranged to: 
         (  )       
Divide each side by ATP2 and simplify: 
       
    
 
 (  )      
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This illustrates that the AMP:ATP ratio will increase as the square of the ADP:ATP ratio. 
The measurements from the cells allowed calculation of the ADP:ATP ratio. Using the 
equation above, and assuming that the equilibrium constant for adenylate kinase is 
1.05 (Lawson and Veech, 1979), the  AMP:ATP ratios could be estimated. From this 
information, it was possible to estimate the ATP, ADP and AMP concentrations in the 
cell extracts. The derivation of this is outlined below. 
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 Assuming a total available intracellular pool of adenosine nucleotides of 5 mM gives: 
[   ]  [   ]  [   ]      
Divide each side by ATP: 
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Simplify: 
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Multiply both sides of the equation by [ATP]: 
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Solve for [ATP]: 
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From this equation, and the AMP:ATP and ADP:ATP ratios previously calculated, the 
total [ATP] in the cell can be estimated. Using the AMP:ATP and ADP:ATP ratios, along 
with the [ATP], the [AMP] and [ADP] in the cell can then be estimated. This was 
performed for all of the samples and is outlined in Table 3.2. Fig. 3.22 shows the [AMP] 
and [AMP]:[ATP] ratio estimates for all samples. 
 
 control A23187 berberine A769662 
ADP:ATP 0.094 0.113 0.262 0.109 
AMP:ATP 0.0093 0.0135 0.0737 0.0125 
ATP (mM) 4.54 4.44 3.75 4.46 
ADP (µM) 426 502 975 484 
AMP (µM) 42.2 59.8 272.6 55.6 
Table 3.2: Estimation of nucleotide concentrations and ratios in G361 cell extracts 
The ADP:ATP ratio was measured by capillary electrophoresis and all other values were 
estimated from this information using the equations outlined above 
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Figure 3.22: Estimate of cellular AMP:ATP ratios in G361 cells 
Using the data from Fig. 3.21 and the assumptions outlined in section 3.3.4, the AMP 
concentrations (A) and AMP:ATP (B) ratios were estimated (mean ± SEM, n = 3). 
Significantly different from DMSO control: **p < 0.01, ***p < 0.001. 
 
The estimated AMP concentrations do not increase significantly in response to A23187 
or A769662 but rise dramatically in response to berberine, exhibiting a 6- to 7-fold 
increase from (42 ± 3 µM to 270 ± 50 µM).  
 
3.3.5 Effect of salicylate, AICAR and other AMPK activators on G361 cells 
Salicylate, the natural breakdown product of aspirin, is a direct activator of AMPK 
operating in a similar manner to the A769662 compound (Hawley et al., 2012). 
Salicylate binds to the β subunit and allosterically activates AMPK as well as protecting 
Thr172 from dephosphorylation. The effect of salicylate on G361 cells was examined. 
Treatment with salicylate increased the phosphorylation of ACC at S79 in a dose-
*** 
** 
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dependent manner while having no effect on either Thr172 phosphorylation or AMPK 
activity measured in well-washed immunoprecipitates (Fig. 3.23). The effects of 10 mM 
salicylate were comparable to those of berberine and A769662.  
 
Figure 3.23: Effect of treatment of G361 cells with salicylate on AMPK activity 
G361 cells were treated with A23187 (10 µM), berberine (100 µM) or salicylate (1, 3 or 
10 mM) for 1 hr and lysed in parallel for analysis of AMPK activity (this figure) or for 
analysis of ADP:ATP ratios (Fig. 3.24). (A) AMPK was immunoprecipitated from cell 
lysates using anti-AMPK-α1/-α2 antibodies and kinase activity measured using the 
AMARA peptide substrate. Results are mean ± SEM (n = 3). (B) Cell lysates were subject 
to Western blotting with the indicated antibodies. The bar chart represents the 
pACC:total ACC ratio obtained from the Western blots. Results are mean ± SEM (n = 3). 
Significantly different from control: **p < 0.01, ***p < 0.001. 
*** 
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In HEK293 cells, it was demonstrated that at high concentrations (>10 mM) salicylate 
was acting as a relatively weak mitochondrial uncoupler and caused an increase in the 
ADP:ATP ratio (Hawley et al., 2012). To investigate if this was also the case in G361 
cells, nucleotide ratios were also examined, from parallel dishes of cells to those in Fig. 
3.23 (Fig. 3.24). The data shows that at concentrations of 3 mM and 10 mM, salicylate 
was causing a small but significant increase in the ADP:ATP ratio. The AMP:ATP and 
AMP, ADP, and ATP concentrations were estimated using the equations outlined in 
section 3.3.4. The estimates (Table 3.3 and Fig. 3.24) indicate that the concentration of 
AMP rose from 30 ± 5 µM to 48 ± 4 µM or 64 ± 1.2 µM (3 mM and 10 mM salicylate 
respectively).  
 
These data is supported by that shown in Fig. 3.25, where the effect of salicylate on 
the oxygen consumption rate (OCR) of G361 cells was measured. This, like the ADP:ATP 
ratio, can be used to determine the effect of a compound on mitochondrial function. 
For example, DNP, a potent mitochondrial uncoupler, induces a large and rapid 
increase in OCR. This parameter has been used in the past to characterize the 
mechanism of action of a panel of AMPK activators (Hawley et al., 2010). Salicylate at  
1 mM had no significant effect on OCR. However, as seen with the ADP:ATP ratios, 
salicylate at 3 and 10 mM caused a significant increase in OCR, confirming that it was 
disrupting mitochondrial function at these concentrations.  
 
This data also confirms the effects of A23187, berberine and A769662. As expected, 
only berberine causes a change in OCR, the other two compounds have no effect. This 
is consistent with data obtained in HEK293 cells (Hawley et al., 2010). 
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Figure 3.24: Effect of treatment of G361 cells with salicylate on nucleotide ratios 
G361 cells were treated with A23187 (10 µM), berberine (100 µM) or salicylate (1, 3 or 
10 mM) for 1 hr and lysed in parallel for analysis of AMPK activity (Fig. 3.23) or for 
analysis of ADP:ATP ratios (this figure). (A) Samples lysed for nucleotide analysis were 
analysed by capillary electrophoresis and the ADP:ATP ratios calculated. Results are 
mean ± SEM (n = 3).  (B) and (C) using the data from (A) and the assumptions outlined 
in section 3.3.4, the AMP concentrations and AMP:ATP ratios were estimated. 
Significantly different from control: *p < 0.05, ***p < 0.001. 
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 DMSO H2O A23187 berb A76 
Sal 
1 mM 
Sal 
3 mM 
Sal 
10 mM 
ADP:ATP 0.073 0.078 0.085 0.182 0.076 0.093 0.100 0.117 
AMP:ATP 0.0056 0.0065 0.0076 0.0346 0.0060 0.0091 0.0106 0.0144 
ATP (mM) 4.64 4.61 4.11 4.54 4.50 4.42 4.62 4.58 
ADP (µM) 338 360 746 422 451 517 350 389 
AMP (µM) 26 30 35 142 28 41 48 64 
 
Table 3.3: Estimation of nucleotide concentrations and ratios in G361 cell extracts 
The ADP:ATP ratio was measured by capillary electrophoresis and all other values were 
estimated from this information using the equations outlined in section 3.3.4. 
 
 
Figure 3.25: Effect of AMPK activators on the oxygen consumption rate of G361 cells 
Oxygen consumption rate (OCR) analysis was performed using a Seahorse Biosciences 
extracellular flux analyser. G361 cells were seeded into plates and the basal OCR 
calculated for every well. A23187 (10 µM), berberine (100 µM), A769662 (100 µM) or 
salicylate (1, 3 or 10 mM) were then injected onto the cells and the OCR calculated 
over a 30 min period. Results are expressed as % of basal OCR before (clear bars) and 
after (grey bars) compound injection (mean ± SEM, n = 3). Significantly different from 
control before compound injection: *p < 0.05, ***p < 0.001. 
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5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) is a widely used activator of 
AMP. AICAR enters cells where it is converted to the monophosphate form 5-
aminoimidazole-4-carboxamide ribonucleoside monophosphate (ZMP) (Sabina et al., 
1985), an AMP mimetic, and causes allosteric activation of AMPK and protection 
against dephosphorylation (Corton et al., 1995). The measured fold allosteric 
activation of AMPK in response to ZMP is similar to that obtained with AMP, around 3-
6 fold, although the latter has a much lower half-maximal effect (4.4 µM for AMP vs 
164 µM for ZMP). 
 
G361 cells were treated with increasing concentrations of AICAR for 1 hr and lysed in 
parallel for analysis of AMPK activity and cellular nucleotides. Similar to berberine, 
AICAR induced phosphorylation of ACC with no increase in AMPK activity or Thr172 
phosphorylation (Fig. 3.26A and B).  Analysis of the nucleotides samples obtained 
showed that, compared to untreated samples, a novel peak appeared in the AICAR-
treated samples and increased with AICAR dose (Fig. 3.27A). The identity of this peak 
was confirmed as ZMP by spiking samples with an internal standard of purified ZMP 
(data not shown) and Fig. 3.27B shows the ZMP:ATP ratios from G361 cell extracts.   
 
There was also no detectable increase in cellular ADP:ATP or AMP:ATP ratios (Fig. 
3.26C, D and E), the latter calculated as outlined in section 3.2.4. This suggested that 
the effects of AICAR were due to conversion into ZMP. This data again illustrates that 
allosteric activation of the AMPK, regardless of the molecule causing it, can make a 
significant contribution to the overall activation mechanism. 
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Figure 3.26: Effect of treatment of G361 cells with AICAR 
G361 cells were treated with A23187 (10 µM), berberine (100 µM) or AICAR (1, 3 or 5 
mM) for 1 hr and lysed in parallel for analysis of AMPK activity or for analysis of 
nucleotide ratios. (A) AMPK was immunoprecipitated from cell lysates using anti-
AMPK-α1/-α2 antibodies and kinase activity measured using the AMARA peptide 
substrate. (B) Cell lysates were subject to Western blotting with the indicated 
antibodies. The bar chart represents the pACC:total ACC ratio obtained from the 
Western blots. (C) Samples lysed for nucleotide analysis were analysed by capillary 
electrophoresis and the ADP:ATP ratios calculated. (D) and (E): using the data from (C) 
and the assumptions outlined in section 3.2.4, the AMP concentrations and AMP:ATP 
ratios were estimated. Results are mean ± SEM (n = 3). Significantly different from 
control: *p < 0.05, ***p < 0.001. 
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Figure 3.26: Effect of treatment of G361 cells with AICAR (continued) 
G361 cells were treated with A23187 (10 µM), berberine (100 µM) or AICAR (1, 3 or 5 
mM) for 1 hr and lysed in parallel for analysis of AMPK activity or for analysis of 
nucleotide ratios. (A) AMPK was immunoprecipitated from cell lysates using anti-
AMPK-α1/-α2 antibodies and kinase activity measured using the AMARA peptide 
substrate. (B) Cell lysates were subject to Western blotting with the indicated 
antibodies. The bar chart represents the pACC:total ACC ratio obtained from the 
Western blots. (C) Samples lysed for nucleotide analysis were analysed by capillary 
electrophoresis and the ADP:ATP ratios calculated. (D) and (E): using the data from (C) 
and the assumptions outlined in section 3.2.4, the AMP concentrations and AMP:ATP 
ratios were estimated. Results are mean ± SEM (n = 3). Significantly different from 
control: *p < 0.05, ***p < 0.001. 
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Figure 3.27: AICAR increases intracellular ZMP levels 
G361 cells were treated with AICAR (1, 3 or 5 mM) for 1 hr and lysed in parallel for 
analysis of AMPK activity or for analysis of nucleotide ratios (same samples as Fig. 
3.25). (A) ZMP peaks obtained from control and AICAR treated samples. Peak identity 
was confirmed by spiking samples with purified ZMP (data not shown). (B) ZMP:ATP 
ratio from AICAR treated samples (mean ± SEM, n = 3). 
 
In addition to berberine, there exist a large variety of compounds that activate AMPK 
in an AMP-dependent manner. Many of these compounds are natural plant products 
used in traditional medicine. These compounds have been shown previously to disrupt 
mitochondrial function and increase the ADP:ATP ratio (Hawley et al., 2010). G361 cells 
were treated with: phenformin, a biguanide closely related to the anti-diabetic drug 
metformin; 2,4-dintrophenol (DNP), a proton ionophore that collapses the 
mitochondrial H+ gradient; troglitazone, a member of the thiazolidinedione family of 
anti-diabetics and quercetin, a plant flavonoid (Fig. 3.28). All of the compounds tested 
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displayed similar effect to berberine in that they increased ACC phosphorylation with 
no detectable increase of Thr172 phosphorylation.  
 
Figure 3.28: Effect of treatment of G361 cells with a range of AMPK activators 
G361 cells were treated with A23187 (10 µM), berberine (100 µM), phenformin (3 
mM), DNP (300 µM), troglitazone (40 µM), or quercetin (150 µM) for 1 hr. (A) AMPK 
was immunoprecipitated from the cell lysate using anti-AMPK-α1/-α2 antibodies and 
kinase activity measured using the AMARA peptide substrate. Results are mean ± SEM 
(n = 3). (B) Cell lysates were subject to Western blotting with the indicated antibodies. 
Significantly different from DMSO control: ***p < 0.001. 
 
3.3.6 ACC phosphorylation is mediated by AMPK 
To confirm that ACC phosphorylation is mediated by AMPK, wild-type (WT) and AMPK-
α1-/--α2-/- double knockout (dKO) mouse embryonic fibroblasts (MEFs) were treated 
with a number of AMPK activators, and the effects on AMPK and ACC phosphorylation 
determined (Fig. 3.29). Results show that, while ACC phosphorylation is increased in 
the WT MEFs in response to these compounds, no effect is seen in the dKO MEFs, 
confirming the necessity of AMPK for ACC phosphorylation. 
 
*** 
119 
 
 
Figure 3.29: Evidence that ACC phosphorylation in MEFs is mediated by AMPK 
Wild-type (WT) and AMPK-α1-/--α2-/- double knockout (dKO) mouse embryo fibroblasts 
were treated with A23187 (10 µM), berberine (300 µM), A769662 (300 µM) or 
salicylate (10 m M) for 1 hr. Cell lysates were subjected to Western blotting with the 
indicated antibodies.  
 
G361 cells stably expressing a dominant negative AMPK-α2 mutant (D157A) were also 
generated. G361 cells predominantly express AMPK-α1 and by expressing the AMPK-
α2 mutant it was hoped that this would compete with the endogenous α1 subunit for 
binding to the β and γ subunits. As AMPK is stable in a cell only as a heterotrimer, this 
would act as a dominant negative mutant cell line with the kinase dead α2 replacing 
the wild-type α1 in the heterotrimer, with the latter being degraded. This approach 
has been successfully used in a previous study from our laboratory (Hawley et al., 
2010) where HEK293 cells overexpressing an AMP-insensitive γ subunit no longer 
responded to any treatment that activated AMPK through changes in AMP levels. Fig. 
3.30 (data courtesy of Dr Fiona Ross) shows that treatment of the dominant-negative 
G361 cells with A23187 gave an AMPK activity ≈30% that of wild-type cells. This is 
similar to the reduction in basal activity observed and indicates that, in contrast to the 
results obtained with HEK293 cells, the expression of the kinase-dead α2 subunit is not 
sufficient to completely replace the active, endogenous α1, and a small amount of 
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active kinase remains. Despite this, the increase in ACC phosphorylation was reduced 
by a similar degree to the measured AMPK activity in the dominant negative cells. ACC 
phosphorylation induced by A769662 was also reduced by a similar amount (Fig. 3.30).  
 
Figure 3.30: Evidence that ACC phosphorylation in G361 cells is mediated by AMPK 
A FLAG-tagged inactive mutant (D157A) of AMPK-α2 was stably expressed in G361 cells 
to create dominant-negative (DN) cells.  (A) Wild-type (WT) and DN G361 cells were 
treated with A23187 (10 µM) for 1 hr. AMPK was immunoprecipitated from cell lysates 
using anti-AMPK-α1/-α2 antibodies and kinase activity measured using the AMARA 
peptide substrate (top). Results are mean ± SEM (n = 4). Cell lysates were also subject 
to Western blotting with the indicated antibodies (bottom). (B) WT and DN G361 cells 
were treated with A23187 (10 µM) or A769662 (30, 100, 300, 500 and 1000 µM) for 1 
hr. Cell lysates were subject to Western blotting using the indicated antibodies. 
Significantly different from control without A23187: ***p < 0.001; significantly 
different from wild-type AMPK plus A23187: †††p < 0.001. 
*** 
††† 
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3.3.7 Berberine increases pACC in cells expressing an α1[T172D] mutant 
In this chapter, results have been presented to show that treatment of G361 cells with 
an AMPK activator can increase ACC phosphorylation with no measureable change in 
Thr172 phosphorylation or AMPK activity. The proposed mechanism for this effect is 
allosteric activation of the kinase. To conclusively prove that allosteric activation of 
AMPK is possible with no changes in Thr172 phosphorylation status, AMPK-α1-/--α2-/-
dKO mouse embryo fibroblasts were transfected with an AMPK-α1 [T172D] mutant 
construct. Dephosphorylated AMPK-α is essentially inactive, as is a T172A mutant. 
However, the T172D mutant does retain a basal activity and can be allosterically 
activated by AMP, although it cannot be phosphorylated and activated by upstream 
kinases (Stein et al., 2000). Thus, any changes in kinase activity in this mutant must be 
due to allosteric activation. MEFs were transfected with plasmids encoding AMPK-β2, 
AMPK-γ1 and AMPK-α1 wild-type (WT) or AMPK-α1[T172D] mutant (Fig. 3.31). The 
recombinant proteins could not be detected by Western blotting (data not shown), 
probably due to the low transfection efficiency. Despite this, a significant basal activity 
could be detected in the cells expressing either of the α1 constructs, although the 
activity was lower in the T172D cells, confirming the results of others (Stein et al., 
2000). The activity of WT AMPK was increased by both A23187 and berberine, with a 
concomitant increase in ACC phosphorylation. Interestingly, the effect of berberine on 
ACC phosphorylation was greater than that of A23187 although the effect of Thr172 
phosphorylation and AMPK activation was smaller.  
 
The AMPK activity, as measured by Thr172 phosphorylation or immunoprecipitation 
followed by kinase assay, was not increased in the T172D mutant in response to either 
A23187 or berberine, as expected. However, phosphorylation of ACC did significantly 
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increase in the T172D cells in response to berberine, which must be due to allosteric 
activation of AMPK. 
 
Figure 3.31: Effects of A23187 and berberine in AMPK-knockout mouse embryo 
fibroblasts expressing α1 [T172D] mutant 
AMPK-α1-/--α2-/- mouse embryo fibroblasts were transiently transfected with DNAs 
encoding AMPK-α1 (WT or T172D mutant) together with AMPK-β2 and AMPK-γ1 for 48 
hr. Cells were then treated with A23187 (10 µM) or berberine (300 µM) for 1 hr. (A) 
AMPK was immunoprecipitated from cell lysates using anti-AMPK-α1/-α2 antibodies 
and kinase activity measured using the AMARA peptide substrate. Results are mean ± 
SEM (n = 3) (B) Cell lysates were subject to Western blot using the indicated 
antibodies. The bar chart represents the ratio of pACC to total ACC quantified from 
these blots and results are mean ± SEM (n = 3). Significantly different from control 
without A23187: **p < 0.01, ***p < 0.001. 
 
 
 
*** 
*** 
*** 
*** 
** 
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3.3.8 The changes in Thr172 phosphorylation in intact cells are modest: 
Bacterially expressed AMPK complexes can be activated >100-fold in cell free assays by 
phosphorylation of Thr172 by either LKB1 or CaMKKβ (Suter et al., 2006). However, it 
remained unclear if changes in Thr172 phosphorylation in the intact cells would ever 
approach this maximal extent. Two methods were used to address this question. In the 
first, bacterially expressed kinase-dead AMPK heterotrimer (α1[D157A]β2γ1) was 
phosphorylated with either LKB1 or CaMKKβ until the phosphorylation, as measured 
by Western blotting using a phospho-Thr172 antibody, reached a maximum. The 
pThr172 signal obtained from equivalent amounts of AMPK-α from cell lysates was 
then measured. Assuming that the phosphorylation of the bacterially expressed α 
subunit was stoichiometric, the degree of Thr172 phosphorylation in cell lysates could 
be calculated. In a second approach, AMPK was immunoprecipitated from cell lysates 
and incubated with and without recombinant CaMKKβ. After removal of CaMKKβ by 
extensive washing of the beads, the kinase activity of the immunoprecipitates was 
determined. 
 
Using these methods, the degree of phosphorylation of Thr172 in G361 (Fig. 3.32) and 
HEK293 (Fig. 3.33) cells (which are LKB1-null and LKB1-expressing respectively, see Fig. 
3.15) in response to AMPK activators was determined. In G361 cells, using the bacterial 
complex to calibrate the signal, basal Thr172 phosphorylation was estimated at 4%, 
rising ≈3.5 fold to 13% of maximum after treatment with A23187. Using CaMKKβ to 
phosphorylate the immunoprecipitates, the basal Thr172 phosphorylation was 
estimated at 3.5%, rising ≈5-fold after A23187 treatment to 18% of maximum. 
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In HEK293 cells, the changes in Thr172 phosphorylation in response to both A23187 
and berberine were determined. Using the bacterial complex, the degree of 
phosphorylation was estimated at 27% of maximum, rising to 36% or 50% of maximum 
in response to A23187 or berberine respectively. Similar results were obtained when 
CaMKKβ was used to phosphorylate the immunoprecipitates. A basal AMPK activity of 
23% of maximum rose to 37% or 60% of maximum after treatment with A23187 or 
berberine respectively. 
 
The two methods therefore gave broad agreement with each other. In LKB1-null G361 
cells, Thr172 phosphorylation is initially very low. This can be increased by activation of 
CaMKKβ by A23187, but the Thr172 phosphorylation never approaches the maximum. 
As expected, HEK293 cells, which express LKB1 (thought to be constitutively active), 
possess a relatively higher basal level of Thr172 phosphorylation and AMPK activity 
compared to G361 cells. Treatment with A23187 or berberine increased the 
phosphorylation of Thr172, but only by <2-fold to ≈60% of maximum. Thus, even after 
treatment with a potent mitochondrial poison, the change in phosphorylation of 
AMPK-α remains quite small. It seems that in both cell lines the actual changes in 
Thr172 phosphorylation are quite modest and operate over a fairly narrow range. Of 
course, these changes would be supplemented by allosteric activation in the intact cell. 
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Figure 3.32: Estimation of Thr172 phosphorylation in intact G361 cells 
G361 cells were treated ± A23187 (10 µM) for 1 hr. (A) Bacterially expressed AMPK 
(α1[D157A]β2γ1 complex) was incubated with increasing amounts of LKB1. Equivalent 
amounts of AMPK-α from G361 cell lysates and the bacterially expressed complex 
were analysed by Western blotting using anti-pThr172 and anti-AMPK-α antibodies.  
Assuming the bacterial complex is stoichiometrically phosphorylated, the degree of 
pThr172 in G361 cell lysates was calculated. The graph shows mean ± SEM from 5 
independent experiments. (B) AMPK was immunoprecipitated from G361 cell lysates 
with anti-AMPK-α1/-α2 antibodies. AMPK activity was then measured before and after 
phosphorylation by purified CaMKKβ. AMPK activity was determined using the AMARA 
peptide substrate. Results are mean ± SEM from 3 independent experiments. Each 
experiment was performed using multiple samples. Significantly different from control 
(before CaMKKβ treatment) by one-way ANOVA with Dunnett’s multiple comparison 
test: **p < 0.01, ***p < 0.001. 
 
 
*** 
** 
126 
 
  
 
Figure 3.33: Estimation of Thr172 phosphorylation in intact HEK293 cells 
HEK293 cells were treated with DMSO, A23187 (10 µM) or berberine (100 µM) for 1 hr. 
(A) Bacterially expressed AMPK (α1[D157A]β2γ1 complex) was incubated with 
increasing amounts of CaMKKβ. Equivalent amounts of AMPK-α from HEK293 cell 
lysates and the bacterially expressed complex were analysed by Western blotting using 
anti-pThr172 and anti-AMPK-α antibodies. Assuming the bacterial complex is 
stoichiometrically phosphorylated, the degree of pThr172 in HEK293 cell lysates was 
calculated. The graph shows mean ± SEM (n = 3) (B) AMPK was immunoprecipitated 
from HEK293 cell lysates (treated as above) with anti-AMPK-α1/-α2 antibodies. AMPK 
activity was then measured before and after phosphorylation by purified CaMKKβ. 
AMPK activity was measured using the AMARA peptide substrate. Results are mean ± 
SEM (n = 3). Significantly different from control (before CaMKKβ treatment) by         
one-way ANOVA with Dunnett’s multiple comparison test: *p < 0.05, ***p < 0.001. 
  
* 
*** 
*** 
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3.4 Discussion 
3.4.1 Promotion of phosphorylation by AMP 
The results presented in this chapter highlight the key role that AMP plays as a 
physiological regulator of AMPK.  
 
Evidence is presented to show that AMP can promote phosphorylation of Thr172 of 
AMPK by the major upstream kinase LKB1, but not by the alternate upstream kinase 
CaMKKβ. No effect of ADP was observed with either upstream kinase. Recent papers 
from the Kemp laboratory (Oakhill et al., 2011, 2010) had reported that both AMP and 
ADP could promote Thr172 phosphorylation by CaMKKβ, results that have not been 
reproduced, either in this thesis or in other published work (Hawley et al., 2005). The 
reasons for these discrepancies are unclear, but a simple explanation could be that the 
experiments of Oakhill et al were contaminated with trace amounts of protein 
phosphatase. 
 
The original experiments showing that AMP promoted Thr172 phosphorylation by the 
as-then unidentified upstream kinase were disputed by other groups as it was 
suggested that one of the preparations used might have been contaminated with a 
magnesium dependent protein phosphatase of the PPM family, and that any effects of 
the nucleotide on Thr172 phosphorylation were due to protecting this site against 
dephosphorylation by phosphatases. This protection would lead to an increase in net 
phosphorylation, similar to that which would be observed if AMP was promoting the 
phosphorylation reaction. 
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 Indeed, a preparation of AMPK purified from rat liver used in other studies was 
contaminated with a PPM phosphatase (Sanders et al., 2007b). However, it seemed 
unlikely that this was true for the preparations used in this chapter, for two reasons:  
i. The preparation used by Sanders et al was purified through two steps, whereas the 
preparation used in this study (see Hawley et al., 1996) was purified through a 
further four steps. Based on a previous analysis of this method (Carling et al., 
1989), this would result in the relative purifications factors being 45-fold vs 708-
fold. In fact, the method of Hawley et al (1996) has since been revised and the 
current method utilizes a Superdex200 column rather than a Sephacryl S-200, 
which is likely to further increase the purity of the preparation. 
ii. If the observed effects were due to protection against dephosphorylation, then 
they should be observed with both LKB1 and CaMKKβ, rather than just with LKB1. 
The upstream kinase used should be irrelevant: it would only be there to provide 
the phosphate for the phosphatase to remove. This would assume that the 
contamination is in the AMPK preparation, not one of the upstream kinase 
preparations. However, based on the results in section 3.3.1, if the contamination 
was in the LKB1 preparation then ADP should have similar effects to AMP, which is 
not the case.  
Taken together, these arguments seem to rule out the contamination of any of the 
preparations with a protein phosphatase. This was further confirmed by the mock 
incubations in Fig. 3.7, where no decrease in phosphorylated Thr172 was observed 
unless exogenous PP2C was added. This confirms that the preparations are not 
contaminated with a PPM family phosphatase, and that the observed effects of AMP 
are due to promotion of phosphorylation. 
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Although Oakhill et al (2010) performed an experiment similar to our Fig. 3.7 to show 
that the AMPK preparation used was not contaminated with phosphatase, this was not 
treated in the same manner as the AMPK used for the phosphorylation experiments. 
Prior to the phosphorylation reactions, AMPK (expressed in COS7 cells as a GST fusion) 
bound to glutathione-Sepharose beads was dephosphorylated using PP2C. This PP2C 
was also expressed as a GST fusion, although the protein had been treated with 
thrombin to cleave and remove the GST tag. The beads were then washed to remove 
PP2C. AMPK was eluted from the beads and incubated with upstream kinase and 
nucleotide to measure the promotion of phosphorylation. If the washing of the beads 
had not removed all of the PP2C (for example, if the GST cleavage had been 
incomplete) then trace amounts could be present in the phosphorylation reactions. 
The AMPK used in the contamination experiments is phosphorylated AMPK expressed 
in COS7 cells and has not been exposed to PP2C. This would explain why Oakhill et al 
observed effects of both AMP and ADP: the effects were not on the phosphorylation 
reaction but were rather on inhibition of the phosphatase reaction. Although this 
explains the results of the COS7 expressed AMPK, Oakhill et al (2010) also examined 
the effect on AMPK co-expressed with NMT (N-myristoyl transferase) in bacteria. 
Again, AMP promoted phosphorylation of Thr172 by CaMKKβ, although examination of 
the Thr172 immunoblots suggested that the effect was modest. It is difficult to 
reconcile these results with those of this chapter and other studies (Hawley et al., 
2005) where no effect of AMP on CaMKKβ mediated phosphorylation was detected. 
Interestingly, Oakhill et al did not repeat the experiments with bacterially expressed 
AMPK using LKB1 as the upstream kinase. In their follow-up study reporting that ADP 
also promoted Thr172 phosphorylation (Oakhill et al., 2011), CaMKKβ was used for all 
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experiments and the effects of using LKB1 were not examined. It would have been 
interesting to examine if similar effects were observed using ADP and LKB1. 
 
Instead of PP2C, the experiments performed in this chapter used PP2A to 
dephosphorylate purified AMPK. PP2A has the advantage that it can be completely 
inhibited by okadaic acid (Cohen, 1989) and therefore does not need to be removed 
from the incubations prior to the phosphorylation reaction. As the AMPK and LKB1 
preparations were not contaminated with protein phosphatase, the effects of AMP on 
LKB1-mediated Thr172 phosphorylation must be via promoting phosphorylation and 
not by inhibiting the dephosphorylation. 
 
The dependence of the effect on β subunit myristoylation was also investigated, but, 
due to technical difficulties, the attempts were not successful. The stable cell lines 
generated contained β1 and β2 with a C-terminal FLAG tag. The goals were to 
immunoprecipitate the recombinant β complexes and determine if AMP could 
promote phosphorylation by LKB1. However, no kinase activity was obtained after 
FLAG immunoprecipitation. It seems that the recombinant β subunit cannot form a 
complex with the α and γ subunits as an anti-FLAG immunoprecipitate, whilst having 
no kinase activity itself, did not deplete the kinase activity of a subsequent 
immunoprecipitation using anti-AMPK-α1/-α2 antibodies, suggesting that no catalytic 
subunits were associated with the FLAG-tagged β subunit. The complex appeared to be 
active in the intact cell, although without the ability to measure kinase activities of 
recombinant and wild-type complexes it is difficult to estimate how successfully the 
wild-type β has been replaced with the recombinant β. It may be that the position of 
the FLAG tag at the C-terminus of the β subunit interferes with complex assembly, as 
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examination of most complete crystal structures suggests that the activation loop of 
the kinase is closely associated with the C-terminus of the β subunit (Xiao et al., 2011). 
Placing the tag at the N-terminus would interfere with the myristoylation of Gly2. The 
β construct used by Oakhill et al (2010) contained no tag, suggesting that they had 
encountered similar problems. However, using an untagged β and performing 
immunoprecipitations with anti-α1/-α2 antibodies means that the contents of the 
immunoprecipitated heterotrimer are not well defined and may contain endogenous, 
rather than recombinant, β subunit.  
 
3.4.2 Protection against dephosphorylation by AMP and ADP 
The results presented in this chapter also show that dephosphorylation of Thr172 by 
protein phosphatases is inhibited by both AMP and ADP, with the effects of both 
nucleotides being antagonized by ATP. While broadly confirming those of Xiao et al 
(2011) these results disagree in one important respect. Xiao et al state that ADP 
provided protection against Thr172 dephosphorylation across a range of 
concentrations similar to that of AMP, however the results in this chapter clearly show 
that AMP is around 10-fold more potent than ADP, regardless of the ATP concentration 
used in the assays (Fig. 3.11). This increased potency of AMP was observed, although 
not commented on, in the study of Xiao et al (2011). Reanalysis of their Fig. 1B shows 
that AMP is at least 3 times more potent than ADP in protecting the kinase against 
dephosphorylation, with 30 µM AMP offering greater protection than 100 µM ADP. 
This is smaller than the 10-fold difference observed in this chapter, but this could be 
due to differences in systems being studied: Xiao et al used bacterially expressed 
AMPK, not rat liver purified AMPK as in this chapter. Mammalian AMPK exhibits a 
greater allosteric activation in response to AMP compared with the bacterially 
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expressed complex. It is possible that this increased degree of activation would also be 
observed when measuring protection against dephosphorylation. Xiao et al (2011) did 
examine the effects of AMP and ADP on rat liver purified AMPK, however they did so 
by Western blotting, which is not as quantitative as kinase assays. The rat liver 
preparation used was also less well defined than our preparation and they used 
endogenous, contaminating, phosphatases to dephosphorylate AMPK. Perhaps if these 
experiments were repeated under similar conditions used in this chapter a 10-fold 
difference between the nucleotides would be observed. 
 
3.4.3 Allosteric activation of AMPK 
Examining the allosteric activation of the rat liver purified AMPK by AMP showed that 
the activity of AMPK could be increased by as much as 13-fold by AMP when this was 
measured at 5 mM ATP, a concentration typical of that found in an intact cell 
(Imamura et al., 2009). These results convincingly demonstrate that AMPK can be 
allosterically activated by low concentrations of AMP, even when ATP is present at 
physiological concentrations. 
 
The data generated from the G361 cell line also supports the role of AMP as a 
physiological regulator of AMPK. Treating these LKB1-null cells with berberine, a 
mitochondrial inhibitor, resulted in a large increase in phosphorylation of ACC with no 
measureable increase in phosphorylation of Thr172 by either kinase assay or Western 
blot. In fact, the increase in ACC phosphorylation was larger with berberine than that 
with the calcium ionophore A23187, which did increase Thr172 phosphorylation. This 
suggests that, in an intact cell, allosteric activation can be quantitatively as important 
as changes in Thr172 phosphorylation. This was further supported by treatment of 
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G361 cells with berberine alone, or berberine plus A23187 (Fig. 3.19). The data shows 
that the allosteric activation in response to berberine could not be increased further by 
the simultaneous addition of A23187, which increased Thr172 phosphorylation. The 
phosphorylation of ACC in response to berberine alone must already be close to 
maximal. These data also illustrates that, in agreement with the cell-free assays, AMP 
can compete with ATP for binding to the nucleotide-binding sites on the γ subunit, 
despite the latter nucleotide being present at far higher levels. 
 
G361 cells were also treated with A769662, a synthetic activator of AMPK. A769662, 
like berberine, increased ACC phosphorylation with no change in Thr172 
phosphorylation. A769662 can also protect the kinase against dephosphorylation but it 
appears that under these conditions in these cells it is eliciting all of its effects via 
allosteric activation. 
 
The experiments performed with other AMPK activators also highlight the contribution 
that allosteric activation makes to the overall regulation of the kinase. Salicylate, a 
recently identified direct activator of AMPK (Hawley et al., 2012) was shown to 
activate AMPK in G361 cells independent of changes in AMP levels and Thr172 
phosphorylation. Salicylate is a relatively poor allosteric activator, which explains the 
small change in ACC phosphorylation at 1 mM salicylate, a concentration that has no 
effect on the ADP:ATP ratio. At higher concentrations (3 and 10 mM) salicylate will still 
allosterically activate AMPK but it also increases the ADP:ATP ratio by partially 
uncoupling the mitochondrial respiratory chain from ATP synthesis, resulting in a rise 
in intracellular AMP. It seems probable that, as the more potent allosteric activator, a 
large proportion of the observed effects in G361 cells at 3 and 10 mM salicylate are 
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actually being caused by AMP, not salicylate. It was estimated that AMP rose from       
30 µM to 64 µM in response to 10 mM salicylate. Plotting these data on the allosteric 
activation curve at 5 mM ATP suggests that this could increase the AMPK activity 
around 2-fold, which would presumably be high enough to contribute to ACC 
phosphorylation. In HEK293 cells, where LKB1 is present, salicylate is able to elicit 
effects on Thr172 phosphorylation as well as allosteric activation, which explains its 
larger effects on AMPK activity and ACC phosphorylation in these cells (Hawley et al., 
2012). 
 
Treatment of G361 cells with AICAR also resulted in a large increase in phosphorylation 
of ACC with no increase in Thr172 phosphorylation, and no change in cellular ADP:ATP 
ratios. A concentration-dependent rise in ZMP was detected in these samples and it is 
likely that the effects on AMPK are due to allosteric activation by ZMP, not AMP. 
 
A range of AMP-dependent AMPK activators applied to G361 cells elicited a similar 
response to that of berberine. These compounds are structurally unrelated and the 
property they have in common is disrupting mitochondrial function and hence cellular 
nucleotide ratios. It therefore seems unlikely that the effects of berberine on ACC 
phosphorylation could be due to off-target effects and the simplest explanation is 
allosteric activation of AMPK by AMP.  
 
Whilst it could be argued that the effects of berberine and the other AMP-dependent 
activators could be due to AMP inhibiting dephosphorylation of ACC, rather than 
allosterically activating AMPK, this also seems unlikely. The effect of AMP on 
protecting AMPK from dephosphorylation is substrate-mediated, as first demonstrated 
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in the original study characterizing this effect (Davies et al., 1995). The authors 
proposed that the protective effect of AMP was independent of the phosphatase used 
as the effects were present with both PP2A and PP2C. Using alternate substrates the 
authors also demonstrated that the phosphatases themselves were not affected by 
AMP (Davies et al., 1995). The authors also proposed that protection against 
dephosphorylation was due to AMP binding to AMPK, as the half-maximal effect of 
AMP was identical to that of AMP on allosteric activation of the kinase and both were 
increased by a similar degree when measured in the presence of 4 mM ATP. While 
Davies et al were unaware at that time of the location of the nucleotide binding sites 
on the γ subunit of AMPK, Sanders et al (2007b) demonstrated that mutation of key 
residues in these sites abolished the protective effects of AMP, again suggesting that 
the effect was substrate-mediated. This was also demonstrated for ADP (Xiao et al., 
2011). In addition to this, an AMPK-α1 fragment (residues 1-312), which lacks the 
nucleotide binding sites on the γ subunit, was not protected against PP2Cα mediated 
Thr172 dephosphorylation by AMP, unlike the full-length heterotrimer (Suter et al., 
2006). Thus the effects of AMP on ACC phosphorylation cannot be attributed to effects 
on the protein phosphatase and must be caused by increased allosteric activation of 
AMPK. This is also likely to be true for the effects of A769662. Serine-108 of the β1 
subunit of AMPK is essential for activation by A769662. Mutation of this residue to an 
alanine almost completely abolished the allosteric activation and protection against 
Thr172 dephosphorylation by A769662, whilst the AMP-mediated effect was 
unchanged (Sanders et al., 2007a). These results confirm that A769662, like AMP, 
exerts its effects on dephosphorylation via binding to AMPK, not the phosphatase. 
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The data presented here also reinforces the requirement of AMPK for phosphorylation 
of ACC. As well as an effect on the ACC phosphatase, one other way in which the data 
could be explained is that the compounds tested are not increasing AMPK activity, but 
a distinct ACC kinase, which might explain why no change in Thr172 phosphorylation 
was detected. However, there is a large body of evidence to indicate that AMPK is the 
only kinase phosphorylating Ser79 on ACC. Using AMPK catalytic subunit knockouts, it 
has been demonstrated that ACC phosphorylation is abolished in a number of different 
cell types including mouse embryonic fibroblasts (Foretz et al., 2010), hepatocytes 
(Laderoute et al., 2006) and T cells (Rolf et al., 2013). It has also been shown in β1 
knockout mouse hepatocytes that A769662, which only activates AMPK complexes 
containing β1 and not those containing β2, has no effect on ACC phosphorylation 
(Scott et al., 2008). This was also demonstrated following activation using salicylate, 
which, like A769662, only activates complexes containing β1 (Hawley et al., 2012). In 
addition, phosphorylation of Drosophila ACC was abolished in response to oligomycin 
when the α, β and γ subunits were knocked down by dsRNAi interference (Pan and 
Hardie, 2002).  
 
Results in this chapter from mouse embryo fibroblasts (Fig. 3.29) and G361 cells (Fig. 
3.30) show that AMPK is the kinase phosphorylating Ser79 on ACC and that the effects 
of the compounds tested are not due to off-target effects on a different kinase. This 
suggests that ACC phosphorylation in G361 cells, like other cell types examined, is 
mediated through AMPK. It is not possible to completely rule out the possibility that 
the low ACC phosphorylation observed in the dominant negative cells was due to a 
kinase other than AMPK, although this kinase would have to be activated by both 
A23187 and A769662, which seems unlikely. This kinase would also have to be absent 
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from mouse embryo fibroblasts as no effect of A23187 or A769662 on phosphorylation 
of ACC was observed in these cells (Fig. 3.29). Taken together, the simplest explanation 
is that rising AMP levels in the intact cell are allosterically activating AMPK and causing 
phosphorylation of ACC. 
 
3.4.4 AMP as the key physiological regulator of AMPK 
Some recent reviews have proposed that ADP, and not AMP, is the critical 
physiological regulator of AMPK (Carling et al., 2012; Oakhill et al., 2012). There seem 
to be two main reasons for these doubts. The first is that allosteric activation is 
reported to be quite modest, usually <2-fold, whereas stoichiometric phosphorylation 
of Thr172 can produce ≈100-fold AMPK activation (Sanders et al., 2007b; Suter et al., 
2006). If changes in phosphorylation status can increase activity 100-fold then the 
relatively small 2-fold activation reported with the bacterially expressed heterotrimer 
would appear to be negligible. However, these estimates for the extent of allosteric 
activation came from studies performed using bacterially expressed heterotrimers. 
Using native rat liver AMPK, an allosteric activation of up to 13-fold was obtained in 
response to AMP, significantly higher than that of the bacterial complex. 
 
The reasons for this discrepancy are not completely clear, but could relate in part to 
the bacterial complex lacking some post-translational modifications that occur with 
the mammalian complex. It should also be pointed out that, to obtain a 13-fold 
increase in AMPK activity, it was necessary to take some precautions to reduce the 
basal activity. As discussed previously, commercial preparations of ADP are often 
contaminated with AMP. This can also be true for ATP, which, by necessity, is present 
in the kinase assay as a source of gamma phosphate for transfer to the synthetic 
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peptide substrate. AMP may also be generated during the assay, most likely from non-
enzymic breakdown of ADP generated during the assay. As AMPK is sensitive to low 
concentrations of AMP, it has already been suggested that the levels of AMP present 
may be high enough to increase the basal activity, thus reducing the apparent extent 
of stimulation (Suter et al., 2006). To alleviate this problem, freshly prepared ATP 
solutions that had been screened for AMP contamination were utilized. The duration 
of the kinase assays was also reduced to 5 minutes to help minimize the amount of 
AMP generated during the incubation. Another way in which the apparent sensitivity 
of AMPK to AMP could have been increased would have been to include 5’-
nucleotidase in the control incubations lacking additional AMP. The 5’-nucleotidase 
would hydrolyse any contaminating AMP in the ATP preparation and may reduce the 
basal activity of the kinase even further. 
 
While it is true that Thr172 phosphorylation can increase AMPK activity ≈100-fold in a 
cell free system, this extent of activation is observed when comparing completely 
dephosphorylated enzyme (which has an almost undetectable activity) to that of 
stoichiometrically phosphorylated enzyme. It seemed unlikely that the changes in 
phosphorylation of Thr172 in an intact cell would operate over such a wide range. 
Indeed, the results in Fig. 3.32 and Fig. 3.33 show that the changes in phosphorylation 
are actually much more modest. In G361 cells, which lack LKB1 and therefore exhibit a 
low basal AMPK activity, A23187 treatment increased AMPK activity by 4-fold, but this 
represented a change from only 4% to around 16% of stoichiometric Thr172 
phosphorylation. In HEK293 cells, which express LKB1, the basal phosphorylation was 
higher, around 25%, and the increases in response to A23187 (1.5 fold) and berberine 
(2 fold) were even more modest. Thus, it seems that, although 100-fold changes in 
139 
 
AMPK activity due to Thr172 phosphorylation can be achieved in cell-free assays, the 
changes that occur in intact cells are generally much more modest. 
 
The intact cell experiments also support the idea of allosteric activation being an 
important component of the overall regulatory mechanism. The data presented here 
show that the phosphorylation of ACC in G361 cells was higher with berberine than 
with A23187, suggesting that allosteric activation can increase AMPK activity to a 
greater extent than that induced by changes in Thr172 phosphorylation. Further 
evidence of this comes from the AMPK-α double knockout mouse embryo fibroblasts 
transfected with wild-type α1. The increase in ACC phosphorylation was higher in 
response to berberine than with A23187, despite the smaller increases in Thr172 
phosphorylation. This can be explained by the effect of berberine on ACC 
phosphorylation being caused by both allosteric activation as well as increased Thr172 
phosphorylation. That the α1[T172D] mutant AMPK could be allosterically activated in 
these double knockout mouse embryo fibroblasts further supports this idea. These 
data conclusively demonstrate that significant allosteric activation can occur in intact 
cells without any changes in Thr172 phosphorylation. 
 
Another argument against AMP being the physiological regulator of AMPK came from 
estimates of the affinities of the nucleotide binding sites on the γ subunit for AMP, 
ADP and ATP (Xiao et al., 2011). The binding affinities were measured indirectly using 
displacement of fluorescent derivatives of ATP from the bacterially expressed 
heterotrimer. The estimated KD at the higher affinity exchangeable site was around 2 
µM for all three nucleotides, while the estimated KD for the lower affinity site was 
around 50-80 µM for all three nucleotides. Site 1 was proposed to be the high affinity 
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site and it was proposed that binding at this site was responsible for allosteric 
activation. This was based on three observations: (i) a crystal structure of the complex 
obtained after co-crystallization with ADP revealed only a single molecule of the 
nucleotide bound at site 1, suggesting that site 1 is the high affinity site; (ii) NADH, 
which was proposed to bind to the high affinity site, was found to competitively inhibit 
allosteric activation by AMP; (iii) AMP competitively inhibited NADH binding with an 
estimated KD of 1.6 µM, similar to the affinity at the high affinity site determined by 
competition with coumarin-ATP. Since AMP is present at much lower cellular 
concentrations that ADP or ATP, it was further suggested that AMP would be unable to 
effectively compete with ADP or ATP for binding at the high affinity site. However, the 
13-fold increase in activity observed at physiological concentrations of ATP (Fig. 3.13 
shows that AMP can compete with other nucleotides. This is also true in intact G361 
cells, where AMP (Fig. 3.17), and ZMP (Fig. 3.26), could compete with ADP and ATP for 
binding at these sites.  
 
The affinities of the nucleotide binding sites discussed above (Xiao et al., 2011) were 
estimated using the assumption that there were only two available sites for binding, 
and that these did not interact. However, given that the crystal structures show that 
certain basic side chains are involved in binding more than one molecule of bound 
AMP (Xiao et al., 2007), it seems unlikely that there would be no interaction between 
the three binding sites. Indeed, mutation of any of the three aspartate residues that 
bind the ribose ring of the bound nucleotide in sites 1, 3 or 4 was found to affect the 
effects of AMP both to cause allosteric activation and to enhance phosphorylation by 
CaMKKβ (Oakhill et al., 2010). Interaction between sites is also suggested by earlier 
work where the binding of AMP and ATP to the CBS domains displayed strong positive 
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cooperativity (Scott et al., 2004). The assumptions that there was no interaction 
between the binding sites therefore may not have been entirely valid. Furthermore, in 
another study (Chen et al., 2012), when the core of the heterotrimer was co-
crystallized with AMP or ATP independently, ATP was found to bind at site 4, the 
proposed “non-exchangeable” site for AMP and this would preclude binding of any 
nucleotide at site 3. Additionally, mutation of site 1 had no effect on allosteric 
activation by AMP, whereas mutation of site 3 or 4 completely abolished this          
(Chen et al., 2012).  
 
The half-maximal concentrations calculated in this chapter for allosteric activation, 
protection against dephosphorylation and promotion of phosphorylation also do not 
fully support the suggestion that allosteric activation is caused by binding at the high 
affinity site (thought to be site 1) and protection against dephosphorylation by binding 
at the lower affinity site (thought to be site 3) (Xiao et al., 2011). The EC50 for AMP on 
allosteric activation and protection against dephosphorylation were very similar (5 µM 
and 2.6 µM respectively, although the former was measured in the presence of        
200 µM ATP), which suggests but does not prove that they are due to binding at the 
same site. These values correlate with the proposed affinity of site 1 (≈2 µM). In 
addition, the half-maximal effect of AMP on inhibition of dephosphorylation was 
approximately 10 times lower than that of ADP, suggesting that the binding affinities 
of the two nucleotides at the site affecting dephosphorylation are not equal. The 
calculated EC50 for promotion of phosphorylation by AMP (160 µM) is closer to the 
proposed affinity of site 3 (≈80 µM), although the former was measured in the 
presence of 200 µM ATP. 
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The data discussed above shows that more work is required before a specific function 
can be allocated to a particular nucleotide binding site. Ideally, this may require the 
use of novel activators of AMPK that elicit only one of the regulatory effects on the 
kinase (allosteric activation, inhibition of dephosphorylation or promotion of 
phosphorylation), as well as solving the crystal structure of the kinase in the presence 
of these activators. However, the most widely used activator of AMPK, A769662, does 
not bind to the nucleotide binding sites on the γ subunit, but rather to a site that 
appears to be located on the β subunit. A current goal of the AMPK field is therefore to 
develop and characterize novel activators or inhibitors that uniquely bind at only one 
of the nucleotide binding sites. However, it is entirely possible that multiple nucleotide 
binding sites contribute to any one regulatory mechanism and it would not be possible 
to assign a role to an individual site. 
 
Nucleotide measurements from intact G361 cells also support a role for AMP in 
regulating AMPK. Previous estimates for AMP levels in the intact cells, based on 
previous estimates in the literature, were quoted to be 1-5 µM, with ADP being 
present at 50-200 µM (Xiao et al., 2011). However, examining these papers suggest 
that the levels of AMP in the cell are, in fact, higher than this. Measuring the ADP:ATP 
ratio and estimating the absolute changes in nucleotide levels in G361 cells gave 
different results. AMP was estimated to rise from 40 µM to 270 µM after berberine 
treatment, with ADP rising from 426 µM to 975 µM. The change in AMP concentration 
is therefore around-6.5 fold, compared with 2-fold for ADP. After berberine treatment 
the ADP concentration is predicted to be only 3-4 times the concentration of AMP. 
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The nucleotide estimates were plotted on the allosteric activation, protection against 
dephosphorylation and promotion of phosphorylation curves obtained (Fig. 3.34). The 
change in AMP corresponds well with the range of concentrations that were shown to 
induce both allosteric activation and protection against dephosphorylation (both 
measured at 5 mM ATP). The predicted increase in AMP also corresponds with the 
estimated EC50 for promotion of Thr172 phosphorylation of 160 µM AMP. However, 
the EC50 was measured at 0.2 mM ATP, so it is unclear how significant the promotion 
of phosphorylation would be at the higher ATP concentrations prevalent in vivo. 
Plotting the ADP concentrations on the dephosphorylation curve, it is also clear that 
the increase in ADP would only be sufficient to produce a very small effect on Thr172 
phosphorylation compared with the larger effect of AMP. 
 
One caveat is that these G361 cells are a transformed cell line from a human 
melanoma and may therefore have altered metabolic function compared with non-
transformed cell lines. As they lack LKB1 and therefore have a low basal AMPK activity, 
it could also be argued that these cells would be more sensitive to any disruption to 
mitochondrial function, resulting in a larger fluctuation in nucleotide levels than in cells 
expressing LKB1. However, examining data from HEK293 cells (isolated from the 
embryonic kidney of a human foetus) suggests that the changes in nucleotide levels 
may actually be greater than those in G361 cells. An increase in ADP:ATP ratio from 0.1 
to 0.6 after berberine treatment was observed (Hawley et al., 2010). Using these 
figures, a rise in AMP from 50 µM to 950 µM would be predicted. This difference might 
be explained by the operation of the Warburg effect in the G361 cells. This 
phenomenon, first described by Otto Warburg in 1924, is the observation that cancer 
cells produce their energy predominantly through high rates of glycolysis, rather than 
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mitochondrial oxidative phosphorylation (Warburg, 1956). Non-transformed cells, by 
contrast, generate the bulk of their energy through oxidative phosphorylation. HEK293 
cells may therefore be more sensitive than tumour cells, such as G361 cells, to 
inhibitors of mitochondrial function like berberine. 
 
Figure 3.34: Changes in AMP and ADP levels vs. AMPK dose-response curves 
Estimates of the changes in AMP and ADP levels in G361 cells in response to berberine 
were calculated in section 3.3.4 and plotted on the dose response curves for allosteric 
activation (top), protection against dephosphorylation (middle) and promotion of 
phosphorylation (bottom). 
145 
 
3.4.5 AMPK may have evolved sensitivity to AMP 
Thus, allosteric activation by AMP, as discussed above, appears to be a quantitatively 
important part of the overall activation mechanism. An interesting proposal is that the 
ability to respond to AMP has arisen during evolution of the kinase. Allosteric 
activation by AMP has been observed with orthologues from insects (Pan and Hardie, 
2002), nematodes (Apfeld et al., 2004) and mammals but not those from fungi 
(Mitchelhill et al., 1994; Wilson et al., 1996; Woods et al., 1994) or plants (Mackintosh 
et al., 1992), which seem to be regulated exclusively by phosphorylation. In S. 
cerevisiae, SNF1 activity is not regulated by AMP, either allosterically or by changes in 
phosphorylation (Sanders et al., 2007b). Instead, SNF1 is protected from Thr210 
(equivalent to Thr172 in mammal) dephosphorylation by ADP (Mayer et al., 2011). As 
the effects of Thr172 phosphorylation and allosteric activation multiply together to 
give the overall activity of the kinase, AMPK orthologues that can respond to AMP 
would exhibit greater sensitivity to changes in cellular energy levels. This is further 
enhanced by the fact that the AMP:ATP ratio rises as the square of the ADP:ATP ratio 
(Hardie and Hawley, 2001). A system that is designed to respond to the former, in 
addition to the latter, will provide larger responses to any disruption in energy. The 
responsiveness of AMPK from higher organisms to AMP may represent an additional 
and more sensitive form of regulation than that in more primitive organisms. 
 
3.4.6 A revised model for regulation of AMPK 
Based upon the results presented in this chapter, a new model for AMPK regulation by 
nucleotides is proposed (Fig. 3.35). While both AMP and ADP can protect Thr172 
against dephosphorylation, AMP is around 10-fold more potent. Promotion of Thr172 
phosphorylation appears to be a genuine regulatory mechanism, but is only observed 
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with AMP and only when LKB1 is the upstream kinase. Allosteric activation by AMP 
appears to be much more significant, both in a cell free system and the intact cell, than 
previously suggested. 
 
 
Figure 3.35: A revised model for regulation of AMPK 
Mechanism by which AMP and ADP regulate AMPK: (1) binding of AMP to AMPK 
promotes Thr172 phosphorylation by LKB1; (2) binding of AMP or ADP protect Thr172 
against dephosphorylation by protein phosphatases, although AMP is more potent; (3) 
binding of AMP causes allosteric activation of AMPK. All three effects are antagonized 
by binding of ATP. 
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CHAPTER 4: INVESTIGATING PHOSPHORYLATION OF LKB1 BY 
AMPK 
4.1 Introduction 
4.1.1 Regulation of LKB1 activity by post-translational modification 
The LKB1 complex, as discussed in Chapter 1, is the major upstream kinase for AMPK 
and the AMPK-related kinases. For full activity, LKB1 is required to be present in the 
cytoplasm, and binding of STRAD and MO25 to LKB1 results in cytoplasmic localization 
of the complex. Several lines of evidence suggest that LKB1, when bound to STRAD and 
MO25, is constitutively active. Treatment of intact cells with phenformin or AICAR, 
which potently activate AMPK, has no effect on the catalytic activity of either LKB1 or 
the ARKs, despite increased phosphorylation and activation of AMPK (Lizcano et al., 
2004). Furthermore, the activity of LKB1 or of the AMPK-related kinases was not 
increased in response to contraction in muscle, despite increased Thr172 
phosphorylation and activation of AMPK (Sakamoto et al., 2004). The lack of effect of 
energy stress on the activity of the AMPK-related kinases can be explained by the 
observation that the AMPK-related kinases, unlike AMPK-α, do not associate with the 
AMPK-β or AMPK-γ subunits and cannot respond to AMP in the same manner (Al-
Hakim et al., 2005). Despite this, many groups have reported that LKB1 activity is 
modulated by post-translational modifications, particularly phosphorylation. LKB1 is 
phosphorylated on multiple residues. Phosphorylation of Ser31, Ser325, Thr366 and 
Ser431 appear to be mediated by upstream kinases, whereas LKB1 autophosphorylates 
on Thr185, Thr189, Thr336 and Ser404 (Alessi et al., 2006). The figure below (4.1) 
illustrates the domain structure of LKB1 and the sites proposed to be modified by 
phosphorylation and farnesylation. 
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Figure 4.1: Domain structure of LKB1 and location of post-translational modifications 
LKB1 has an N-terminal domain (containing an NLS), a kinase domain, and a C-terminal 
domain proposed to be a regulatory region. The location of phosphorylation and 
farnesylation sites are shown, together with the proposed upstream kinases. Sites 
Thr185, Thr189, Thr336 and Ser404 are autophosphorylation sites. 
 
Phosphorylation of Ser325 has been reported to have no regulatory effect on LKB1 
function, as mutation of this site to either alanine or the phosphomimetic aspartate 
did not alter the ability of LKB1 to reduce cell growth (Sapkota et al., 2002a). The 
upstream kinase(s) acting on this site are unknown, although it was suggested that, as 
the region around Ser325 is proline-rich, this site may be the target of a proline-
directed kinase (Sapkota et al., 2002a). Recently, ERK was proposed as the upstream 
kinase for Ser325 (Zheng et al., 2009). Mutation of this site to alanine appeared to 
increase the activity of LKB1 towards AMPK in intact cells, suggesting that 
phosphorylation of this site inhibited LKB1 function. This result has been disputed in 
unpublished work from our laboratory where ERK did not phosphorylate LKB1 to any 
significant degree and where mutation of Ser325 to alanine had no effect on the ability 
of LKB1 to activate AMPK in a cell-free system (Dandapani, PhD thesis, 2013).  
 
Mutation of Thr366 partially reduced the ability of LKB1 to suppress growth of G361 
cells, although not to the same extent as a kinase-dead mutant, and seemed to have 
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no effect on its ability to phosphorylate either itself or p53 (Sapkota et al., 2002a). 
Phosphorylation of Thr366 was increased in response to ionizing radiation, and the 
upstream kinase was identified as ATM (Sapkota et al., 2002b). The functional 
consequence of phosphorylation at this site remains unclear. 
 
The C-terminus of LKB1 was shown to be phosphorylated at Ser431 by cAMP-
dependent protein kinase (PKA) in cell-free systems and in response to forskolin, a 
compound that raises intracellular cAMP levels and activates PKA, in intact cells 
(Collins et al., 2000). The authors also identified Cys433 as a prenylation site. Work 
from the Alessi laboratory then demonstrated that full-length LKB1 was 
phosphorylated at Ser431 and that this was mediated by either PKA or p90RSK (Sapkota 
et al., 2001). Mutation of Ser431 to an alanine had no effect on the ability of LKB1 to 
autophosphorylate or to phosphorylate p53 (AMPK had not been identified as an LKB1 
substrate at the time) but did reduce the ability of LKB1 to inhibit cell growth, having a 
similar effect as kinase-dead LKB1. In vivo prenylation at Cys433 was confirmed, 
although this did not influence the ability of LKB1 to inhibit growth (Sapkota et al., 
2001). It has recently been reported that mutation of Ser431 had no effect on the 
ability of LKB1 to phosphorylate and activate AMPK in either cell-free or intact cell 
systems (Fogarty and Hardie, 2009). Expression of an S431A mutant of LKB1 was able 
to halt progression of LKB1-null G361 cells through the cell cycle just as well as wild-
type LKB1, suggesting that phosphorylation of Ser431 is not required for LKB1 function 
(Fogarty and Hardie, 2009). Further support comes from the discovery that LKB1S, a 
splice variant of LKB1 in which the last 63 residues are replaced with a 39 residue 
sequence lacking the Ser431 and Cys433 sites, could activate AMPK and the AMPK-
related kinases to a similar extent as the wild-type protein (Towler et al., 2008). This 
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short form of LKB1 appears to play a role in spermiogenesis, because male mice lacking 
LKB1S were sterile (Towler et al., 2008). 
 
The function of the autophosphorylation sites is unclear. Mutation of Thr336 to 
glutamic acid, a phosphomimetic, had no effect on LKB1 catalytic activity but did 
reduce the ability of LKB1 to suppress cell growth (Sapkota et al., 2002a). More 
recently, phosphorylated Thr336 was proposed to bind to 14-3-3 proteins, resulting in 
decreased association of LKB1 with its substrates, such as AMPK (Bai et al., 2012). 
Overexpression of 14-3-3 proteins attenuated LKB1-induced cell cycle arrest (Bai et al., 
2012). 
 
4.1.2 Phosphorylation of Ser31 of LKB1 
The original AMPK consensus sequence was defined as φ(β/x)xxSxxxφ, where φ is a 
hydrophobic residue, present at the -5 and +4 positions (relative to the 
phosphoacceptor) and β is a basic residue at either position -3 or -4 (Dale et al., 1995). 
Using the sequence surrounding Ser79 of ACC1 (fused to GST) as a substrate for AMPK, 
an extended consensus motif was examined and revealed that AMPK interacted with 
its substrates over a wider area than previously thought (Scott et al., 2002). The 
interaction was reported as occurring over a region of 21 residues, from -16 to +4, 
compared with the 10 residues outlined above. In particular, a region extending from    
-5 to -16 was proposed to form an amphipathic helix that interacted across a 
hydrophobic groove in the kinase domain of AMPK, and mutation of this region 
increased the Km of AMPK for ACC by around 6-fold (Scott et al., 2002). Additionally, a 
basic residue at -6 was identified as important in determining the activity of AMPK 
towards ACC (Scott et al., 2002). 
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This work was expanded by the use of a peptide scanning library, where each peptide 
contained one fixed amino acid at a given position relative to a phosphoacceptor. Each 
peptide was used as a substrate for AMPK and the incorporation of phosphate 
determined, giving a measure of the selectivity of the kinase for each amino acid at 
each position (Gwinn et al., 2008). In agreement with the earlier study, a basic residue 
was strongly selected for in the -3 and -4 positions and a hydrophobic residue in the -5 
and +4 positions. Furthermore, a polar residue was selected for in the +3 position. An 
optimal AMPK motif was determined, with additional secondary and tertiary selections 
also detailed (Fig. 4.2). Serine 31 of LKB1 lies within a region that bears similarity to 
this AMPK consensus motif. The sequence contains a hydrophobic residue at positions 
-5 and +4 as well as a basic residue at -3 and -4 (Fig 4.2). The sequence, although not 
conforming to the consensus as closely as other well-known substrates in that there is 
a hydrophobic rather than a polar residue at +3, appears to be a reasonable match for 
phosphorylation by AMPK. Additionally, the sequence around Ser31 is highly 
conserved amongst higher eukaryotes, suggesting it may have some functional role. 
 
Figure 4.2: Protein sequence surrounding Ser31 of LKB1  
(A) Comparison of the AMPK consensus motifs and the sequences around Ser79 of 
ACC1 and Ser31 of LKB1 (adapted from Gwinn et al., 2008). (B) The sequence 
surrounding Ser31 of LKB1 is conserved amongst higher eukaryotes. 
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4.2 Aim 
The main aim of this chapter was to determine whether AMPK could phosphorylate 
Ser31 of LKB1 and to estimate the stoichiometry of this phosphorylation. This was 
investigated in a cell-free system using bacterially expressed wild-type LKB1 and a non-
phosphorylatable serine to alanine mutant. Phosphorylation at this site was measured 
by 32P incorporation and by the use of a phospho-specific antibody. The effect of Ser31 
mutation on LKB1 function was investigated in intact G361 cells by measuring Thr172 
phosphorylation and AMPK activity.  
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4.3 Results 
4.3.1 AMPK can phosphorylate LKB1 in cell-free assays 
The ability of AMPK to phosphorylate LKB1 was tested in a cell-free system. Bacterially 
expressed GST-LKB1 was incubated with increasing concentrations of native AMPK 
purified from rat liver with MgCl2 and [γ-
32P]-ATP, with or without AMP. LKB1 is 
inactive in the absence of its binding partners STRAD and MO25, excluding the 
possibility of autophosphorylation or phosphorylation of Thr172 on AMPK-α. 
 
Fig 4.3 shows that incubation with AMPK results in incorporation of 32P into LKB1. This 
incorporation reached a maximum stoichiometry of approximately 0.14 nmol 
phosphate per nmol protein and was stimulated three-fold by AMP. The increase in 
phosphorylation in response to AMP suggests that it was mediated by AMPK and not a 
contaminating kinase in the rat liver preparation. AMPK alone gave significant 
autophosphorylation (data not shown) on the α and β subunits. This supports work 
performed in our laboratory where AMPK-α2 was demonstrated to autophosphorylate 
on Ser491 (Dr Simon Hawley, personal communication) and work in the literature 
where AMPK-β autophosphorylates on Ser108 (Mitchelhill et al., 1997). No 
autophosphorylation on the γ subunit has been reported, consistent with these 
results. 
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Figure 4.3: Phosphorylation of LKB1 by AMPK 
Bacterially-expressed LKB1 and rat liver purified AMPK were incubated with Mg-[γ-
32P]-ATP for 15 minutes at 30°C. Reactions were stopped by the addition of SDS and 
analysed by PAGE. The gel was stained with Coomassie Blue (bottom) before 
autoradiography (top). The bar chart displays the incorporation of 32P into LKB1. 
 
4.3.2 Phosphorylation of LKB1 by AMPK occurs at Ser31 
To investigate if the observed 32P incorporation into LKB1 was at Ser31, a                  
non-phosphorylatable alanine was introduced by site-directed mutagenesis of the 
wild-type construct. This generated a GST-fusion of LKB1 [S31A]. This construct was 
expressed and purified in E. coli (Fig. 4.4). 
 
155 
 
 
Figure 4.4: Purification of GST-LKB1 [S31A] 
LKB1 containing a S31A mutation was expressed as a GST-fusion protein in bacteria 
and purified using a glutathione-Sepharose column. Purified protein was resolved by 
SDS-PAGE and visualized using Coomassie staining (left) or probed with an anti-LKB1 
antibody (right). 
 
Wild-type and S31A LKB1 were incubated with rat liver AMPK in the presence of MgCl2, 
[γ-32P]-ATP and AMP. Reactions were terminated by addition of SDS and analysed by 
SDS-PAGE and autoradiography (Fig. 4.5). As before, incorporation of 32P was observed 
with wild-type LKB1 but this was lost with the S31A mutant protein, suggesting that 
the majority of the 32P was being incorporated at Ser31 and that this site can be 
phosphorylated by AMPK in a cell-free assay. The stoichiometry of this 
phosphorylation, 0.5 mol phosphate/mol protein, was higher than that obtained in Fig. 
4.3. The incubations in Fig. 4.5 were performed with a fresh preparation of rat liver 
AMPK which may explain the higher stoichiometry. To investigate if the 32P 
incorporation had reached a maximum, the incubation times were increased to 30 
minutes (Fig. 4.6). These results support those in Fig. 4.5, with only wild-type LKB1 
displaying any significant 32P incorporation. The stoichiometry of phosphorylation was 
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increased to 1.0 mol phosphate/mol protein for wild-type LKB1 after 30 minutes 
incubation with AMPK, although the stoichiometry of phosphorylation of the S31A 
mutant also increased to 0.3 mol phosphate/mol protein. This shows that close to 
stoichiometric amounts of phosphate can be incorporated at Ser31 on LKB1 by AMPK. 
 
 
Figure 4.5: Phosphorylation of wild-type LKB1 and LKB1 [S31A] by AMPK after 15 min 
Bacterially-expressed LKB1 and rat liver purified AMPK (100 U/ml) were incubated with 
Mg-[γ-32P]-ATP for 15 minutes at 30°C. Reactions were stopped by the addition of SDS 
and analysed by PAGE. (A) The gel was stained with Coomassie Blue (bottom) before 
autoradiography (top). (B) Bar chart displays the incorporation of 32P into the wild-type 
and S31A mutant of LKB1. 
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Figure 4.6: Phosphorylation of wild-type LKB1 and LKB1 [S31A] by AMPK after 30 min 
Bacterially-expressed LKB1 and rat liver purified AMPK (100 U/ml) were incubated with              
Mg-[γ-32P]-ATP for 15 or 30 minutes at 30°C. Reactions were stopped by the addition 
of SDS and analysed by PAGE. (A) The gel was stained with Coomassie Blue (bottom) 
before autoradiography (top). (B) The bar chart displays the incorporation of 32P into 
the wild-type and S31A mutant of LKB1. 
 
To further confirm that Ser31 was being phosphorylated, an antibody against phospho-
Ser31 LKB1 was tested. Incubations of rat liver AMPK and wild-type or S31A LKB1 were 
carried out as above, using unlabelled ATP. Samples were analysed by Western 
blotting. Three different titrations of the phospho-Ser31 LKB1 antibody are shown in 
Fig. 4.7. The antibody shows increased reactivity with WT LKB1 that has been 
incubated with AMPK compared with LKB1 alone, most apparent in the 1000× 
antibody dilution.  
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Figure 4.7: Titration of a phospho-Ser31 LKB1 antibody 
Bacterially-expressed LKB1 and rat liver purified AMPK were incubated with Mg-ATP 
for 15 minutes at 30°C. Reactions were stopped by the addition of SDS and analysed by 
Western blotting using the phospho-Ser31 antibody at the indicated dilutions (stock 
antibody concentration was 0.7 mg/ml). 
 
The antibody was not, however, particularly phosphospecific because a significant 
signal was obtained with the S31A mutant protein, although this signal did not increase 
in response to AMPK. The antibody had originally been purified by applying the 
collected sheep serum to a column bearing the phosphorylated form of the peptide 
originally injected, resulting in the purification of antibodies that cross-react with the 
phosphopeptide. This mixture may contain antibodies that also recognize the 
dephosphorylated form of the peptide, resulting in an antibody with poor 
phosphospecificity. To combat this, a dephosphorylated form of the peptide was 
included in antibody incubations. This dephosphorylated peptide was expected to 
compete with dephosphorylated LKB1 for binding to the non-phosphospecific antibody 
and thus reduce background for both wild-type and S31A LKB1 samples. Results from 
these incubations are shown in Fig. 4.8 and show that phosphospecificity has improved 
compared with Fig. 4.7. Quantification of the signals (at 50-fold excess of peptide) 
show that the signal obtained with the phosphospecific antibody increased 
approximately two-fold when wild-type LKB1 was incubated with Mg.ATP and AMPK, 
with no change observed with the S31A mutant of LKB1. These results suggest that 
AMPK can phosphorylate LKB1 at Ser31 and support those obtained in Fig. 4.5. 
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Figure 4.8: Effect of dephospho-peptide on the signal obtained using the phospho-
Ser31 LKB1 antibody 
Bacterially-expressed LKB1 and rat liver purified AMPK were incubated with Mg.ATP 
for 15 minutes at 30°C. Reactions were stopped by the addition of SDS and analysed by 
Western blotting using the phospho-Ser31 antibody (1000-fold dilution) and the 
indicated excess of dephospho-peptide. (B) The bar chart displays quantification of the 
pSer31 signal from the incubation containing 50-fold excess of dephospho-peptide. 
 
To investigate if Ser31 of LKB1 is phosphorylated by AMPK in intact cells, HEK293 cells 
were treated with a range of AMPK activators and the lysates subjected to Western 
blotting using the phospho-Ser31 LKB1 antibody. Incubations were performed in the 
presence of an excess of the dephosphorylated Ser31 peptide. All treatments 
increased phosphorylation of ACC at S79, used as a marker for AMPK activity, but no 
change in Ser31 phosphorylation was detected (Fig. 4.9).  
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Figure 4.9: Effect of AMPK activators on phosphorylation of LKB1 at Ser31 
HEK293 cells were treated with the indicated compounds for 60 min prior to lysis and 
cell lysates probed with the indicated antibodies. The Ser31 dephospho-peptide was 
included in the pSer31 LKB1 blot at a 50-fold excess. 
 
4.3.3 Effect of Ser31 mutation in intact cells 
Site-directed mutagenesis of human LKB1 fused to GFP (WT LKB1) was performed to 
generate alanine (S31A LKB1) and aspartic acid (S31D LKB1) mutants. G361 cells, which 
lack LKB1, were transfected with WT and mutant LKB1 along with its accessory 
proteins, FLAG-tagged STRAD-α and myc-tagged MO25-α, and cells were then treated 
with berberine or A23187 to activate AMPK. Berberine, via changes in AMP and ADP 
levels, activates AMPK via the LKB1 pathway and allosteric activation, while A23187, by 
increasing intracellular Ca2+, activates AMPK through the CaMKKβ pathway. Fig. 4.10 
shows the result of AMPK assays and Western blotting of the G361 cell lysates. 
Mutation of S31 to either alanine (non-phosphorylatable mutant) or aspartic acid 
(phospho-mimetic mutant) had no effect on the function of LKB1. In response to 
berberine, the S31A and S31D mutant LKB1 activated AMPK, as measured by AMPK 
kinase assay, Thr172 phosphorylation and ACC phosphorylation, to a similar extent as 
the wild-type LKB1.  
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Figure 4.10: Transfection of G361 cells with LKB1 
G361 cells were transfected with STRAD-α, MO25 and wild-type or mutant LKB1 (as 
indicated). After 36 hr, cells were treated with A23187 (10 µM) or berberine (300 µM) 
for a further 60 min before lysis. AMPK was immunoprecipitated from cell lysates using 
anti-AMPK-α1/-α2 antibodies and kinase activity measured using the AMARA peptide 
substrate (top). Results are mean ± range (n = 2). Cell lysates were subject to Western 
blotting with the indicated antibodies. 
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4.4 Discussion 
These results demonstrate that, as predicted by others (Sapkota et al., 2002a), AMPK 
can phosphorylate LKB1 on Ser31. The stoichiometry of phosphorylation approaches 
0.8 mol phosphate/mol protein, although the amount of AMPK required to achieve 
this is somewhat higher than that required to phosphorylate a bona fide AMPK 
substrate such as ACC or HMGR. Stoichiometric phosphorylation of LKB1 at Ser31 
required incubation with 100 units of AMPK for 30 minutes, whereas phosphorylation 
of other substrates require up to 10-fold less AMPK. Ser31 appears to be the only site 
on LKB1 being significantly phosphorylated by AMPK, as mutation of this residue 
greatly reduced phosphorylation. 
 
Although AMPK can phosphorylate LKB1 in a cell free system, it is unclear whether this 
occurs in intact cells. Using a phospho-specific antibody, no change in Ser31 
phosphorylation was observed in response to a number of AMPK activators (Fig. 4.9). 
Equally, no difference in phosphorylation of Ser31 was observed when LKB1 from wild 
type and AMPK-α1-/- -α2-/- double knockout mouse embryo fibroblasts was probed 
with the phospho antibody (data not shown). These results, however, do not 
completely rule out the possibility that this site is phosphorylated by AMPK in intact 
cells. The antibody used displays reasonable phosphospecificity using purified LKB1 
treated with and without AMPK but this may not be the case with cell lysates. 
Although the sequence around Ser31 is well conserved across higher eukaryotes      
(Fig. 4.2), the antibody was raised against the human LKB1 sequence, not mouse LKB1, 
and this could explain the fact that no difference was observed between the wild type 
and knockout mouse embryo fibroblasts. Future investigations require the generation 
of a more phosphospecific antibody. 
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Although Ser31 of LKB1 is phosphorylated in intact cells and can be phosphorylated to 
a reasonable stoichiometry by AMPK, it seems unlikely that the phosphorylation of 
Ser31 plays a major role in regulating the kinase. Mutation of Ser31 to either an 
alanine or aspartic acid had no effect on the ability of LKB1 to activate AMPK in G361 
cells (Fig. 4.11). The basal AMPK activities in cells transfected with the Ser31 mutants 
were increased to the same level as that from cells transfected with wild type LKB1. 
Berberine, as discussed previously, increases cellular AMP levels and this increases 
Thr172 phosphorylation and AMPK activity in an LKB1-dependent manner. The AMPK 
activities measured in response to berberine treatment were similar in the cells 
transfected with wild type and S31A or S31D mutant LKB1. Thus, this site does not 
appear to be crucial for LKB1 function under the conditions examined. It is possible 
that the phosphorylation of Ser31 is mediated by a distinct kinase that is inactive 
under these conditions, explaining why no effect was observed. The data with the 
phosphomimetic mutant does not support this theory, but it could be that any effects 
on LKB1 function require the presence of a phosphate group and are not particularly 
well mimicked by an aspartate side chain. These results match those of Sapkota et al  
(2002a) where they observed no effect of S31 mutation on the ability of LKB1 to 
suppress growth of G361 cells. At the time, AMPK was not known to be a downstream 
target of LKB1 and phosphorylation of p53 or autophosphorylation was used as a 
measurement of LKB1 catalytic activity. However, mutation of Ser31 had no effect on 
LKB1 activity, agreeing with the data obtained in this chapter. 
 
Although the phosphorylation of Ser31 on LKB1 by AMPK can be achieved in cell-free 
assays, it seems unlikely that this is a physiological event. The activity of LKB1 is not 
increased by treatment with phenformin or AICAR, two treatments that increase AMPK 
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activity (Hawley et al., 2003) or by muscle contraction (Sakamoto et al., 2004). Thus 
the physiological kinase for this site, and any functional relevance, remains to be 
identified. 
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CHAPTER 5: AMPK AND THE RESPONSE TO mTOR INHIBITION 
 
5.1 Introduction 
mTOR, in response to growth factors and nutrients, transmits pro-growth and pro-
survival signals through a number of downstream targets (Laplante and Sabatini, 
2012). As mTOR activity is increased in a number of different cancers and cancer 
syndromes, inhibition of mTOR is an attractive therapeutic option for these conditions. 
Rapamycin, a naturally occurring inhibitor, would appear to be an ideal candidate for 
this. However, there are a number of limitations to the use of rapamycin. Rapamycin 
is, except under certain circumstances (Sarbassov et al., 2006), a specific inhibitor of 
mTORC1. As seen in Fig. 1.8 of chapter 1, p70 S6 kinase forms a negative feedback loop 
to the insulin receptor substrate (IRS) proteins, reducing the stimulatory effect of 
growth factors on PI 3-kinase (PI3K). As mTORC1 is the upstream activating kinase for 
p70 S6 kinase, treatment with rapamycin removes this negative feedback loop and 
increases PI3K activity, providing pro-survival signals through PKB (Sun et al., 2005; 
O’Reilly et al., 2006). In addition, p70 S6 kinase inhibition activates the MAPK 
(Carracedo et al., 2008) and platelet-derived growth factor (Zhang et al., 2007) 
pathways, which act positively to mediate growth factor signalling. Treatment with 
rapamycin therefore increases pro-survival and proliferative signals and has not been 
as successful in tumour suppression as predicted, having only a cytostatic, rather than 
cytotoxic, effect (Efeyan and Sabatini, 2010). Additionally, rapamycin only partially 
inhibits phosphorylation of 4E-BP1 by mTORC1 (Chresta et al., 2010; García-Martínez 
et al., 2009), which, as discussed in Chapter 1, plays a key role in regulating cell 
proliferation downstream of mTORC1.  
166 
 
Recently, potent and highly-specific inhibitors that target both mTORC1 and mTORC2 
have been identified, such as Torin1 (Thoreen et al., 2009), PP242 (Feldman et al., 
2009) and Ku-0063794 (García-Martínez et al., 2009). Unlike rapamycin, which appears 
to work by weakening the interaction between raptor and mTOR and thus preventing 
the recruitment of certain substrates (Yip et al., 2010), these compounds function as 
ATP-competitive inhibitors of the mTOR catalytic subunit. By targeting both complexes, 
they remove the feedback inhibition problems associated with rapamycin. Thus, while 
inhibition of mTORC1 would still relieve the feedback inhibition loop from p70 S6 
kinase to the IRS proteins, the inhibition of mTORC2 prevents the increase in 
phosphorylation of Ser473 on PKB (Chresta et al., 2010). Phosphorylation of Ser473 is 
required for subsequent phosphorylation of Thr308 and full activation of PKB. These 
compounds therefore dampen the increased signalling through the PI3K pathway 
induced by mTORC1 inhibition. In addition, and unlike rapamycin, the mTOR kinase 
inhibitors block phosphorylation of all mTOR targets, including 4E-BP1 (Chresta et al., 
2010; García-Martínez et al., 2009). Indeed these compounds appear to be more 
potent than rapamycin in reducing cell proliferation (García-Martínez et al., 2009; 
Feldman et al., 2009). 
 
Dual target mTOR inhibitors have been tested for anti-cancer properties in a range of 
in vitro and in vivo situations. AZD8055, a dual-target mTOR inhibitor, was reported to 
decrease tumour volume in a mouse model that spontaneously develops B-cell 
follicular lymphomas (García-Martínez et al., 2011). These mice are heterozygous for 
expression of PTEN and have depleted LKB1, resulting in elevated PKB activity and 
reduced AMPK activation (Huang et al., 2008). AZD8055 also induced a dose-
dependent inhibition of tumour growth in mice bearing xenografts derived from cell 
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lines isolated from gliomas or lung adenocarcinoma (Chresta et al., 2010). Treatment 
of an acute myeloid leukemia cell line with AZD8055 reduced cell proliferation and cell 
cycle progression and increased the activity of caspase-3, part of the apoptotic cascade 
(Willems et al., 2011). Additionally, AZD8055 reduced the tumour volume, possibly by 
induction of caspase-dependent apoptosis, and increased survival of mice bearing a 
xenograft derived from this cell line (Willems et al., 2011). AZD8055 also decreased the 
proliferation and survival of primary cells isolated from acute myeloid leukemia 
patients, whilst having little effect on normal, immature cells (Willems et al., 2011). 
AZD8055 was also demonstrated to increase apoptosis, in combination with an HDAC 
inhibitor, in hepatocellular carcinoma cell lines and to reduce the size of tumours of 
mice bearing a patient-derived primary hepatocellular carcinoma xenograft (Shao et 
al., 2011). Finally, AZD8055 was reported to decrease tumour volume and increase 
survival of mice bearing a xenograft derived from a cultured head and neck squamous 
cell carcinoma cell line, and these effects were more potent than those observed with 
rapamycin (Li et al., 2013). 
 
mTOR inhibitors are clearly promising as anti-cancer therapeutics. However, the status 
of other signalling pathways may determine the response to mTOR inhibitors. For 
example,  treatment of TSC1-/-/TSC2-/- cells with rapamycin increases their survival via 
removal of the p70 S6 kinase negative feedback loop and increased PKB signalling (see 
Fig. 1.8) (Shah et al., 2004). Given that the LKB1-AMPK pathway, like TSC1/TSC2, is a 
negative regulator of mTOR signalling, it is possible that this would also be the case 
when LKB1-null cells are treated with rapamycin. However, in the TSC1-/-/TSC2-/- cells, 
the AMPK pathway would be intact whereas in the LKB1-null cells it would, under most 
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conditions, have a very low activity. The LKB1-AMPK pathway may therefore play a key 
role in determining the cellular response to mTOR inhibition. 
 
The importance of understanding the link between LKB1-AMPK status and the 
response of cells to mTOR inhibition is accentuated when the extent to which the 
LKB1-AMPK pathway is implicated in the development and maintenance of tumours is 
considered. LKB1 is mutated in Peutz-Jeghers syndrome, a hereditary condition that 
pre-disposes suffers to cancer. Additionally, LKB1 is frequently lost in both lung 
(Sanchez-Cespedes et al., 2002) and cervical (Wingo et al., 2009) cancers. There is a 
growing body of evidence to suggest that AMPK itself can act as a tumour suppressor. 
In mice heterozygous for PTEN, inhibition of AMPK led to accelerated tumour 
development, while treatment with metformin, phenformin or A769662 delayed 
tumour onset (Huang et al., 2008). Further genetic evidence for the role of AMPK as a 
tumour suppressor in vivo comes from the observation that the loss of AMPK signalling 
in mice acts, via HIF-1α, to drive development of myc-induced B cell lymphomas 
(Faubert et al., 2013). These results support the idea that AMPK, rather than one or 
more of the AMPK-related kinases, is the key downstream mediator of the tumour 
suppressor effects of LKB1. Additionally, AMPK signalling appears to be down-
regulated in many tumours, potentially providing them with a competitive growth 
advantage by removing any constraints on cell proliferation and protein synthesis 
(Hadad et al., 2009; Zheng et al., 2009). As the LKB1-AMPK pathway is disrupted in a 
large number of tumours, and mTOR inhibition is a promising therapeutic option, 
determining whether the LKB1-AMPK pathway influences the response to mTOR 
inhibition could give valuable insights into appropriate treatments for cancer.   
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5.2 Aims 
To aim of this chapter was to characterize the response of mammalian cells to AZ4, a 
dual mTORC1 and mTORC2 inhibitor, and to determine if the status of the LKB1-AMPK 
pathway influenced this response. Using a variety of cell lines, the concentration of 
AZ4 required to inhibit the two TOR complexes was determined. The effect of AZ4 on 
AMPK activity was also investigated. The effect of mTOR inhibition on apoptosis was 
investigated in the presence and absence of serum, and under conditions where the 
AMPK pathway was either active or inactive.  
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5.3 Results 
5.3.1 Generation of HeLa cells expressing wild-type or kinase-dead LKB1 
HeLa cells, isolated from a human cervical cancer, do not express LKB1 due to a large 
deletion within the gene encoding it (Wingo et al., 2009). Using Flp-In technology (see 
Chapter 2 for details), HeLa cells expressing either wild-type LKB1 or a kinase-dead 
mutant were generated. The kinase-dead LKB1 contains a mutation in the DFG motif 
(D194A) that prevents it from binding Mg2+ ions and correctly positioning ATP for 
phosphotransfer, and is therefore catalytically inactive (Pearce et al., 2010). LKB1 
function was assessed by treating cells with A23187, which increases AMPK activity via 
CaMKKβ, or phenformin, which activates AMPK in an LKB1-dependent manner. As 
expected, AMPK activity, as measured by kinase assay and phosphorylation of Thr172 
and ACC, was increased in both cell lines in response to A23187, whereas only the cells 
expressing wild-type LKB1 responded to phenformin (Fig. 5.1). LKB1 activity was also 
assessed by measuring its ability to activate recombinant AMPK. LKB1 was 
immunoprecipitated from cell lysates, incubated with bacterially-expressed AMPK and 
the activity of AMPK measured. Only immunoprecipitates from wild-type LKB1 cells 
phosphorylated and activated AMPK (Fig. 5.2). 
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Figure 5.1: Characterization of HeLa cells expressing wild-type or kinase-dead LKB1 
HeLa cells expressing wild-type or kinase-dead LKB1 were generated using Flp-In 
technology. Replicate dishes of cells were incubated for 1 hr with A23187 (10 µM) or 
phenformin (10 mM). AMPK was immunoprecipitated from cell lysates using anti-
AMPK-α1/-α2 antibodies and kinase activity measured using the AMARA peptide 
substrate (top). Results are mean ± range (n = 2). Cell lysates were also subject to 
Western blotting with the indicated antibodies. 
 
 
Figure 5.2: LKB1 activity of HeLa cells expressing wild-type or kinase-dead LKB1 
LKB1 was immunoprecipitated from either wild-type or kinase-dead LKB1 HeLa cell 
lysates using anti-LKB1 antibodies. For the control, no lysate was added. LKB1 was 
incubated with dephosphorylated, bacterially expressed AMPK (α2β2γ1 complex) plus 
MgCl2 and ATP. The activity of the AMPK complex was then assessed using the AMARA 
peptide substrate. Results are mean ± SEM (n = 3), except the blank where n = 1.  
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5.3.2 Effects of AZ4 on LKB1-expressing HeLa cells 
The concentration of AZ4 required for inhibition of mTORC1 and mTORC2 in HeLa cells 
was examined. Phosphorylation of p70 S6 kinase at Thr389 was used as a marker of 
mTORC1 activity and phosphorylation of PKB at Ser473 used as a marker mTORC2 
activity. A concentration of 0.1 µM AZ4 was found to completely inhibit mTORC1, while 
higher concentrations (> 1 µM) were required for complete inhibition of TORC2        
(Fig. 5.3). 
 
Figure 5.3: Titration of AZ4 in HeLa cells 
HeLa cells expressing wild-type or kinase-dead LKB1 were incubated with the indicated 
concentrations of AZ4 for 1 hr. Cell lysates were subject to Western blotting with the 
indicated antibodies. 
 
A wide variety of compounds can non-specifically act as mitochondrial poisons, 
altering cellular metabolism and activating AMPK. To ensure that this did not occur 
with AZ4, HeLa cells expressing wild-type LKB1 were treated with AZ4 up to 3 µM and 
the effects on AMPK activity were monitored (Fig. 5.4). No increase in AMPK activity, 
as measured by kinase assay, Thr172 phosphorylation or ACC phosphorylation was 
detected. In addition, no effect of AZ4 on the oxygen consumption rate of HeLa cells 
expressing wild-type or kinase-dead LKB1 was observed (Fig. 5.5). Taken together, 
these results demonstrate that, in HeLa cells, acute AZ4 treatment has no effect on 
mitochondrial function or AMPK activity. 
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Figure 5.4: Effect of AZ4 on AMPK activity in HeLa cells 
HeLa cells expressing wild-type LKB1 were incubated with phenformin (10 mM), 
A23187 (10 µM) or AZ4 (0.1, 1 or 3 µM) for 1 hr. AMPK was immunoprecipitated from 
cell lysates using anti-AMPK-α1/α2 antibodies and kinase activity measured using the 
AMARA peptide substrate (top). Results are mean ± range (n = 2). Cell lysates were 
also subject to Western blotting with the indicated antibodies (bottom). 
 
 
Figure 5.5: Effect of AZ4 on oxygen consumption rate (OCR) in HeLa cells 
OCR analysis was performed using a Seahorse Biosciences XF24 extracellular flux 
analyser. HeLa cells (expressing wild-type or kinase-dead LKB1) were seeded into 
plates and the basal OCR calculated for every well. AZ4 was injected onto the cells and 
OCR measured over a 30 min period. Results are expressed as % of basal OCR (mean ± 
SEM, n = 3). 
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As mTOR inhibitors are considered promising anti-cancer therapies, the effects of AZ4 
on the long-term growth and survival of the wild-type LKB1 and kinase-dead LKB1 HeLa 
cells were also examined. HeLa cells were treated with AZ4 for a period of 7 days and 
the number of cells determined. The results in Fig. 5.6 show that AZ4 at 0.1 µM, which 
was sufficient to inhibit mTORC1, had little effect on the growth of HeLa cells. 
However, at a concentration of 3 µM, which was sufficient to inhibit mTORC2, AZ4 
greatly reduced the number of HeLa cells alive after 7 days, compared to untreated 
control. Cells expressing wild-type LKB1 appeared to be more resistant to AZ4-induced 
cell death, as a greater number remained alive after 7 days. To further investigate this, 
HeLa cells were treated for 48 hours with AZ4 and the effect on apoptosis determined 
by measuring cleavage of poly (ADP-ribose) polymerase (PARP). PARP is found in the 
nucleus and is involved in detecting and repairing DNA single strand breaks. PARP 
binds to single strand breaks and generates a chain of poly (ADP-ribose), which acts as 
a signal to recruit other DNA-repairing enzymes, such as DNA ligases. During apoptosis, 
PARP is cleaved by caspase-3 between Asp214 and Gly215, separating the DNA binding 
domain (24 kDa) from the catalytic domain (89 kDa). PARP helps cells to maintain their 
viability and its cleavage is used as a common marker for apoptosis. AZ4 did increase 
PARP cleavage, indicating an increase in apoptosis, and this effect was reduced in the 
cells expressing wild-type LKB1 compared with the controls expressing kinase-dead 
LKB1 (Fig. 5.7). These results suggest that a functional LKB1-AMPK pathway can protect 
cells from AZ4-induced apoptosis. 
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Figure 5.6: Effect of AZ4 on HeLa cell survival 
HeLa cells expressing wild-type or kinase-dead LKB1 were incubated with AZ4 at 0.1 or 
3 µM for 7 days. At the end of the treatment, cells were stained with trypan blue and 
the number of viable cells counted using a haemocytometer. Results are expressed as 
the % of viable cells compared to untreated control plates (mean ± SEM, n = 4). 
Significantly different from control without AZ4: ** p < 0.01, ***p < 0.001; significantly 
different from wild-type LKB1 with 3 µM AZ4: †††p < 0.001. 
 
 
Figure 5.7: Effect of AZ4 on apoptosis in HeLa cells 
HeLa cells expressing wild-type or kinase-dead LKB1 were incubated with AZ4 for 48 
hr. Cell lysates were subject to Western blotting with the indicated antibodies. The bar 
chart displays the ratio of cleaved PARP to full-length PARP (mean ± SD, n = 2). 
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5.3.3 Response of G361 cells to AZ4 
Although some effect of LKB1 expression were therefore observed in the HeLa cells 
they were relatively modest, possibly due to the low levels of LKB1 expression in these 
cells (the protein was hard to detect by Western blotting) and the resistance of the 
cells to AZ4-induced apoptosis. The response of other LKB1-null cell lines to AZ4 was 
therefore examined. G361 cells, as discussed previously, are an LKB1-null cell line 
isolated from a human melanoma. The effect of AZ4 on G361 cells was examined. The 
concentration of AZ4 required to inhibit mTORC1 and mTORC2 was similar to that in 
HeLa cells (Fig. 5.8) and AZ4 had no effect on AMPK activity (Fig. 5.9). 
 
 
Figure 5.8: Titration of AZ4 in G361 cells 
G361 cells were incubated with a range of concentrations of AZ4 for 1 hr. Cell lysates 
were subject to Western blotting with the indicated antibodies. 
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Figure 5.9: Effect of AZ4 on AMPK activity in G361 cells 
G361 cells were incubated with AZ4, A23187 (10 µM) or berberine (100 µM) for 1 hr. 
AMPK was immunoprecipitated from cell lysates using anti-AMPK-α1/α2 antibodies 
and kinase activity measured using the AMARA peptide substrate (top). Results are 
mean ± SEM (n = 3). Cell lysates were also subject to Western blotting with the 
indicated antibodies (bottom). Significantly different from control: *p < 0.05,            
***p < 0.001. 
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* 
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Cancer cells growing in the centre of a solid tumour may be exposed to conditions 
where growth factors are in limited supply. To simulate this, experiments were carried 
out in the presence and absence of serum. Cells were treated with AZ4 (3 µM, 
sufficient to inhibit both TORC1 and TORC2) for a period of 48 hours with and without 
A769662, a direct activator of AMPK. A769662 was selected as, unlike some other 
AMPK activators, it does not affect cellular energy status, which might result in cell 
death. Additionally, some AMPK activators, such as phenformin and quercetin, reduce 
phosphorylation of PKB at Ser473. This occurs independently of AMPK, as 
phosphorylation of Ser473 in response to phenformin or quercetin was reduced in 
both wild-type and AMPK-α1/-α2 double knockout mouse embryo fibroblasts (MEFs). 
No effect on Ser473 phosphorylation was observed with berberine, A769662 or 
A23187 (Fig. 5.10). 
 
 
Figure 5.10: Effect of AMPK activators on phosphorylation of PKB at Ser473 in MEFs 
Wild-type (WT) or AMPK-α1-/- -α2-/- double knockout (dKO) MEFs were incubated with 
berberine (300 µM), A769662 (300 µM), phenformin (10 mM), quercetin (300 µM) or 
A23187 (10 µM) for 1 hr. Cell lysates were also subject to Western blotting with the 
indicated antibodies. 
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In the presence of serum, AZ4 had little effect on PARP cleavage in G361 cells (Fig. 
5.11). However, under serum-free conditions, a large increase in PARP cleavage was 
detected. Interestingly, the inclusion of A769662 greatly reduced PARP cleavage, 
restoring it almost back to basal levels. A769662 alone had no effect on PARP cleavage, 
and did not interfere with the ability of AZ4 to inhibit mTORC2 as measured by 
phosphorylation of Ser473 of PKB. The results in Chapter 3 have already demonstrated 
that A769662 can activate AMPK in LKB1-null cell lines. 
 
The method for harvesting cells used in these experiments involves aspiration of the 
medium and washing of the cells, followed by rapid lysis with detergent. If A769662 
was accelerating cell death it was possible that dead or dying cells had already been 
removed during the washing step, so that PARP cleavage would not be detected by 
Western blot. To rule this out, and to investigate the time course for AZ4-induced cell 
death, G361 cells were treated with AZ4 (0.1 µM or 3 µM) and A769662 in serum-free 
conditions and samples collected over a period of 48 hours (Fig. 5.12). To confirm that 
the compounds were active, the phosphorylation of ACC (marker of AMPK activity), 
PKB (marker of mTORC2 activity), GSK3 (marker of PKB activity) and p70 S6 kinase 
(marker of mTORC1 activity) were monitored. As expected, A769662 increased ACC 
phosphorylation. Treatment with 0.1 µM AZ4 decreased p70 S6 kinase 
phosphorylation, but had no effect on PKB or GSK3 phosphorylation. However, 
treatment with 3 µM AZ4, by inhibiting both mTORC1 and mTORC2, reduced 
phosphorylation of PKB, GSK3 and p70 S6 kinase. AZ4 had no effect on AMPK activity 
assessed by ACC phosphorylation, confirming previous observations. After 2 hours, AZ4 
had no effect on PARP cleavage. At 24 hours, 3 µM AZ4 had increased PARP cleavage, 
but this was prevented by A769662. Similar results were obtained after 32 and 48 
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hours. Treatment with 0.1 µM AZ4, which does not inhibit mTORC2, had little effect on 
PARP cleavage until the 48 hour time point where a small increase was observed, 
although again this was reduced by A769662. Treatment of G361 cells with A769662 
protected against AZ4-induced apoptosis. 
 
Figure 5.11: Effect of AZ4 on apoptosis in G361 cells 
G361 cells were incubated with AZ4 (3 µM), A769662 (150 µM) or both in culture 
media ± foetal bovine serum for a period of 48 hr. Cell lysates were subject to Western 
blotting with the indicated antibodies. The bar chart displays the ratio of cleaved PARP 
to full-length PARP (mean ± SD, n = 2). 
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Figure 5.12: Time course of effects of AZ4 on apoptosis in G361 cells 
G361 cells were incubated with AZ4 (0.1 or 3 µM), A769662 (150 µM) or both in 
serum-free culture media for a period of 48 hr. Lysates were prepared at various times 
throughout the course of the experiment. (A) Cell lysates were subject to Western 
blotting with the indicated antibodies. (B) Ratio of cleaved PARP to full-length PARP for 
each sample. 
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5.3.4 Effects of AZ4 on wild-type and AMPK-α1-/--α2-/- mouse embryo fibroblasts  
The results described previously suggest that, in both HeLa and G361 cells, the 
presence of an active LKB1-AMPK pathway can protect cells against apoptosis. 
Although A769662 is a specific activator of AMPK, it is possible that these results are 
due to off-target effects of the compound. To further investigate the role of AMPK, 
experiments were performed using wild-type and AMPK-α1-/- -α2-/- knockout mouse 
embryo fibroblasts. Again, like the other cell lines, a higher concentration of AZ4 was 
required to inhibit mTORC2 compared with mTORC1 (Fig. 5.13). No effect of AZ4 on 
AMPK activity was observed (Fig 5.14). 
 
 
Figure 5.13: Titration of AZ4 in wild-type and AMPK-α1-/--α2-/- MEFs 
Wild-type (WT) and AMPK-α1-/--α2-/- dKO mouse embryo fibroblasts were treated with 
a range of concentrations of AZ4 for 1 hr. Cell lysates were subject to Western blotting 
with the indicated antibodies. 
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Figure 5.14: Effect of AZ4 on AMPK activity in wild-type MEFs 
Wild-type MEFs were incubated with AZ4, A23187 (10 µM) or berberine (300 µM) for 1 
hr. AMPK was immunoprecipitated from cell lysates using anti-AMPK-α1/-α2 
antibodies and kinase activity measured using the AMARA peptide substrate (top). 
Results are mean ± SEM (n = 3). Cell lysates were also subject to Western blotting with 
the indicated antibodies (bottom). Significantly different from control: ***p < 0.001. 
 
MEFs were also more sensitive to the serum-free conditions, with periods of greater 
than 12 hours in serum-free media resulting in the death of all cells (data not shown). 
Wild-type and AMPK-α1-/--α2-/- knockout MEFs were therefore treated with AZ4 in the 
presence and absence of serum for 6 hours (Fig. 5.15). Even under serum-free 
conditions, AZ4 had little effect on PARP cleavage in the wild-type cells. In contrast, 
*** 
*** 
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AMPK-α1-/--α2-/- knockout MEFs were sensitive to serum-free conditions, with AZ4 
causing an even greater level of PARP cleavage. In contrast to G361 cells, where no 
signal was observed, it was also possible to monitor the cleavage of caspase-3 in the 
MEF cells. Caspases (cysteine-aspartic proteases) are a family of proteases that play 
key roles in the regulation of cell death, via both apoptosis and necrosis. Caspases are 
regulated at the post-translational level, allowing for rapid activation. Cleavage of 
caspase-3 mirrored that of PARP, with only small effects observed in the wild-type 
MEFs compared with AMPK-α1-/--α2-/- knockout MEFs (Fig. 5.15). 
 
The time course of these effects were also investigated (Fig. 5.16). Wild type and                 
AMPK-α1-/--α2-/- knockout MEFs were treated in the presence and absence of serum 
with AZ4 and samples taken for analysis over a 9 hour period. Results show that, even 
after 9 hours in serum-free media, AZ4 had no effect on apoptosis of the wild-type 
MEFs as measured by PARP or caspase-3 cleavage (quantified in Fig. 5.17). The AMPK-
α1-/- -α2-/- knockout MEFs, however, were much more sensitive to the absence of 
serum and AZ4 treatment, and an increase in PARP and caspase-3 cleavage was 
evident after 6 hours. 
 
In G361 cells, the AMPK activator A769662 protected cells from AZ4-induced 
apoptosis. To investigate if this was an off-target effect of the compound, the ability of 
A769662 to protect wild-type and AMPK-α1-/--α2-/- knockout MEFs from apoptosis was 
examined (Fig. 5.18). As before, AZ4 had little effect on wild-type MEFs but induced 
apoptosis in the AMPK-α1-/--α2-/- knockout MEFs. However, A769662 did not protect 
the knockout MEFS from AZ4-induced apoptosis. In fact, A769662 alone increased 
apoptosis in the knockout MEFs. 
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Figure 5.15: Effect of AZ4 on apoptosis of wild-type and AMPK α1-/--α2-/- dKO MEFs 
Wild-type (WT) and AMPK-α1-/--α2-/- double knockout (dKO) MEFs were incubated ± 
AZ4 (3 µM) in the presence or absence of serum for a period of 6 hours. Cell lysates 
were subject to Western blotting using the indicated antibodies. The bar charts 
represent quantifications of the PARP and caspase-3 blots and are expressed as mean 
± range of cleaved protein: total protein (n = 2). 
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Figure 5.16: Time course of effects of AZ4 on apoptosis of MEF cells 
Wild-type and AMPK-α1-/- -α2-/- dKO MEFs were incubated ± AZ4 (3 µM) in the 
presence of serum (top) or the absence of serum (bottom). Lysates were prepared at 
the indicated timepoints and subject to Western blotting with the indicated 
antibodies. 
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Figure 5.17: Quantification of PARP and caspase-3 blots 
The ratio of cleaved PARP:total PARP (top) and cleaved caspase-3:total caspase-3 
(bottom) was calculated from the blots in figure 5.16. WT, wild-type MEFs; dKO, 
AMPK-α1-/- -α2-/- dKO MEFs; SFM, serum-free media. 
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Figure 5.18: Effect of A769662 on AZ4-induced apoptosis in MEFs 
Wild-type (WT) and AMPK-α1-/--α2-/- double knockout (dKO) MEFs were incubated ± 
AZ4 (3 µM) and ± A769662 in the presence or absence of serum for a period of 6 
hours. Cell lysates were subject to Western blotting using the indicated antibodies. The 
bar charts represent quantifications of the PARP and caspase-3 blots and are 
expressed as mean cleaved protein: total protein (n = 1).  
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5.4 Discussion 
The aim of this chapter was to determine the effect of mTOR inhibition on a range of 
cell lines, and to determine whether the status of the LKB1-AMPK pathway influenced 
this response. The evidence presented in this chapter suggests that, in a number of cell 
lines, inhibition of mTOR by AZ4, particularly under serum-free conditions, can result in 
apoptosis and cell death. Every cell line tested required higher concentrations of AZ4 
to inhibit mTORC2 compared with mTORC1, and the induction of apoptosis appears to 
require the high concentrations of AZ4 that inhibited mTORC2 as well as mTORC1. 
Activation of the LKB1-AMPK pathway by A769662, a direct AMPK activator, prevented 
apoptosis in the LKB1-null G361 cell line. Additionally, genetic deletion of AMPK in 
mouse embryo fibroblasts sensitized the cells to apoptosis in response to mTOR 
inhibitors or serum deprivation, as seen when comparing the responses of wild-type 
and AMPK-α1-/- -α2-/- knockout mouse embryo fibroblasts. This supports the proposed 
role of the AMPK pathway in protecting cells against AZ4-induced death.  
 
One important consideration in planning the treatment of any given cancer is the 
nature of the genetic lesion(s) giving rise to the tumour. In some cases, depending on 
which signalling pathways are hyper- or hypo-activated, the treatment may either have 
no effect or have detrimental side effects. For example, a recent study has 
demonstrated that 4E-BPs, which negatively regulate protein synthesis and are lost or 
strongly inhibited in a number of tumours, are essential for mediating the anti-
proliferative effects of dual mTORC1/mTORC2 inhibition (Dowling et al., 2010). 
Similarly, inhibition of mTORC1 by rapamycin, under conditions where TSC1/TSC2 have 
been lost, actually promotes cell survival by removing a negative feedback loop to the 
PI3 kinase pathway (Shah et al., 2004).  
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The results in this chapter suggest that, whilst treatment of cells with mTOR inhibitors 
can slow growth and promote apoptosis, cells lacking a functional AMPK pathway are 
more susceptible to this treatment. The LKB1-AMPK status of a tumour may therefore 
partly determine the response to mTOR inhibition, and knowledge of this could help in 
designing effective and specific treatments. It would also be of interest to determine 
what components of the mTOR pathway require to be inhibited in order to induce 
apoptosis. From the results in this chapter it seems that it is inhibition of mTORC2 that 
drives apoptosis, as lower concentrations that only inhibited mTORC1 had much less 
effect on G361 cells. Using inhibitors of PKB and SGK, or cells lacking these proteins, it 
might be possible to determine whether either of these proteins are the key mediator 
of the effects of AZ4. However, it could also be that it is inhibition of 4E-BP1 
phosphorylation by mTORC1 that transmits the pro-apoptotic signals, and that loss of 
4E-BP1 would reduce the effects of AZ4 on apoptosis, similar to the effects discussed 
above (Dowling et al., 2010). Work on compounds structurally related to AZ4, such as 
AZD8055, demonstrates that concentrations of AZD8055 that inhibit phosphorylation 
of p70 S6 kinase also inhibit phosphorylation of 4E-BP1 (Chresta et al., 2010). This 
suggests, but does not prove, that apoptosis in response to AZ4 requires inhibition of 
mTORC2 activity. Equally, although the LKB1-AMPK pathway appears to protect against 
cell death induced by AZ4, it remains unclear by what mechanism this is occurring. 
 
Given that AMPK regulates cell growth, protein synthesis and energy metabolism via 
many different pathways, it is not surprising that AMPK activators have been 
considered as potential anti-cancer therapies. Indeed, treatment of diabetic patients 
with metformin, an AMPK activator, reduced their risk of cancer by around 30% 
compared with diabetics on other treatments (Evans, 2005; Bowker et al., 2006). 
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However, as observed in this chapter, treatment of cells with an AMPK activator may 
actually protect against apoptosis and thus promote inappropriate survival of the 
cancer cells. Interestingly, this was observed in LKB1-null cells where the major 
upstream kinase activity is lost. While it is possible that the effects of A769662 on 
G361 cells (Fig. 5.12) were due to off-target effects, this seems unlikely because 
A769662 did not protect AMPK-α1-/- -α2-/- double knockout mouse embryo fibroblasts 
from apoptosis, suggesting that AMPK is required for this effect (Fig. 5.18). 
 
Supporting the work in this chapter are reports that the LKB1-AMPK pathway 
determines the response of cells to other types of stress. A549 cells (which were 
isolated from a lung adenocarcinoma and do not express LKB1) were transfected with 
wild-type or kinase-dead LKB1 and the effect of phenformin treatment on apoptosis 
determined. The results show that the presence of wild-type, but not kinase-dead, 
LKB1 protects cells from the energy stress induced by phenformin (Shackelford et al., 
2013). 
 
In conclusion, the results presented in this chapter suggest that the LKB1-AMPK 
pathway can play an important role in regulating the response to mTOR inhibition. 
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CHAPTER 6: CONCLUSIONS AND PERSPECTIVES 
6.1 Introduction 
In this thesis, the regulation of AMPK by adenine nucleotides was investigated. Using 
studies both in cell-free systems and intact cells, the central role of AMP as an 
activator of AMPK has been re-established. Phosphorylation of LKB1 by AMPK was also 
investigated. Whilst this phosphorylation was demonstrated in cell-free assays, its 
physiological significance remains unclear. Finally, it has been shown that the LKB1-
AMPK pathway can play an important role in determining the cellular response to 
mTOR inhibition. This final chapter discusses the overall implications of the findings in 
this thesis and suggests directions for future research. 
 
6.2 Regulation of AMPK by AMP 
The work in this thesis was initiated by reports in the literature that ADP, and not AMP, 
may be the main regulator of AMPK. The data presented in Chapter 3 of this thesis 
demonstrates that while both AMP and ADP can protect AMPK against Thr172 
dephosphorylation by protein phosphatases, AMP has the more potent effect. 
Additionally, AMP was demonstrated to promote the phosphorylation of Thr172 by 
LKB1, whereas ADP was found to have no effect. Finally, allosteric activation of AMPK 
by AMP was demonstrated to play a significant role in the overall AMPK activation 
mechanism. 
 
The results showing that Thr172 phosphorylation by LKB1 is promoted by binding of 
AMP, and not ADP, are supported by a recent report suggesting that AXIN forms a 
stable complex with LKB1 and AMPK (Zhang et al., 2013). The formation of this 
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complex, which was suggested to promote phosphorylation of Thr172 on the AMPK-α, 
was greatly enhanced by the presence of AMP in cell-free systems, or by glucose 
deprivation of intact cells. Consistent with the results presented in this thesis, ADP was 
reported to have no effect on the formation of the LKB1-AMPK-AXIN complex (Zhang 
et al., 2013). The interaction appeared to be specific for LKB1, as no interaction 
between AXIN and CaMKKβ was detected, and knockdown of AXIN did not reduce 
AMPK activation in response to increases in intracellular Ca2+ (Zhang et al., 2013). This 
supports the results presented in Chapter 3, where the phosphorylation of Thr172 of 
AMPK-α by CaMKKβ was not stimulated by AMP, unlike the LKB1-mediated 
phosphorylation. These authors also reported that the formation of the complex 
required myristoylation of the β-subunit of AMPK, supporting the work of Oakhill et al 
(2010). The AMPK heterotrimer used for the promotion of phosphorylation 
experiments in Chapter 3 was purified from rat liver, and the LKB1 from insect cells. 
Using an anti-AXIN antibody, no AXIN was detected in either the LKB1 or AMPK 
preparations, so preliminary attempts to confirm the observations of Zhang et al 
(2013) were unsuccessful (data not shown). However, AXIN could be present at levels 
undetectable by Western blotting. Alternatively, the promotion of phosphorylation of 
Thr172 may be enhanced if the AMPK purified from rat liver was supplemented with 
AXIN. Regardless, the work of Zhang et al (2013) does support the observations, 
reported in Chapter 3, that it is AMP, and not ADP, that is the key regulator of Thr172 
phosphorylation and AMPK activity. 
 
One aspect not covered by this thesis is whether the activation of AMPK in LKB1-null 
cells has a physiological relevance. Treatment of LKB1-null G361 cells with AMPK 
activators increased phosphorylation of ACC at Ser79 and it would be interesting to 
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examine whether this resulted in changes in lipid metabolism, although there is no 
reason to suspect that it would not. AMPK also has significant anti-proliferative 
properties and activation of AMPK may result in changes in cell growth, survival and 
cycle progression. The results from Chapter 5, discussed below, suggest that this may 
be the case. 
 
6.3 Phosphorylation of LKB1 by AMPK 
LKB1 has been shown to be phosphorylated in intact cells at Ser31 and this does not 
occur due to autophosphorylation (Sapkota et al., 2002a). The sequence around Ser31 
is well conserved and bears resemblance to the AMPK consensus motif (Dale et al., 
1995; Gwinn et al., 2008; Scott et al., 2002). However, although AMPK can 
phosphorylate Ser31 to a reasonable stoichiometry in cell-free assays, it remains 
unclear whether this is a physiologically relevant event. To further investigate this, a 
more specific antibody against phospho-Ser31 would be required. Alternatively, mass 
spectroscopy of samples from cells treated with a specific AMPK activator may 
demonstrate whether this phosphorylation can occur in intact cells. The 
phosphorylation of LKB1 by AMPK was initially an attractive hypothesis, given that it 
could form part of a feedback loop. However the Ser31 site does not appear to alter 
LKB1 function, as demonstrated by work in this thesis and from other groups (Sapkota 
et al., 2002a). 
 
6.4 AMPK protects against apoptosis induced by mTOR inhibition 
Another goal of this thesis was to investigate the response of cells to AZ4, a dual 
mTORC1/mTORC2 inhibitor, and to determine whether the LKB1-AMPK pathway 
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influenced this response. The results suggest that treatment of intact cells with AZ4 
can induce apoptosis and reduce cell number, which was the case in both transformed 
and non-transformed cell lines. However, more work is required to understand the 
molecular mechanisms, including the key signalling components underlying these 
effects. Does apoptosis require inhibition of mTORC2, as suggested by the results in 
Chapter 5? If so, which of the multiple downstream targets of mTORC2 must be 
inhibited to induce apoptosis? Alternatively, the effects could be due to increased 
phosphorylation of the 4E-BPs and a decrease in expression of anti-apoptotic genes. 
Examining gene expression patterns of cells treated with AZ4 may shed light on this.  
 
Results in Chapter 5 also suggest that the LKB1-AMPK pathway may play a role in 
determining the response of cells to mTOR inhibition. Treatment with A769662, a 
direct AMPK activator, decreased AZ4-induced apoptosis of G361 cells; an effect not 
observed in mouse embryo fibroblasts lacking the AMPK-α1/-α2 subunits. G361 cells 
do not express LKB1, and the results in Chapter 5 support the observation that 
A769662 can significantly activate AMPK even in LKB1-null cell lines, and suggests that 
this activation may be translated into physiologically relevant changes. Additionally, 
mouse embryo fibroblasts lacking AMPK-α subunits were more susceptible than their 
wild-type counterparts to AZ4-induced apoptosis. Future work could study whether 
activation of the LKB1-AMPK pathway in tumours in vivo, rather than in cell culture 
models, regulates the response to mTOR inhibition. 
 
These results suggest that the loss of LKB1-AMPK pathway, a common effect in a 
number of tumours, may sensitize cancer cells to mTOR inhibition and may have 
implications for combination therapies, where AMPK activators such as metformin, 
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which have anti-proliferative properties, are administered together with mTOR 
inhibitors. The results presented here suggest that this may actually increase the 
survival of cancer cells and could reduce the efficacy of the treatment. This may also 
have implications for treatment with inhibitors targeted against other components of 
the mTOR pathway, such as PI3 kinase. It may even be that inhibition, rather than 
activation, of the AMPK pathway may be efficacious in treatment of some types of 
tumour. 
 
Despite this, activating the AMPK pathway may still have benefits in preventing the 
onset of cancer. AMPK regulates a host of cellular functions that would be expected to 
reduce tumour formation, including inhibition of protein and lipid synthesis and 
promotion of autophagy. This idea is supported by emerging evidence that AMPK itself 
is a tumour suppressor (Evans, 2005; Huang et al., 2008; Faubert et al., 2013), as well 
as the established tumour suppressor role of LKB1. AMPK may therefore act as a 
“double-edged sword” in cancer therapy: AMPK activation may prevent the formation 
of tumours but increase their survival once they are formed. Understanding the status 
of the LKB1-AMPK pathway in the tumours of individual patients may therefore form 
an important part of future personalized medicine. 
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